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ABSTRACT 
 
Neuroendocrine tumours (NETs) are uncommon tumours which have a diverse biology. 
The aims of this thesis were to identify potential new biomarkers and further develop 
understanding of tumour biology in NETs. The following were assessed i) somatostatin 
receptor (SSTR)  and  dopamine-2 receptor (D2R)  expression in NETs, ii)HER 
expression and their associated prognosis, iii) Angiopoietin expression in NETs and their 
prognostic significance, iv) proteomic analysis of serum and NET cell lines to identify 
novel markers and finally v) the role of 
68Ga-DOTATATE PET in imaging of NETs.  
 
Immunohistochemical studies were performed to determine whether SSTR and D2R are 
co-expressed in NETs. D2R was co-expressed with SSTR-2 and -5 in 93% of low grade 
tumours, with lower co-expression in higher grade tumours.  
 
HER family of receptors are involved in oncogenesis; the expressions of these receptors 
were assessed. Immunohistochemical analysis of these receptors was performed in 82 
cases. EGFR was expressed in 86%, HER-2 0%, HER-3 8.5% and HER-4 91.5%. The 
expression of EGFR was not associated with poor prognosis. 
 
Angiopoietins (Ang) are involved in tumourogenesis. Serum Ang-1 and Ang-2 were 
measured in patients and healthy controls. Ang-2 was significantly higher in patients 
compared to controls. Patients with Ang-2 levels >4756pg/ml had a shorter time to 
progression.  
 
Proteomic analysis using gel electrophoresis and LC/MS/MS of plasma from NET 
patients and established NET cell lines was performed to identify biomarkers. Proteomic  
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cell line analysis identified 17 proteins in all cell lines including Mac-2 binding protein. 
We validated Mac-2 binding protein and it appears to be a potential marker for NETs.  
 
Finally, we performed a study to ascertain whether 
68Ga-DOTATATE PET identifies 
more lesions in NET patients in whom 
111In-DTPA-Octreotide showed faint/negative 
lesion uptake. 
111In-DTPA-Octreotide scintigraphy identified 27 lesions compared to 168 
lesions identified with Ga-68-DOTATATE PET. 
68Ga-DOTATATE PET is a sensitive 
imaging modality for identifying NETs. 
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visualization of tumours.  
PCR: polymerase chain reaction 
PSA: prostrate specific antigen  
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RT-PCR: reverse transcriptase polymerase chain reaction 
RIA: radio immunoassay  
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for assessing tumour.  
ROC curve- receiver operator characteristic curve  
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Scintigraphy - A diagnostic test in which a two-dimensional picture of a body radiation 
source is obtained through the use of radioisotopes. 
SDS PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEER: surveillance, epidemiology and end results  
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SPECT: single photon emission computed tomography  
SSTR- somatostatin receptor  
STZ: Streptozotocin 
TAE: transarterial embolization  
TACE: transarterial chemoembolization 
VEGF: Vascular endothelial growth factor 
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Chapter 1. Introduction 
Abstract 
 
Neuroendocrine tumours (NETs) are thought to arise from multipotent stem cells of the 
diffuse neuroendocrine system. The incidence is reported as 2.5-5 cases per 100 000 
population and the incidence is rising. NETs are generally low grade indolent tumours 
however; the histological spectrum varies from low grade well differentiated tumours to 
high grade poorly differentiated tumours. A number of biochemical markers are 
available to diagnose these tumours, the most commonly used general marker is 
chromogranin A. Patients often present with advanced disease and treatment comprises 
of curative surgery or a number of palliative therapies. Biotherapy with somatostatin 
analogues and interferon-α,  form the cornerstone of symptomatic therapy in patients 
with functional tumours. A number of other palliative therapies are available and 
advances are being made with new molecular targeted therapies.  
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1.1 Introduction 
Neuroendocrine tumours (NETs) are derived from cells of the diffuse neuroendocrine 
system, which are present in organs throughout the body. Originally Pearse proposed 
that NETs developed from migration of cells from the neural crest, however, it is now 
thought that the tumour cells are derived from multipotent stem cells 
1.   
 
The term ‘karzinoide’ (meaning carcinoma like) was initially introduced by Siegfried 
Oberndorfer in 1907
2. His initial observations describe small and multiple tumours 
which have the potential to become invasive but do not metastasize. Whilst some of 
these observations are correct these tumours do metastasize and should not be regarded 
as benign tumours. The term carcinoid tumour has historically been used, however, with 
advances in the understanding of the tumour biology and the recent WHO classification, 
the term NET or endocrine tumour is considered more appropriate.  
 
1.1a Incidence 
The reported incidence is 2.5 -5 cases per 100 000 population 
3. Approximately 0.5% of 
all malignant diseases are NETs of either bronchopulmonary or gastroenteropancreatic 
(GEP) origin 
3. There appears to be an increased incidence in small bowel NETs in 
blacks versus Caucasians in the USA 
4. The incidence of different NETs has risen over 
the last three decades; the greatest increase has been in bronchial and midgut NETs 
5. 
The increase in incidence of NETs will partly be due to improved diagnostic techniques 
both radiological and endoscopic.  
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1.1b Prevalence  
Whilst the incidence of these tumours is relatively low, the long duration of disease 
means the prevalence is much higher than would be initially expected. Using the 
Surveillance, Epidemiology and End Results program registries (SEER 9), Yao et al 
demonstrated that prevalence of NETs was 35 per 100 000 population 
6. Recently studies 
have demonstrated an increased survival for patients leading an overall increase in 
prevalence 
6;7. 
 
1.1c Aetiology 
Most cases are sporadic, however, some occur as part of genetic syndromes, these 
include multiple endocrine neoplasia -1 (MEN-1), MEN-2, Von Hippel Lindau 
syndrome and neurofibromatosis-1 
8. Certain types of NETs are common in MEN-1, for 
example  individuals with MEN-1  may  develop gastric carcinoids. Non-functional 
pancreatic NETs and gastrinomas are also common with between 25-40% of MEN-1 
patients developing gastrinomas. Bronchial NETs are relatively uncommon in MEN-1 
with a reported incidence of 5% 
9.  Midgut NETs are uncommon in MEN-1 patients.  
 
1.2 Classification  
Neuroendocrine cells were originally thought to be derived from neural crest cells as 
they expressed markers for neuronal differentiation and proteins involved in the 
biosynthesis of neurotransmitters. Pearse introduced the amine precursor uptake and 
decarboxylation (APUD) cell concept based on the ability of neuroendocrine cells to 
synthesize bioactive amines such as dopamine, adrenaline, noradrenaline, serotonin and 
histamine 
1. This theory however, is not thought to be correct since a number of studies 
have identified that gut endocrine cells share a common stem cell and are endodermally 
derived 
10. The currently accepted hypothesis proposes that the gut is derived from  
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endodermal stem cells. As it is developing the gut acquires an underlying tendency to 
differentiate into intestine. The endoderm has the potential to form a wide range of 
endocrine cell types. There is thought to be a pre-selected regional pattern of endocrine 
cells within the gut starts to develop, the factors responsible for directing this may be 
derived from the mesenchyme . Once these cells have started to develop their maturation 
is thought to be directed by the mesenchyme 
11.    
 
Neuroendocrine cells scattered within the gastrointestinal mucosa from stomach to colon 
represent the largest population of hormone-producing cells in the body. There are at 
least 14 different neuroendocrine cell types in the GI tract, all with a specific regional 
distribution 
12. The cells are specialized in the synthesis, storage and secretion of a wide 
range of polypeptide hormones and amines, all of which have an important role in bowel 
movement and fine tuning of hormonal secretion along the GI tract.  Malignant change 
in specific neuroendocrine cells can lead to development of a number of different types 
of NETs 
13. 
 
In 1963, Williams and Sandler divided NETs according to their embryological origin 
into foregut (bronchial, stomach, pancreas, gall bladder and duodenum), midgut 
(jejunum, ileum, appendix and colon- up to ascending colon) and hindgut (transverse 
and remaining colon, rectum). This old type of classification is being replaced gradually; 
the WHO classification of endocrine tumours divides these tumours into well 
differentiated endocrine tumours, well differentiated endocrine carcinomas and poorly 
differentiated endocrine carcinomas. This classification is described in more detail in 
section 1.2a. More recently ENETS have developed a TNM classification system and 
grading system, this is further discussed in section 1.2. It is becoming apparent that 
tumours within each region can have markedly different clinical behaviour and  
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therefore, a shift towards tumours being categorized purely by anatomical location is 
being introduced 
14. For the purposes of the studies in this thesis the William and Sandler 
classification of NETs by embryological site has been used.  
 
1.2a Pathology and Staging 
NETs can exhibit a diverse spectrum of pathology, from benign tumours to highly 
aggressive poorly differentiated tumours 
14. The WHO classification is used for 
describing tumours of gut and pancreas 
15. Separate classifications systems are in use for 
bronchial, thymic and thyroid NETs. The WHO classification for tumours is based on 
degree of differentiation and clinical behaviour, there are three types see table 1.1. 
 
1. well-differentiated endocrine tumours, with benign (1.1) or uncertain behaviour 
(1.2) at the time of diagnosis. 
2. Well-differentiated endocrine carcinomas with low-grade malignant behaviour. 
3. Poorly differentiated endocrine carcinomas, with high-grade malignant 
behaviour. 
 
Table 1.1. WHO classification of NETs adapted from Koppel et al,
15. 
 
Bronchial carcinoid tumours are classified into four groups dependent on histological 
parameters including mitotic activity and proliferation index. These groups are typical 
carcinoids, atypical carcinoids, large cell neuroendocrine carcinoma and small cell lung 
carcinoma 
16. Histological subtypes were diagnosed according to WHO Classification. 
Typical bronchial carcinoids are classified as carcinoid morphology with less than two 
mitotic figures per 2mm
2  and no evidence of necrosis. Atypical carcinoids have 
carcinoid morphology with a mitotic count of 2-10 per 2mm
2  and necrosis can be  
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present. LCNEC classification is based upon features of neuroendocrine morphology, 
mitotic rate up to 70 per 2 mm
2, necrosis, and cytologic features of large cell carcinoma. 
Small cell carcinoma has characteristic histological features such as small size, scant 
cytoplasm, high mitotic rate and large areas of necrosis.  
 
The European Neuroendocrine Tumour Society (ENETS) proposed a TNM staging 
classification and this also includes a grading system of low, intermediate or high grade 
tumours dependent  on their proliferation index, mitotic activity and histological 
phenotype 
17-19. Using this classification low grade tumour was regarded as mitotic count 
<2 per 10 high power fields (HPF) and Ki67  ≤2%,  intermediate  grade  as  having  a 
mitotic count 2-20 per 10 HPF and Ki67 3-20% and high grade as mitotic count of >20 
per 10 HPF and Ki67 >20.  
 
ENETS have provided guidelines for staging tumours using a TMN classification (Table 
1.2). The classification so far has been published for GEP NETs and not other NETs. 
Retrospective studies have shown prognostic value in this staging system.  
 
1.3 Clinical features 
NETs can be separated into non-functioning and functioning tumours. The majority 
(approximately 60%) are non-functional tumours i.e. with no symptoms attributable to 
secretion of metabolically active peptides. Functional tumours secrete substances that are 
metabolically active; which can lead to development of specific clinical syndromes. The 
most common functional syndrome is carcinoid syndrome which is thought to be due to 
secretion of amines, kallikrein and prostaglandins. Serotonin (5-hydroxytryptamine) is 
one of the main amines which is synthesized and secreted by these tumours.  
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Table 1.2. TNM staging system for foregut NETs proposed by ENETs 
20;21 
T indicates tumour classification; N, lymph node status; M, metastatic status.  
† T0 indicates no evidence of primary tumour, Tis tumour in situ/dysplasia (size <5mm); 
T1, gastric or duodenal tumour invading lamina propria or submucosa and size <10mm 
or pancreatic  tumour limited to pancreas and size <20mm; T2, gastric or duodenal 
tumour invading the muscularis propria or submucosa, or size >10mm, or pancreatic 
tumour limited to pancreas and size between 20-40mm; T3, gastric or duodenal tumour 
penetrating the serosa, or duodenal tumour infiltrating the pancreas, or pancreatic tumour 
limited to the pancreas and size >40mm, or pancreatic tumour invading the duodenum or 
common bile duct; T4, gastric, duodenal or pancreatic tumour invading adjacent 
structures.  
‡ N0 indicates absence of regional lymph node metastasis; N1, invasion of regional 
lymph nodes. 
§  M0 indicates absence of distant metastasis, M1, presence of distant 
metastasis.  
 
1.3a Carcinoid syndrome 
Carcinoid syndrome occurs in 20-30% of patients with mid-gut carcinoid tumours and 
approximately 5% of bronchial carcinoids 
22. Other foregut tumours (e.g. pancreatic 
neuroendocrine tumours) can cause carcinoid syndrome although this is uncommon 
(1%). Hind gut tumours are generally non-functional and occasionally cause carcinoid 
syndrome. 
 
Carcinoid syndrome is usually seen in patients with liver metastases (in 95% patients), 
but excess tachykinins and serotonin production from retroperitoneal metastases or 
ovarian tumours can bypass the liver to cause carcinoid syndrome.  
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Normally serotonin is synthesized from tryptophan, and is subsequently metabolized by 
monoamine oxidase to 5-hydroxyindoleacetic acid (5-HIAA), which is subsequently 
secreted in the urine in healthy individuals. Approximately 99% of tryptophan is used 
for the synthesis of nicotinic acid and less than 1% converted to 5-HT. However, in 
patients with carcinoid tumours there is a shift towards the production of 5-HT. The 
increased production of 5-HT and other products and their direct release into the 
systemic circulation, due to liver metastases, leads to the development of carcinoid 
syndrome 
23. 
 
Patients often describe having symptoms for many months prior to presentation. The 
two most common symptoms are diarrhea and flushing, whilst wheeze occurs less 
commonly. Often diarrhoea is associated with crampy abdominal pain and urgency, 
and can occur during both day and night. Flushing is characteristically described as a 
sudden onset of pink to red discoloration involving the face and upper trunk. This 
usually lasts a few minutes and can occur intermittently throughout the day. Triggers 
leading to flushing and diarrhoea include stress, tyramine-containing foods (chocolate, 
bananas, and walnuts) and alcohol. Classic facies of carcinoid syndrome consists of 
pink-to-red discoloration around the face and upper trunk. In patients with atypical 
flushing, which may last for several hours, telangiectasia and hypertrophy of the face 
may be seen. Wheeze is caused by bronchial constriction mediated via tachykinins and 
bradykinins. This is more common in those with bronchial carcinoid tumors. 
 
A raised jugular venous pressure and features of right heart failure may be present in 
patients with carcinoid heart disease related to carcinoid syndrome. Right-sided cardiac  
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murmurs of tricuspid regurgitation and pulmonary stenosis may be heard on 
cardiovascular examination 
24. 
 
Other hormone-related manifestations include morphoea (subcutaneous thickening of 
the lower limbs) and a pellagra-type rash if nicotinic acid deficiency has been induced. 
With severe long-standing hepatomegaly or local infiltration, IVC obstruction or even 
lymphangiectasia leading to ascites may occur. 
 
A number of other clinical syndromes occur in NETs dependent on the hormones 
secreted. Table 1.3 demonstrates the clinical features seen in different types of NETs.  
 
1.4 Diagnostic investigations 
Diagnosis of NETs requires biochemical, topographical imaging and importantly 
histological diagnosis. Efforts should be made to identify primary site of tumour, which 
can be difficult, since some primary lesions are small and not detected by conventional 
cross sectional imaging.  
 
1.4a Biochemical tests 
Patients with suspected NETs should undergo biochemical testing, including fasting gut 
hormones (glucagon, vasoactive intestinal peptide, somatostatin, gastrin), Chromogranin 
A (CgA) and pancreatic polypeptide 
17. Neuroendocrine cells contain typical secretory 
granules, called large dense-core vesicles based on their characteristic appearance on 
electron microscopy. In addition  to the specific peptide hormones or neuropeptides, 
these granules also contain one or more secretogranin proteins. The first member of this 
family and the most widely studied is CgA.   
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Site  Clinical features  Cell type  MEN-1 
Pancreatic        
Insulinoma   Hypoglycaemia, whipples triad, 
clammy, sweating, weight gain 
Beta islet cell  5-10% 
VIPoma  Werner- Morrison syndrome, 
watery diarrhoea 
VIP  10% 
Glucagonoma  Diabetes Mellitus, Necrolytic 
migratory erythema 
  5-10% 
Somatostatinoma  Gallstones, Diabetes Mellitus, 
Steatorrhoea 
D cells  5-10% 
Gastrinoma  Zollinger Ellison syndrome  G cells  25% 
Non-functional  Symptoms related to mass 
effect 
  15% 
Bronchial  Majority non-functional, 8% 
carcinoid syndrome, atypical 
flushing 
Pulmonary 
neuroendocrine 
cells,  
5% 
Midgut  Majority non functional, 40% 
develop carcinoid syndrome 
K, L , Motilin   
Hindgut  Usually non-functional, 
however tumours may secrete 
somatostatin other peptide and 
occasionally carcinoid 
syndrome may occur 
Enterochromaffin 
cell 
 
 
Table 1.3. The clinical features of NETs. Midgut tumours arise from the jejunum to 
caecum and hindgut encompasses tumours from the ascending colon to rectum.  
 
 
Since CgA is stored in a majority of different NETs, its release to the circulation can be 
used as a ‘general’ marker for various NETs. This is of particular interest in 
‘nonfunctioning’ tumours, which may lack other suitable markers. Currently CgA is the 
best general biochemical marker for NETs currently available 
25;26. The plasma 
concentrations of CgA are elevated in various peptide-producing NETs and the highest 
concentrations are noted in patients with metastatic carcinoid tumours, particularly 
midgut carcinoids. Tumour burden and plasma CgA concentrations has been studied and 
it shown that in patients with midgut carcinoids those with multiple liver metastases had 
significantly higher concentrations of CgA than those with only a few liver metastases or  
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lymph node metastases only 
27. A study by Arnold et al 
28  demonstrated increased 
plasma chromogranin A in patients with metastatic neuroendocrine tumours is predictive 
for shorter survival. There was a modest correlation between chromogranin A 
concentrations and hepatic tumour burden.  
 
There are some other pitfalls in the interpretation of CgA concentrations. ‘False-positive’ 
elevation of CgA can be seen in patients with renal impairment, liver failure, atrophic 
gastritis  and inflammatory bowel disease 
29.  Also patients receiving proton pump 
inhibitors have a slight increase in CgA due to gastrin-induced ECL cell hyperplasia. 
Furthermore, physical stress induced by exercise or trauma can produce a slight 
elevation in CgA (about twofold) 
30. 
 
The introduction of radioimmunoassay for various peptide hormones led to increased 
diagnosis of NETs. The peptides and amines secreted by NETs may serve as tumour 
markers not only for diagnosis but also for follow-up of treatment. Biochemical tumour 
markers can be divided into specific and general markers, see Table 1.4. Specific 
markers include urinary 5-HIAA, neuropeptide K for carcinoid syndrome.  For specific 
pancreatic tumours other markers can be measured for example glucagon in 
glucagonoma, vasointestinal peptide for VIPoma. General tumour markers for NETs 
include Chromogranin A and B and pancreatic polypeptide, see table 1.4. 
 
Routine lab tests including Full Blood Count, Urea and Electrolytes, Liver Function 
Tests, CEA, AFP, HCG-beta, Ca-19.9, ESR should be performed. Urinary 5-HIAA 
should also be performed in all patients with suspected carcinoid syndrome 
31. AFP and 
HCG-beta if elevated are poor prognostic indicators in NETs 
31. Table 1.4, shows the 
different biochemical tests that used for diagnosis of NETs.   
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A good biomarker needs to be sensitive and specific, whilst CgA provides good 
sensitivity and specificity it is not 100% for the reasons described above. CgA has been 
shown in some studies to provide prognostic information though this has not been 
demonstrated in all studies 
28. 
 
There is a need for other markers which provide better prognostic information and also 
markers that may be used in conjunction with CgA to identify NETs. One of the main 
focuses in this thesis is to identify new plasma markers which can be used for diagnosis 
of NETs or aid prognosis.   
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Table 1.4. General and specific biochemical plasma markers raised in NET dependent on 
anatomical site.  
 
1.4b Histology 
Histology remains the gold standard for diagnosing NETs. Immunohistochemistry 
should be performed using a panel of antibodies to general neuroendocrine markers. 
These include chromogranin A, synaptophysin, PGP9.5. In addition the tumour should 
be stained with an antibody to the Ki67 protein, since the Ki67 proliferation index is of 
benefit in grading tumours 
17.  
 
Type of tumour  Plasma marker  Urinary marker 
Carcinoid   Chromogranin A 
Chromogranin B 
Neuron Specific Elonase 
HCG-beta 
Substance P 
Gherlin 
Neuropeptide K 
Alpha fetoprotein 
5-Hydroxyindoloacetic 
acid 
Phaeochromocytoma  Chromogranin A 
Chromogranin B 
Neuron Specific Elonase 
HCG-beta 
Neuropeptide Y 
Metanephrins 
Alpha fetoprotein 
Catecholamines 
Vanillylmandelic acid 
Dopamine 
Homovallinic acid 
Pancreatic NETs  Chromogranin A 
Chromogranin B 
Pancreatic polypeptide 
Neuron Specific Elonase 
HCG-beta 
Alpha fetoprotein 
Glucagon 
Gastrin  
Insulin  
Somatostatin  
Calcitonin  
Vasoactive intestinal 
peptide 
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The histological characteristics of NETs vary according to the degree of differentiation. 
Low grade NETs originating from the gut were previously termed ‘typical’ carcinoids; 
these tumours had classic histological architecture of trabecular, or ribbon like cell 
clusters, with little of no cellular pleomorphism and occasional mitoses. The higher 
grade and poorly differentiated tumours had increased mitotic activity and evidence of 
necrosis. The WHO classification gives clear parameters for categorizing NETs into the 
three main categories described earlier, see Table 1.1 
15.   
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1.5 Imaging 
Cross sectional imaging is principally with contrast computer tomography (CT) 
including arterial phase enhancement abdomen, chest and pelvis. Magnetic resonance 
imaging (MRI) is the most sensitive modality for liver metastases 
32. Studies of CT in 
carcinoid tumours show an overall sensitivity of 80% in detecting lesions 
33;34. Both MRI 
and CT appear to have similar sensitivities for localization of pancreatic NETs; however 
most studies involve small numbers and heterogeneous cases 
35-37. Both modalities are 
important in identifying extent of metastatic disease, and assessing response to 
treatment. In cases where the primary is not identified, both modalities can be useful in 
identification of primary lesions. As technology improves there will be advances in the 
role of cross sectional imaging 
34. The sensitivity and specificity of CT and MRI alone 
are lower than in combination of 
111In-Octreotide scan with CT or MRI 
38.  
 
1.5a Nuclear Medicine 
Nuclear medicine (NM) imaging is important in staging of disease and suitability for 
therapy with somatostatin analogues and peptide receptor therapy. The two main NM 
scans used in staging NETs are 
111In-Octreotide, 
123I-MIBG, with the advent of newer 
modalities including PET scanning being introduced. 
 
There are 5 different somatostatin receptor (SSTR) subtypes all of which have strong 
affinity to somatostatin 
39. 
111In-DTPA-Octreotide (Octreotide™) is a somatostatin 
analogue which has a strong affinity to SSTR-2 and to lesser extent SSTR-5 receptors. 
Most NETs predominantly express SSTR-2. Synthetic radiolabelled SSTR analogues 
such as 
111In-DTPA-Octreotide enable somatostatin receptor scintigraphy (SRS) to be 
performed 
40. Scintigraphy is a technique which leads to the production of two- 
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dimensional images of the distribution of radioactivity in tissues, following the internal 
administration of a radiopharmaceutical imaging agent, the images being obtained by a 
scintillation camera. Spatial localization using 2-D planar images can be inaccurate 
especially when imaging the abdomen. Development of single photon emission 
computed tomography (SPECT) has enabled much better spatial resolution within the 
abdomen also increased lesion detection using this technique. SPECT  imaging is a 
technique whereby the gamma photon–emitting radionuclides are detected by one or 
more gamma cameras rotated around the patient, using the series of two-dimensional 
images to recreate a three-dimensional view. 
 
SRS is now established in localizing NET 
41. Prospective studies have shown that 
inclusion of SRS in the diagnostic work-up of patients alters management in up to 47% 
of cases 
42. The sensitivity of SRS for detection of GEP NETS has been well studied. 
The sensitivity has been reported between 67-100%, with no significant difference in 
carcinoid tumours from foregut, midgut or hindgut origin 
43-45. With pancreatic NETs 
sensitivity of SRS is dependent on the type of functional tumour. Gastrinomas have 
reported sensitivity between 56-80%, VIPoma is 60-70% and insulinoma is lower at 
50% due to a lower expression of SSTR-2 
40. With phaeochromocytomas SRS is often 
negative and other imaging modalities such as Meta-iodobenzylguanidine  (MIBG) 
should be used. Medullary thyroid cancer express SSTR-1 therefore may be negative on 
SRS. False positive scans can be seen in patients with chronic inflammation, 
granulomatous disease. SRS detection is also affected by the size of NET and will often 
not detect lesions <1cm 
46. The current gold standard nuclear medicine imaging modality 
for NETs is regarded as being 
111In-DTPA-Octreotide; however other techniques such as 
PET scanning are producing promising results.   
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Meta-iodobenzylguanidine (MIBG) has been used for two decades to visualize carcinoid 
tumours. The method was initially developed to detect phaeochromocytomas. MIBG 
shares the same method of uptake as norepinephrine and is not dependent on SSTR 
receptor expression. In phaeochromocytomas 
123I-MIBG has sensitivity of 87% and 
specificity of 99%, however for carcinoid tumours only has 50% sensitivity and 
specificity; whilst in pancreatic NETs uptake may be seen in <10% cases 
47. In general 
123I-MIBG scintigraphy was shown to be less sensitive than 
111In-DTPA-Octreotide 
scintigraphy in identifying carcinoid tumours 
47.  
 
1.5b Positron Emission Tomography 
Positron emission tomography (PET) is a technique that produces a three-dimensional 
image or picture of functional processes in the body. The system detects gamma rays 
emitted indirectly from a radionuclide tracer usually bound to a biologically active 
molecule or receptor ligand/ analogue. The radionuclide tracer then accumulates in areas 
of interest and computer reconstruction allows development of 3-D images. Newer 
scanners combine PET with either CT or MRI thereby enabling better topographical 
localization. The radio-isotope usually has a short half-live and undergoes positron 
emission decay, whereby it emits a positron and after travelling a few millimetres the 
positron encounters and annihilates with an electron, producing a pair of photons. These 
often move in opposite directions, i.e. 180° apart. These are detected when they reach a 
scintillator in the scanning device creating a burst of light.  If a biologically active tracer, 
such as fluorodeoxyglucose (FDG) is used then metabolic activity in terms of regional 
glucose uptake can be determined; which can be useful in determining the response to 
treatment for example following chemotherapy. 
18FDG-PET is suitable for high grade  
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tumours; however its role in low grade tumours due to their slow glucose turnover is 
unclear 
48. However, it has been used in imaging gastrointestinal stromal tumours which 
can be well differentiated and have a low mitotic activity 
49;50. PET scanning in other 
malignancies is well established; however its role in NETs is still evolving. 
 
New agents of interest include 
68 Ga-DOTA-Octreotide and 
68Ga-DOTA-Octreotate, 5-
hydroxytryptophan (5-HTP) and 3,4-dihydroxyphenylalanine (DOPA). Studies with 
68Ga-DOTA-Octreotide showed it had a greater sensitivity than conventional SRS 
51;52. 
Preliminary studies using these different agents have been published, most generally 
showing improved sensitivity over 
111In-DTPA-Octreotide scintigraphy. Some agents 
such as 5-HTP and DOPA which may have good sensitivities are not able to demonstrate 
SSTR-2 status, which would be important if considering these patients for radiotargeted 
therapy. In this thesis the role of 
68Ga-DOTATATE PET in patients with negative or 
weak uptake on 
111In-DTPA-Octreotide scintigraphy is assessed.   
 
1.5c Endoscopy 
If the primary site has not been identified by conventional imaging, it is worthwhile 
performing endoscopy of the upper and lower gastrointestinal tract (GIT). In addition if 
patients are known to have a primary lesion in the GIT, endoscopy will allow 
visualization of the lesion and the option of histological diagnosis. For detection of 
gastric, pancreatic and duodenal lesions, endoscopic ultrasound (EUS)  is a sensitive 
method for staging disease and providing information regarding depth of invasion and 
potential resectability 
53. In addition biopsies can be performed to provide histological 
diagnosis. EUS has an accuracy of 90% in staging of rectal carcinoids 
54.  
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Capsule endoscopy can be used to diagnose small bowel carcinoid tumours, and appears 
to be at least as sensitive as enteroscopy at identifying lesions. Obviously the drawback 
is the inability to obtain a histological diagnosis. In small case series there appears to be 
advantage of capsule endoscopy over conventional small bowel investigations using CT 
and barium follow-through 
55. To exclude possibility of obstruction barium follow 
through or patency capsule study should be performed prior to capsule endoscopy. 
 
For bronchial NETs which commonly arise in large to midsize airways bronchoscopy is 
of use in assessing the lesion and obtaining histological diagnosis 
5.  
 
1.6 Management  
Therapies for NETs incorporate those required for symptom control, due to hormonal 
secretion from tumours and also anti-proliferative therapies. The management of NETs 
requires the use of a number of different therapies including surgery, biotherapy, 
chemotherapy, peptide receptor targeted therapy and tumour embolization. The best way 
to provide the most appropriate management plan for patients is through a 
multidisciplinary approach.  Different therapies may be required at different clinical 
stages, and in patients with indolent disease and mild symptoms merely symptomatic 
relief may be all that is required for some years.    
 
1.6a Surgery 
 
Primary resection of NETs is recommended for all patients with localized disease, unless 
contraindicated or patient’s decline surgical therapy. A proportion of primary small 
bowel ileal tumours present with bowel obstruction, which requires urgent surgical  
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intervention. Survival of patients, who have curative resections, is better than those with 
unresectable disease
17. 
Patients with advanced functional tumours, in whom maximal medical therapy is unable 
to control symptoms, surgical resection of tumour enable  better  symptom control. 
However, in patients with non-syndromic tumours, the value of surgery cannot be 
assessed in the same way; in these patients alterations in survival time would be the best 
method to assess benefit of surgery.  
The role of surgery for hepatic metastases is more difficult. Only 10-15% of patients 
with liver metastases has unilobar diseae and is suitable for surgical resection. The 
majority of patients have bilobar disease. In studies looking at surgical resection vs. 
TACE and/or TAE, there is a significant survival benefit for patients undergoing 
surgery
22. However, most of these studies are biased since patients not suitable for 
surgery usually have bilobar and larger volume disease.  
There is a general consensus that if the primary can be resected or has been resected and 
that >95% of the tumour load can be surgically resected there is a role for debulking 
surgery. Patients with liver metastases that have curative resections have a 5 year 
survival of 75-81%
17.  There is currently no randomised control data showing whether 
this aggressive surgical approach offers any survival benefit. These studies are required 
to help determine whether this approach is valid.  
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1.6b Somatostatin analogues 
Somatostatin is a small polypeptide hormone which occurs naturally in the human body 
and binds with a high affinity to the five recognized SST receptors. Activation of SST 
receptors leads to activation of common signalling pathways such as inhibition of adenyl 
cyclase and modulation of mitogen activated protein kinase through G-protein dependent 
mechanisms 
56. The effect of somatostatin on tumour growth may be through the 
suppression of synthesis and secretion of growth factors and growth promoting 
hormones (see Figure 1.1). Somatostatin also appears to inhibit angiogenesis and cell 
proliferation in in vitro models. Its anti-angiogenic effect appears to be through 
inhibition of angiogenic factors like VEGF, IGF-1 and PDGF 
57;58.   
 
In view of the short half life of SST, synthetic analogues were developed, initially 
Octreotide™ and subsequently Lanreotide. Short acting Octreotide which needs to be 
administered three times a day and long acting Octreotide-LAR and Lanreotide Autogel 
with 28 day duration of action 
59.  Both are equally effective at controlling symptoms 
related to carcinoid syndrome. Improvement is seen in approximately 85% of cases 
60. 
Biochemical markers such as CgA and urinary 5-HIAA are found to decrease by at least 
50% in 60-80% of cases following therapy 
61. In a study performed by Garland et al, of 
27 patients with positive SRS and commenced on Octreotide LAR all had  good 
symptom control initially. However, the majority of patients developed progressive 
disease and required further therapies for symptom control 
62. Side-effects  with 
somatostatin analogues include gastro-intestinal  disturbances, including pancreatic 
insufficiency that may require enzyme replacement therapy, gallstones and glucose 
intolerance.   
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Anti-proliferative effects of SST analogues have been demonstrated in vitro in a 
number of studies and a number of clinical studies have demonstrated slower rate of 
progression in patients receiving SST analogues. Recently the results from the 
PROMID study were published, this was a placebo-controlled, double blind, 
prospective randomized study to examine the effect octreotide on tumour growth in 
patients with NETs. It demonstrated median time to tumour progression in the 
octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio 
[HR] = 0.34; 95% CI, 0.20 to 0.59; P<0.001) 
63.  
 
Tolerance to SST analogues is a recognized phenomenon and there is a need for new 
biotherapy agents. Parsireotide a new multi-ligand SST analogue is currently being 
trialled. Recent studies have demonstrated that the majority of NETs co-express 
dopamine and somatostatin receptors, which have led to development of chimeric agents 
which have shown promising results in NET cell lines 
64;65.  
 
1.6c Interferon α 
Interferon therapy has been used for symptomatic control in patients with NETs since 
1982. It has been found to be beneficial in reducing symptoms of flushing and diarrohea 
in patients with carcinoid syndrome in 50-60% of cases. Significant biochemical 
responses are reported in 40-50% of cases 
66. Its mechanism is action is unclear though is 
thought to act through antisecretory and immunomodulatory functions. Its anti-tumour 
effect is generally reported to be <20% partial response rate in most studies. In a study of 
111 patients treated with interferon-α 15% demonstrated a greater than 50% reduction in 
tumour size 
67. 
  
  42 
Studies have shown disease stabilization occurs in 40% of patients with combined 
therapy with somatostatin analogues and interferon-α, which is similar to that of SST 
analogues alone 
68. A randomised study with over 100 patients showed there was no 
significant survival benefit of SST analogues with interferon-α  compared to SST 
analogues alone 
69. 
 
 
 
Figure  1.1. The downstream signalling  pathways activated following somatostatin 
binding to the SSTR-2 receptor. 
 
1.6d Chemotherapy 
Chemotherapy has been widely used in the treatment of NETs for over three decades. Its 
precise role is not clearly defined; it is however often used as first line therapy for 
unresectable poorly-differentiated NETs and pancreatic well differentiated NETS, which 
are often chemosensitive. Studies have demonstrated wide variation in response rates  
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with chemotherapy; this may in part be due to inclusion of different types and grades of 
NETs (see Table 1.5). Overall response rate for intestinal carcinoid is <30% 
70-77. 
1.6e Hepatic artery embolization 
 
Metastases from NETs are often predominantly in the liver and therefore embolization 
of the liver can result in necrosis of tumour tissue and consequent decrease in hormonal 
secretion. Embolization is commonly performed radiologically and can be performed 
with particles or chemoembolization. Contraindications to performing hepatic artery 
embolization include; portal vein thrombosis, liver failure, biliary reconstruction and 
poor performance status of patient. Symptomatic response is seen in 40-80% of cases 
78, 
with a biochemical response of 50-75%  for hepatic embolization and 12-75% for 
hepatic chemoembolization 
79 (see table 1.6). A study by Gupta et al, demonstrated no 
additional benefit of TACE (with doxorubicin) to TAE in metastatic midgut tumours. 
Complications post procedure includes ileus, portal vein thrombosis, hepatic abscess, 
hepatic fistula, encephalopathy, and renal insufficiency. 
 
 Hepatic embolization of liver metastases  with 
90Yttrium selective internal radiation 
therapy (SIRT) has been in use for over a decade to treat patients with primary and 
secondary liver cancers 
80. There have been a number of small non-randomised trials to 
assess the role of 
90Yttrium microspheres in NETs liver metastases 
81-83. A study by 
Kennedy et al in 148 patients with unresectable NET liver metastases demonstrated 
stable disease in 22.7%, partial response in 60.5% and complete response in 2.7% 
81. In 
all three small studies Yttrium-90 microspheres has been well tolerated.   
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Table 1.5. Chemotherapy studies performed to date in NETs separated into well 
differentiated and poorly differentiated tumours. s.d= stable disease. Objective response 
is a reduction in tumour size, either partial >25% of tumour volume or complete 
response. STZ, streptozoscin; 5-FU, 5-flurouracil; dox, doxorubicin.  
 
 
 
 
Study  Regimen  No of 
pts 
Objective 
response 
(%) 
Response 
duration 
(months) 
Median 
survival 
(months) 
Well differentiated GEP NETs 
Moertel 
75   STZ 
+cyclophosphamide 
STZ + 5-FU 
 42 
 
47 
33 
 
26 
17 
 
17 
28.4 small bowel 
 
28.4 pancreas 
Moertel 
77  Dox+ STZ 
 
STZ+ 5-FU 
36 
 
33 
69 
 
45 
20  
 
6.9  
26 
 
18 
Eriksson 
70  Dox + STZ 
 
STZ +5-FU 
25 
 
19 
24 
 
11 
22    
Sun 
840)  Dox + 5-FU 
 
STZ+ 5-FU 
85 
 
78 
15.9 
 
16 
4.5  
 
5.3 
 
Kulke 
85  Irinotecan+ cisplatin  18  78 (only 
s.d) 
4.5   11.4 
Kulke 
72  Gemcitabine  18  65 (only 
s.d) 
8.3   11.5 
Rivera 
86  Dox+ STZ+ 5-FU  12  55  15  21 
Kulke 
73  Thalidomide + 
temozolomide 
29  25  13.5    
Poorly differentiated GEP NETs 
Moertel 
76  Etoposide + cisplatin  18  67  8  19 
Mitry 
87  Etoposide + cisplatin  41  42  9  15 
Mani 
88  Irinotecan + cisplatin  20  58  4    
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Study  Type of 
NET 
HACE 
or HAE 
No. of 
patients 
Clinical 
response 
Biochemical 
response 
Radiological 
response  
Rusniewski 
89  Carcinoid  HACE  24  73%  57%  33% 
Therasse 
90  Carcinoid  HACE  23  100%  91%  35% 
Clouse 
91  Carcinoid  HACE  14  90%  69%  78% 
Diaco 
92  Carcinoid  HACE  10  100%    60% 
Roche 
93  Carcinoid  HACE  14  70%  75%  86% 
Kim 
94  Pancreatic 
Carcinoid 
HACE  14 
16 
- 
-  
90% 
75% 
50% 
25% 
Drougas 
95  Carcinoid  HACE  14  66%  100%   
Gupta 
79  Carcinoid 
 
Pancreatic 
HAE or 
HACE 
69 
 
54 
    67% 
 
35% 
Marrache 
96  Carcinoid 
Pancreatic  
HACE  48 
19 
91%  65%  37% 
 
Table 1.6. Response rates to hepatic embolization and chemoembolization.  
HACE; hepatic artery chemoembolization, HAE; hepatic artery embolization. 
Biochemical response is >50% reduction in tumour markers CgA. Radiological response 
is reduction in tumour volume >50% using cross sectional imaging. 
 
1.6f Radionuclide peptide receptor therapy 
The first reports of 
131I-MIBG therapy in NETs were reported in 1994 
97. Since then a 
number of studies have been published showing variable radiological response rates, 
with symptom response between 60-80%, with median duration of response between 6-
24 months 
98-102. Treatment is well tolerated and toxicity is often limited usually to 
temporary myleosupression following therapy.   
 
The over  expression of SSTR-2 has facilitated  the development of targeted peptide 
receptor therapy. The mechanism of action appears to be that the radiopeptide binds to 
SSTR-2 receptor and is internalized to the cell therefore delivering radioactivity. The 
beta emitting radionuclides then irradiate neighbouring tumour cells. Contraindications 
include bone marrow suppression, renal impairment, liver failure, very poor performance  
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status and inability to self care. A number of studies have been published using peptide 
receptor radionuclide therapy, however, the criteria for objective response has varied in 
studies, see table 1.7. Two radiopeptides that are currently in use these are 
90Yttrium and 
177Lutetium. Unfortunately there are no randomised studies of peptide-receptor 
radionuclide therapy, which makes evaluating their true benefit and optimal radionuclide 
difficult. 
 
Kwekkeboom et al recently published the largest series to date of over 500 patients 
treated with 
177Lu-DOTATATE 
103. Of these patients response data was available in 310; 
of which 2% had complete response, 28% partial response, 16% had minor response. 
The median time to progression was 40 months and median overall survival from start of 
treatment was 46 months, median survival from diagnosis was 128 months. The overall 
survival for these patients seems much higher than historic controls were survival was 
usually around 60 months.  
 
The main adverse effect with radiopeptide receptor therapy is related to bone marrow 
suppression and this is usually a cumulative effect, often seen after 3 doses of therapy. 
Other side effects include fatigue, tiredness, nausea and occasionally liver failure. Long 
term impairment of renal function can occur, and therapy is contraindicated in patients 
with poor renal function. Bodei et al, reported a decrease in creatinine clearance of 
between 5-10% in 20 of 23 patients treated with Y
90 at one year post therapy 
104.  
 
1.7 Future therapies 
Understanding the biology of cancer has improved over the last few decades and this has 
led to the development of new potential targets for treatment. There is a new focus for 
‘targeted therapies’ which have had success in other cancers for example Trastuzumab in  
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breast cancer and Imatinib in management of chronic myelogenous leukaemia. With new 
agents being trialled the radiological objective response rates are usually low, however 
disease stabilization and time to progression seem to more useful markers of 
effectiveness of these therapies especially in low grade GEP NETs.  
 
 
Authors  No.                                   Response (%) 
    CR  PR  MR  SD  PD 
Y
90-DOTATOC 
Otte 
105  29  0  2 (7%)  4 (14%)  20 (69%)  3 (10%) 
Waldherr 
106  39  2 (55%)  7 (18%)  n/a  27 (69%)  3 (8%) 
Bodei 
107  29  1 (3%)  7 (24%)  n/a  14 (48%)  7 (24%) 
Valkema 
108  52  0  5 (10%)  7 (13%)  29 (56%)  14 (26%) 
Y
90-Lanreotide 
Virgolini 
109  39  0  0   8 (20%)  17 (44%)  14 (36%) 
Y
90-DOTATATE 
Baum 
110  75  0  28 (37%)  n/a  39 (52%)  8 (11%) 
Lu
177- DOTATATE 
Kwekkeboom 
103  310  5 (2%)  96 (28%)  51 (16%)   107 (35%)  61 (20%) 
 
Table 1.7. Peptide receptor studies looking at different radiopeptides and response rates 
seen in NETs. No., number of cases; CR, complete response; PR, partial response; MR, 
minor response; SD, stable disease; PD, progressive disease.  Criteria for response used 
WHO criteria. 
 
1.7a Tyrosine kinase inhibitors  
The tyrosine kinase  receptor family comprise  approximately 20 different classes 
including platelet derived growth factor receptors (PDGFR), c-kit and epidermal growth 
factor receptor (EGFR); they have become increasingly important as targets for cancer 
treatment. Inhibition of different receptor tyrosine kinases has shown promising results 
in a number of cancers.Currently a number of trials are underway assessing different 
receptor tyrosine kinase inhibitors in NETs.  
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Immunohistochemical studies have demonstrated that PDGF and c-kit receptors are 
expressed in the majority pancreatic NET cells as well as in the stroma 
111. Expression of 
c-kit and PDGF receptors in midgut tumours is less clear with one study showing no 
expression for c-kit and only 38% expressing PDGFR-alpha 
112; other groups have 
shown c-kit expression in midgut carcinoid tumours 
113. There has been one phase II 
study assessing the response rate of Imatinib, a specific tyrosine kinase inhibitor directed 
at the TK domain in abl (the Abelson proto-oncogene), c-kit and PDGF-R (platelet-
derived growth factor receptor). Twenty seven patients with advanced carcinoid tumours 
received Imatinib of which 1 had a partial response,  17 had stable diseases and  9 
progressive with disease. Median progression free survival was 24 weeks and median 
overall survival was 36months 
114. A single agent therapy shows only a modest effect, 
possibly combination with other therapies could improve the effect.  
 
EGFR is a member of the HER family of transmembrane tyrosine kinase receptor. It is 
involved in the pathophysiology of a number of malignancies. EGFR and pEGFR has 
been shown to be over expressed in NETs 
115, pEGFR expression has been associated 
with worse survival in patients with pancreatic endocrine tumours 
116. A phase II study 
of gefitinib (EGFR inhibitor) in patients with progressive metastatic NETs (57 carcinoid 
tumour and 39 islet cell carcinomas) showed a modest treatment response with 3 cases 
having a partial response and 2 minor response by radiological criteria and progression 
free survival at 6 months was 61% in carcinoid tumour group and 31% in islet cell 
carcinoma 
117. As a single agent although well tolerated this therapy has limited effect.  
 
Sunitinib malate, an oral tyrosine kinase inhibitor with action against all VEGFRs, 
PDGFR, stem-cell factor receptor and FMS-like tyrosine kinase-3 was studied in a phase  
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II trial. One hundred and seven patients received Sunitinib with overall response rate of 
16.7% and 68% stable disease, median time to progression was 7.7 months for 
pancreatic NET and 10.2 for carcinoid patients 
118. In view of this response a further 
randomised study  to assess Sunitinib have been undertaken with good responses 
identified in the patients with well differentiated pancreatic NETs 
119.   
 
Sorafenib, a small molecule inhibitor of Raf kinase, VEGFR-2 and PDRGFR-β tyrosine 
kinase domains is being explored in patients with metastatic NETs. Preliminary results 
available in 41 patients showed partial responses in 10% and minor responses in 29% of 
cases. However, 43% of patients developed grade 3-4 toxicity. Further studies using 
Sorafenib in conjunction with cyclophosphamide are currently underway.  
 
Other trials are currently in progress assessing other VEGF inhibitors 
120;121; this includes 
PTK787/ ZK222584 (PTK/ZK), an oral angiogenesis inhibitor which selectively blocks 
VEGF receptor tyrosine kinase signalling from all known VEGFRs. Twenty patients 
have been enrolled in a phase II, open label study. All had progressive disease prior to 
enrolment and following therapy 50% had achieved stable disease at 6 months and 27% 
at 1 year, median time to progression was 7 months. There were no complete or partial 
responses by radiological criteria. However, seven  patients stopped therapy due to 
adverse effects 
121. It appears to have some antiproliferative activity inducing disease 
stabilization. 
 
1.7b Tyrosine kinase antibody inhibitors  
Angiogenesis is essential for the growth of tumours; the process of new blood vessel 
development is complex with a number of pro- and anti-angiogenic factors involved.  
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Angiogenic inhibitors are able to block pathways and factors and thereby directly or 
indirectly inhibit tumour growth. Vascular endothelial growth factor (VEGF) is a potent 
promoter of angiogenesis and is expressed in NETs. Studies looking at VEGF 
expression in NETs found its expression to be present in low grade well differentiated 
NETs, however, loss of VEGF expression was noted in poorly differentiated tumours. A 
phase II study of Octreotide plus bevacizumab or octreotide plus PEG interferon, found 
that 18% (n=4) in the bevacizumab arm had partial response and 95% no progression at 
18 weeks compared to one partial response with PEG interferon and 68% progression 
free survival at 18 weeks. So it appears progression free survival was better in patients 
on bevacizumab 
122. Currently studies are underway using bevacizumab in combination 
with other therapies. A phase II study using bevacizumab and temozolomide has shown 
promising early results 
123. Another study looking at capecitabine, oxaliplatin, and 
bevacizumab is still recruiting but shows this combination appears to be generally well 
tolerated; of the 13 patients enrolled 4 have achieved partial response and 6 stable 
disease 
74.  
 
1.7c mTOR inhibitors 
Mammalian target of rapamycin (mTOR) is a threonine kinase that regulates cell growth 
and also mediates signalling to key downstream receptors including IGF receptor and 
EGFR. mTOR is thought to play a role in sporadic NETs as well as pancreatic islet cell 
tumours in patients with tuberous sclerosis 
124.  Studies in pancreatic neuroendocrine cell 
lines (BON-1) have shown that rapamycin inhibits mTOR leading to decreased IGF-1 
and neuroendocrine tumour cell growth 
125.  
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Temsirolimus was trialled as a single agent in a phase II study where it had modest 
effects. Thirty seven patients with advanced NETs and evidence of progressive disease 
were treated on an intention to treat basis.  Partial radiological response occurred in 2 
cases (5.6%) and disease stabilization in 21 (58.3%); median time to progression of 6 
months 
126. A number of patients suffered from fatigue, hyperglycaemia and rash.  
 
Yao et al, recently published the results of a phase II study using  everolimus and 
Sandostatin LAR in patients with advanced NET. They observed a response rate of 20% 
in the 60 patients enrolled, 70% achieved stable disease, the overall median progression 
free survival was 60 weeks, and survival at 3 years is 78% 
127.  These promising results 
have led to two everolimus trials, RADIANT-1 and RADIANT-2.  RAD001 In 
Advanced
 Neuroendocrine Tumors-1 is an open label, stratified, single-arm phase II 
study
 of everolimus in patients with advanced pancreatic NETs having
 failed previous 
cytotoxic chemotherapy. RADIANT-2 is a randomised double-blind, placebo controlled, 
multi-centre phase  III study of octreotide combined with everolimus or placebo in 
patients with advanced NETs.  
 
1.7d Immunotherapy 
The aim of T-cell immunotherapy is to enhance the immune response against tumour-
associated antigens; several different approaches are currently being trialled. The ideal 
response will be to create a therapy that targets tumour cell with minimal effects on 
normal tissue. Dendritic cells are regarded as ‘professional’ antigen presenting cells and 
dendritic cell based immunization can lead to immune memory 
128. Dendritic cells play a 
central role in the initiation and regulation of immune responses. This action has been 
utilized to present tumour material to cytotoxic T cells.  
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Only small case series using immunotherapy have been published in NETs. A study by 
Scholt in three patients with pancreatic NETs showed evidence of biochemical response 
and no tumour progression at 20 months post therapy 
129. In a study of 20 patients with a 
variety of different cancers including 4 patients with NETs, patients were administered 
dendritic cell therapy with adjuvant interleukin-2 for 12 days post therapy 
130. Survival 
for the patients with NETs ranged from 4-32 months. Other potential immunotherapy 
techniques include genetically engineered T-cells with altered functions to enable them 
to target tumour tissue 
131. 
 
1.8 Tumour angiogenesis 
Angiogenesis is essential for tumour development and is thought to arise secondary to an 
increase in proangiogenic factors within tumours that leads to development of a vascular 
network which is essential for tumours to grow beyond 2-3mm 
132. A number of 
different angiogenic factors have been described which seem to interact in a number of 
complex pathways. It is now assumed that the critical event in the regulation of 
angiogenesis is the signalling  cascade involving vascular endothelial growth factor 
(VEGF). This conclusion is based first of all on the biological properties of this growth 
factor; as VEGF has been shown to induce angiogenesis in both in vivo and in vitro 
models 
133;134. In addition to the VEGF signalling  system the angiopoietins/ Tie2 
receptor system is necessary for vascular system development in embryogenesis 
135(see 
Figure 1.2).  
 
VEGF and angiopoietins are factors that have been extensively studied in certain 
cancers. VEGF expression has been demonstrated in NETs using 
immunohistochemistry. However, to date there are no reports regarding the expression  
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or role of angiopoietins in NETs. The angiopoietin family is comprised of four members 
Angiopoietin-1 to Angiopoietin-4.  
 
 
 
 
Figure 1.2.  Postulated pathways of action of Ang-1 and Ang-2. Ang-2 blocks the 
binding of Ang-1 to the Tie-2 receptor. This leads to inhibition of the survival and anti-
inflammatory actions which are normally triggered by Ang-1 ligand binding.  
 
Most research to date has focussed on Angiopoietin-1 (Ang-1) and Angiopoietin-2 
(Ang-2), which have both been demonstrated to bind to Tie-2 receptor.  It appears that 
Ang-2 blocks the binding of Ang-1 to Tie-2, which consequently promotes angiogenesis. 
However, the true interaction of these factors and consequent downstream effects are 
thought to be much more complex. Studies have demonstrated induction and up-
regulation of Tie-2 and Ang-2 expression in endothelial cells are regulated by hypoxia 
and proinflammatory cytokines, such as TNF-α 
136;137. These same stimuli down-regulate  
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the expression of Ang-1, this suggests an inverse relationship between Ang-1 and Ang-2 
138.  
 
In the era of targeted therapies a number of studies in NETs have demonstrated good 
response in terms of disease stabilization using angiogenic inhibitors, such as 
Bevacizumab. As part of this thesis serum Ang-1 and Ang-2 have been measured and 
compared in patients with NETs to the circulating concentrations in control subjects.  
 
1.9 Cellular receptors and targeted therapy in NETs 
Chemotherapy and radiotherapy show limited efficacy in most patients with midgut 
NETs. Pancreatic tumours are relatively chemo-responsive with a 40-65% reported 
response rate; whilst mid-gut NETs have a response rate of 20-30%. The low response to 
traditional therapies has led to development of targeted therapies in NETs. Following the 
success of Imanitinib in chronic myeloid leukaemia and gastrointestinal tumours, 
targeted therapies offer a new avenue for potential therapy.  
 
NETs are known to express SST receptors 1-5 in differing concentrations and this has 
led to development of somatostatin analogues to control symptoms and tumour 
progression in patients. Recently studies have demonstrated that other G-protein coupled 
receptors specifically dopamine receptors can dimerize with each other as well as with 
SST receptors leading to augmentation of their effect. This has led to development of 
chimeric molecules to target both the dopamine-2 receptor and the SST-2 receptor. The 
expression of dopamine-2 receptors in NETs using immunohistochemistry has not been 
reported previously. A study was performed to determine whether dopamine and 
somatostatin receptors are co-expressed in NETs.  
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The Epidermal growth factor receptor (EGFR) family of receptors comprise of 4 
members, EGFR, HER-2, HER-3 and HER-4. Of these the most extensively studied are 
EGFR and HER-2, both of which have been shown to have important roles in 
oncogenesis. Over expression of HER family receptors is associated with reduced 
survival in patients with breast, colon and ovarian cancer 
139-143.  
 
The four HER receptors share structural homology which includes two cysteine-rich 
regions in their extracellular domain,  and a kinase domain flanked by the  carboxy-
terminal tail which possesses tyrosine autophosphorylation sites. HER-3 is devoid of 
intrinsic kinase activity, whilst HER-2 seems to have no direct ligand 
144-146. Hetero- or 
homo-  dimerism is required for initiation of downstream signalling pathways; since 
HER-2 has no direct ligand it often heterodimerizes with EGFR or HER-3. To date, ten 
genes have been identified to encode ligands to this group of receptors. Epidermal 
growth factor, amphiregulin and Transforming growth factor α bind EGFR specifically, 
whilst neuregulins bind HER-3 and HER-4. Betacellulin, epiregulin bind to both EGFR 
and HER-4. Ten possible homo- and hetero- dimers can be formed from HER receptors 
146.   
 
Inhibition of HER-2 receptor in breast cancer using Trastuzumab a humanised 
monoclonal antibody specific to HER-2 has demonstrated improved prognosis in 
patients with HER-2 positive breast cancer-  HER-2 staining identified using 
immunohistochemistry. EGFR inhibition with cetuximab in conjunction with 
radiotherapy in head and neck cancers demonstrated improved prognosis compared to 
radiotherapy alone.  
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It is well established that growth factor binding to the extracellular region of EGFR 
promotes dimerization of the monomeric receptor and increases the tyrosine kinase 
activity of its intracellular domain 
147 (Figure 1.3). Receptor molecules in the ligand-
induced EGFR dimer become tyrosine autophosphorylated. The resulting 
phosphotyrosines recruit the SH2 domains of multiple downstream signalling molecules, 
thus initiating an array of intracellular signalling pathways (Figure 1.4).  
 
Figure 1.3. EGFR receptor and downstream pathways 
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Figure 1.4. Schematic diagram showing EGFR family receptor pathways (from Cell 
signalling technology).  
 
1.10 Rationale of Thesis 
The first part of this thesis was focussed on identifying new therapeutic targets to help in 
the management of NETs. Two experiments were performed the first studied expression 
of the somatostatin and dopamine family of receptors in NETs using 
immunohistochemistry. Somatostatin analogues have been used for symptomatic control 
for over two decades, and there is evidence to suggest they have  anti-proliferative 
actions. The mechanisms underlying this are complex and a number of different 
pathways have been postulated. Recently studies have shown dimerization of SSTR-5 
and D2R as well as SSTR-2 and D2R following activation by ligands to both dopamine 
and SSTR-2 and SSTR-5 receptors. Development of chimeric molecules which bind 
both SSTR and D2R receptors have shown promising results in cell lines and also  
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patients with pituitary adenomas. Co-expression of SSTR and D2R receptors in NETs 
has not previously been demonstrated. Therefore, an immunohistochemical study was 
undertaken looking at SSTR-2, SSTR-5 and D2R expression in NETs.  
 
The second study was to examine the HER family of receptors. HER family comprises 
four receptors (EGFR, HER-2, HER-3, HER-4). EGFR and HER-2 are both known to be 
essential in oncogenesis and targeted therapies are now available to inhibit these 
receptors. As mentioned earlier studies have examined EGFR and HER-2 expression in 
NETs  but no studies have examined  all members of the HER family. There is no 
evidence regarding whether expression of the HER family of receptor is associated with 
poorer prognosis 
 
In addition to identifying novel markers, serum analysis of angiopoietins was performed 
in patients with NETs and healthy controls to determine whether angiopoietins were 
raised in patients. Furthermore, analysis was performed to determine whether 
angiopoietins provide any prognostic information 
 
Identification of new biomarkers in NETs is required due to the lack of prognostic and 
diagnostic markers currently available. Whilst CgA is widely used marker, its role is 
limited in providing prognostic information and dependent on the specific assay used. 
Therefore the second part of this thesis is focussed on aiming to identify new diagnostic 
tools for  the management of NETs; specifically aimed at developing new potential 
biomarkers for identification and prognostication of disease, evaluating new radiological 
techniques and finally to demonstrate dual expression of somatostatin and dopamine-2 
receptors in NET, since this may provide a potential new therapeutic options. 
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Determination of new biomarkers was achieved using proteomic techniques focussed on 
plasma and NET cell lines. A number of different proteomic approaches are available for 
analysis of different media; this study used 2-D gel electrophoresis with MS/MS for 
analysis of plasma. For analysis of conditioned media from NET cell lines, 1-D gel 
electrophoresis and MS/MS was used. The use of plasma and cell lines for identifying 
potential markers of cancer has been well validated in previous studies. 
 
Currently a combination of nuclear medicine and traditional cross sectional imaging 
techniques are employed in aiding in the diagnosis of NETs. Two nuclear medicine 
scans currently used are 
111In-DTPA-octreotide scintigraphy and 
123I-MIBG. However, 
as described earlier neither  of these techniques are a  100% sensitive  nor specific. 
Furthermore, positive uptake with 
111In-DTPA-octreotide  scintigraphy is used to 
determine the treatment with peptide receptor targeted therapy. The advent of 
68Ga-
DOTATATE PET offers a new imaging modality for identifying SSTR-2 positive 
tumours. The clinical benefit of this technique over 
111In-DTPA-octreotide scintigraphy 
has yet to be elucidated.  A study was performed to compare the total number of lesions 
identified using 
68Ga-DOTATATE PET in patient with negative or equivocal uptake on 
111In-DTPA-octreotide scintigraphy and whether clinical management is altered.  
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Chapter 2: Expression of somatostatin and dopamine 2 receptors in 
neuroendocrine tumours. 
 
Abstract 
 
Introduction: Somatostatin and dopamine receptors are both G-protein coupled 
receptors. Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been 
well characterised. There is evidence of dopamine receptor expression in neuroendocrine 
tumours. This study examined expression of D2R and SSTR-2 and SSTR-5 receptors 
using immunohistochemistry in tumour tissue from patients with neuroendocrine 
tumours.  
 
Methods: Consecutive samples of formalin-fixed paraffin-embedded tumour tissue were 
available from 56 patients with a histologically confirmed diagnosis of neuroendocrine 
tumour (NET). The study population was divided into low grade (n=29), intermediate 
grade (n=18) and high grade (n=9). Immunohistochemical evaluation was performed for 
the expression of SSTR-2a, SSTR-5 and D2 receptors (D2R).  
 
Results: Both SSTR-2 and SSTR-5 were expressed in 100% of low grade, 94.4% of 
intermediate grade and 66.7% of high grade NETs. D2R was expressed in 93.1% low 
grade, 77.8% intermediate and 44.4% of high grade tumours. Co-expression of all three 
receptors was present in 93.1% of low grade tumours. There was an inverse correlation 
of SSTR-2 (r=-0.380, p<0.005) and SSTR-5 (r=-0.472, p<0.0001) with tumour grade. 
D2R was positively correlated with SSTR-2 (r=0.269, p=0.041) and SSTR-5 (r=0.267,  
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p=0.045). Also D2R expression was inversely correlated with grade of tumour (r=0.395, 
p=0.006). Octreoscan correlated with SSTR-2, SSTR-5 and D2R receptor expression.  
 
Conclusion: Dopamine-2 receptor is expressed in the majority of low and intermediate 
grade tumours. It is co-expressed with SSTR-2 and SSTR-5 in the majority of cases. The 
advent of new chimeric molecules that bind both somatostatin and dopamine receptors 
may provide a new therapeutic option in the management of neuroendocrine patients. 
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2.1 Introduction  
The somatostatin and dopamine systems constitute two major receptor networks that 
share similar structural features 
148. Both families of receptors are G-protein coupled 
membrane receptors. There are five subtypes of somatostatin receptor (SSTR) which 
have been characterised to date 
149;150. Neuroendocrine tumours (NETs) are known to 
over express SSTR most commonly SSTR-2 and SSTR-5. SSTR-1 and SSTR-3 are 
expressed less frequently, whilst SSTR-4 is only occasionally expressed in NETs 
151-153. 
There is some heterogeneity with regards to SSTR receptor expression, dependent in part 
on the type of tumour. Somatostatin plays an important role in controlling cell function 
including inhibition of hormone release, neurotransmission and angiogenesis 
154;155. 
Over time there is evidence of tolerance to somatostatin analogues and some loss in their 
efficacy 
156.  
 
Currently five dopamine receptors have been cloned and characterised. They modulate 
activity of adenylate cyclase via G-proteins 
157;158. Generally dopamine receptors (DR) 
are sub-divided to two subfamilies, the DR1-like (DR1 and DR5) and the D2R-like 
(D2R, DR3 and DR4). Co-expression of dopamine and somatostatin receptors in 
endocrine tumours including pituitary tumours has been demonstrated 
159. Expression of 
dopamine receptor-2 (D2R) and SSTRs has been demonstrated in BON-1 a pancreatic 
neuroendocrine cell line 
160. A study of SSTR and D2R  co-expression in 35 
gastroenteropancreatic tumours using RT-PCR demonstrated  SSTR-1, SSTR-2 and 
D2R receptor expression in all cases 
65. Pivonello et al, have demonstrated D2R receptor 
expression in 10 of 10 cases of NETs, however, in two of these cases staining was very 
weak 
161. New chimeric somatostatin-dopamine compounds such as BIM-23A387 have 
shown promising results in vitro studies in pituitary adenomas and lung carcinoma cell 
lines.   
  63 
 
The aim of this study was to demonstrate,  using immunohistochemistry,  whether 
somatostatin and dopamine receptors are co-expressed in NETs and whether there is any 
difference in expression between different grades of NETs 
159;162.  
 
 
2.2 Materials and Methods 
Consecutive samples of formalin-fixed paraffin-embedded tumour tissue were available 
from 56 patients with a histologically confirmed diagnosis of neuroendocrine tumour. 
All cases had been assessed for grade of tumour; including Ki67 proliferation index 
and/or number of mitoses per 10 high power fields were available in all cases. Of the 
tumour samples 39 were surgical specimens from patients who had undergone tumour 
resection. The remainder were from tumour biopsies. The study population included all 
major NET subtypes including: foregut (n=20), midgut (n=25), hindgut (n=3), ovarian 
(n=1) and NETs of unknown primary (n=7). Tumours were graded using the system 
proposed by ENETS consensus group 
18;21;163. Using this classification low grade tumour 
was regarded as mitotic count  ≤ 2 per 10 high power fields (HPF) and Ki67  ≤2%, 
intermediate grade as having a mitotic count 2-20 per 10 HPF and Ki67 2-20% and high 
grade as mitotic count of >20 per 10 HPF, Ki67 >20 and appropriate poorly 
differentiated tumour morphology. Twenty nine patients had a low grade tumour, 18 
were intermediate grade and 9 high grade tumours. The proposed criteria currently only 
encompasses GEP NETs, however, for the purpose of this study tumours of unknown 
primary, ovarian and bronchial NETs were graded using the same criteria. The study 
was performed under the auspices of the Royal Free Hospital Pathology Department 
ethics recommendation for the studies of archive histology samples. Clinical details  
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including sex, age at diagnosis and previous nuclear medicine imaging was collected 
where available.  
 
3 micrometer sections of tumour tissue were dewaxed three times in xylene and 
rehydrated in ethanol. Endogenous peroxidase activity was blocked by incubation in 1% 
hydrogen peroxide and diluted in acetone, for 10 minutes. For SSTR-2a and dopamine 2 
receptor staining, slides were submersed in 10mM citric acid (pH=6.0) for 10 minutes in 
microwave at 600w, then cooled immediately in water. Slides for somatostatin 5 were 
submersed in 10mM citric acid (pH=6.0) for 20 minutes in microwave at 600w; then left 
to cool at room temperature for 20 minutes.  Following which all specimens were 
washed in TBS-Tween. All slides were blocked with normal serum for 30 minutes.  
 
Primary antibodies comprised: anti-SSTR2a antibody (SS-800) a polyclonal rabbit 
antibody raised against the c-terminus of human SSTR-2a receptor (Gramsch 
Laboratories, Germany). Anti-SSTR-5 antibody (SS-890) a polyclonal rabbit antibody 
raised against the c-terminus of the human SSTR-5 receptor (Gramsch Laboratories, 
Germany). Anti-D2R  antibody (NLS-1403) a polyclonal rabbit antibody (Novus 
Biologicals, USA). Sections were incubated with anti-SSTR2a 1:800 for 1 hour, anti-
SSTR5 1: 800 with 1% bovine serum albumin as antibody diluent and incubated 
overnight. Anti-D2R 1:600 with 0.2% bovine serum albumin as antibody diluents and 
incubated overnight.   
 
For  D2R  and SSTR-5 slides biotinylated secondary antibody was used with slides 
incubated for 30mins. The antibody binding was visualized using a DAB peroxidase 
substrate kit. The sections were counterstained with Mayer’s haematoxylin for 3.5  
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minutes. For SSTR-2 slides envision polymer kit was used and antibody binding was 
visualised using a DAB peroxidise substrate kit. 
 
Positive controls for anti-SSTR-2a and anti-SSTR-5 were pancreatic tissue; negative 
controls included substitution of the primary antibody with normal sera. Positive 
controls for D2R included bowel tissue; negative controls included substitution of the 
primary antibody with normal sera.  
 
2.2a Histological interpretation  
Tumours were classified according to their site of origin, degree of differentiation and 
their initial mitotic index. Two examiners (R.S and J.W) performed the interpretation of 
immuno-histological staining for the antibodies studied, independently of each other. 
Any discordant results were then reviewed together to reach agreement or determine an 
average value for disputed sections. At time of interpretation neither examiner was 
aware of the histological grade of the tumour or the results from staining of other 
receptors. Scoring was based on intensity of staining whereby 0= negative, 1= weakly 
positive, 2= moderate, 3= strongly positive. The extent of tumour staining was also 
scored, whereby 10 random high power fields were assessed and the average percentage 
of positive staining cells in which: 1= <25%, 2= 25-75% and 3=>75%. The product of 
the density of staining and the percentage of tumour cells staining positive was used as 
the immunohistochemical score, giving final values of 0,1,2,3,4,6,9 
164. Scores of 0 were 
counted as negative, 1-2 weak staining, 3-4 moderate staining and 6-9 strong staining.  
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2.2b Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com.  Spearman’s 
correlation test for nonparametric data was performed to reveal any relationships 
between receptors studied: SSTR-2, SSTR-5 and DR-2, tumour grade (low, intermediate 
and high), anatomical site of primary tumour and Octreoscan result. 
 
2.3 Results 
Fifty six tumour samples were examined, 25(44.6%) from males and 31 (55.4%) from 
females (Table 2.1). The median age of patients at diagnosis was 56.5 years (18-80). All 
samples had a histologically confirmed diagnosis of NET. Overall, 52 of 56 (92.9%) 
patients expressed SSTR-2; the staining was predominantly membranous with some 
cytoplasmic staining of the tumour cells. Fifty two of 56 (92.9%) cases were positive for 
SSTR-5 again staining was predominantly membranous and slight cytoplasmic staining. 
Forty five of 56 (80.3%) cases stained positive for DA2R receptor, tumour cells 
displayed both membranous and cytoplasmic staining (Figure 2.1). 
 
 
Table 2 .1. Characteristics of the patients, grade and origin of tumours.  
 
  Low 
grade 
Intermediate grade  High grade  Total 
Male  16  5  4  25 
Female  13  13  5  31 
Total  29  18  9  56 
Median age (range)  60 (18-
78) 
62 (22-75)  44.5 (34-80)  56.5 (18-80) 
Location of primary         
Foregut  9  6  5  20 
Midgut  17  7  1  25 
Hindgut + ovarian  1  2  1  4 
Unknown  2  3  2   7  
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In low grade tumours: SSTR-2 staining was positive in 29/29 (100%), of which 22 
(75.9%) had strong staining (IHC score ≥6). SSTR-5 was positive in 29/29 (100%), of 
which 22 (75.9%) exhibited strong staining. D2R was positive in 27/29 (93.1%) cases, 
of which 19 (65.5%) had strong staining, see Figure 2.2a.  
 
In intermediate grade tumours: SSTR-2 was expressed in 17/18 (94.4%), of which 9 
cases (50%) has strong staining. SSTR-5 was expressed in 17/18 (94.4%) samples, of 
which 11 (61.1%) exhibited strong staining. D2R was expressed in 14/18 (77.8%) 
samples, of which 7 cases (38.9%) had strong staining, Figure 2.2b. 
 
In high grade tumours: SSTR-2 was expressed in 6/9 (66.7%), of which 3 (33.3%) 
exhibited strong staining, SSTR-5 was expressed in 6/9 (66.7%) of which 2 cases 
(22.2%) showed strong staining. D2R receptor was expressed in 4/9 (44.4%) strong 
staining seen in 1 (11.1%) of cases, Figure 2.2c.  
Co-expression of all three receptors was seen in 93.1% of low grade tumours and 72.2% 
of intermediate and only 33.3% high grade tumours. Only in two cases was staining for 
all three receptors negative, one was a large cell neuroendocrine carcinoma of the lung 
and the other a high grade colonic NET. There was no difference in pattern of receptor 
expression dependent on primary site of tumour, see Table 2.2. The specific staining 
patterns seen in tumours of different primary sites and tumour grades are shown in Table 
2.2.  
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Figure 2. 1. Immunohistochemical staining of SSTR-2,SSTR-5 and D2R in NETs. A) 
SSTR- 2 staining in an ileal NET, predominantly membranous with some cytoplasmic 
staining of tumour cells, x 200 magnification.  B) SSTR-5 staining shows predominantly 
membranous with some cytoplasmic staining, x 200 magnification. C) Dopamine-2 
receptor staining shows predominantly membranous staining, x200 magnification. 
Images A to C are consecutive slides from same patient. D) SSTR-2 staining in low 
grade NET, shows strong membranous staining, x 400 magnification. E) SSTR-5 
staining in NET, strong membranous staining, x 400 magnification. F) D2R staining in 
NET, marked membranous staining and some cytoplasmic staining, x 400 magnification.  
  
  69 
0
2
4
6
8
10
12
14
16
0 1 2 3 4 6 9
IHC score
N
o
.
 
o
f
 
c
a
s
e
s
SST-2
SST-5
DA-2
 
0
1
2
3
4
5
6
7
0 1 2 3 4 6 9
IHC score
N
o
.
 
o
f
 
c
a
s
e
s
SST-2
SST-5
DA-2
 
0
1
2
3
4
5
6
0 1 2 3 4 6 9
IHC score
N
o
.
 
o
f
 
c
a
s
e
s
SST-2
SST-5
DA-2
 
Figure 2.2.  Bar charts demonstrating strength of staining for SSTR and D2R. A) 
Breakdown of tumour samples according to the overall score for immunohistochemical 
staining in low grade tumours. The method for creating a immunohistochemical score is 
described in the methods. B)  Immunohistochemical scores for intermediate grade 
tumours. C) Immunohistochemical score for high grade tumours, it can be seen a large 
number of these cases are negative or weak staining for all three antibodies. 
A 
B 
C  
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There was strong positive correlation between SSTR-2 and SSTR-5 receptors (r, 0.625 
p<0.001) and also SSTR-2 and SSTR-5 expression correlated with positive Octreoscan, 
see Table 2.3. In addition grade of tumour was inversely correlated (i.e. low grade 
tumours had high SSTR expression and high grade had lower SSTR expression) with 
SSTR-2 (r =– 0.38, p<0.005) and SSTR-5 (r = -0.0472, p< 0.005). D2R was positively 
correlated with SSTR-2 (r = 0.269, p< 0.05) and SSTR-5 expression (r = 0.267, p 
<0.05). D2R expression was also inversely correlated with tumour grade (r= -0.357, p 
<0.005). Octreoscan reports were available in 29 cases, there was a positive correlation 
between D2R expression and positive Octreoscan (r=0.395, p<0.05).  
 
2.4 Discussion 
This study has demonstrated co-expression of SSTR-2, SSTR-5 and D2R in a wide 
variety of NETs using immunohistochemistry. Overall expression of D2R expression 
was in 80.3% of cases, with significantly higher expression in low grade compared to 
intermediate and high grade NETs. Both SSTR-2 and SSTR-5 receptor expression was 
identified in 92.9% of cases, with higher expression seen in low and intermediate grade 
tumours compared to high grade tumours. Immunohistochemical and RT-PCR studies 
have shown similar levels of SSTR expression in NETs 
165. Furthermore, lower SSTR-2 
and SSTR-5 expression has been demonstrated in higher grade tumours 
166. This 
correlates with negative somatostatin receptor scintigraphy seen in these patients. Papotti 
illustrated there was >90% correlation between IHC and RT-PCR in identification of 
SST 2,3 and 5 receptors 
165.  
 
Contrary to a previous study 
65 indicating 100% D2R expression in 36 NETs using RT-
PCR  this study found lower levels of receptor expression and also a difference in  
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expression between high and low grade tumours a finding not previously described. This 
could be due to a number of reasons; possibly related to low concentrations of receptor 
expression in these specimens which were below the threshold of detection by 
immunohistochemistry or that D2R is not expressed in all NETs.  
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Table 2.2. SSTR-2, SSTR-5 and D2R receptor expression in NETs. Grade of tumour 
was based on proposed ENETS classification (see methods). +ive, is number of positive 
cases for which staining was seen with specific antibody. Score, is based on the 
histological score calculated from intensity of staining and area of tumour stained (see 
methods). Octreotide scan was performed in some patients total number is listed in 
column (Octreotide scan) and the number positive is listed in +ive scan column.  
 
Location  Grade/ Type  Total 
Cases 
    SSTR-2    SSTR-5 
 
    D2R              Octreotide 
Scan 
+ive 
scan 
    +ive  Score  +ive  Score  +ive  Score     
Bronchial  A.C/  INTER  1  1  4  1  6  1  3  1  1 
  LCNEC/HIGH  2  0    1  4  0    1  0 
Gastric  LOW  1  1  9  1  9  1  6  0  n/a 
  INTER  1  1  2  1  6  1  2  0  n/a 
  HIGH  1  1  6  1  6  0  0  1  0 
MTC  LOW  2  2  4-9  2  4-9  2  4  1  1 
Pancreatic  LOW  6  6  4-9  6  6-9  5  4-9  4  4 
  INTER  2  2  4  2  6-9  2  4-6  2  2 
  HIGH  3  2  2-6  2  4  1  2  2  2 
Duodenal  LOW  1  1  3  1  6  1  9  0  n/a 
Ileal  LOW  14  14  1-9  14  4-9  14  1-9  11  11 
  INTER  7  7  3-9  7  4-9  7  4-6  3  3 
  HIGH  1  1  6  0    0    0  n/a 
Colon  LOW  3  3  6-9  3  4-9  3  3-9  1  1 
  INTER  2  2  2  2  4  1  9  1  1 
  HIGH  1  0    0    0    0  n/a 
Ovarian  INTER  1  1  9  1  9  1  6  1  1 
Unknown  LOW  2  2  4-6  2  6  1  2  0  n/a 
  INTER  3  3  6-9  3  4-6  1  4  0  n/a 
  HIGH  2  2  1-3  2  2-6  2  3-6  0  n/a  
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     SSTR-2  SSTR-5  D2R 
SSTR-2  Correlation Coefficient    0.625  0.269 
   Sig. (2-tailed)    <0.0001  0.041 
SSTR-5  Correlation Coefficient  0.625    0.267 
   Sig. (2-tailed)  <0.0001    0.045 
Grade  Correlation Coefficient  -0.380  -0.472  -0.357 
   Sig. (2-tailed)  0.003  <0.0001  0.006 
Octreoscan  Correlation Coefficient  0.803  0.360  0.395 
   Sig. (2-tailed)  <0.0001  0.043  0.025 
Location  Correlation Coefficient  0.803  0.360  0.395 
  Sig. (2-tailed)  1.00  0.108  0.958 
 
Table 2.3. Correlation Table for SSTR-2, SSTR-5 and D2R receptor expression and a 
number of other parameters. Correlations were performed using a Spearman non-
parametric correlation test. Significant results are in bold text, with p value <0.05. 
Tumour grade is inversely correlated with receptor expression.  
 
In this study there was a significant difference in SSTR-2, SSTR-5 and D2R expression 
between low and high grade tumours. This may be in part because high grade tumours 
are poorly differentiated and loose SSTR expression. In this study we did not identify 
any significant difference between receptor expression in pancreatic and midgut NETs.  
 
Strong correlation between SSTR2 receptor staining using immunohistochemistry and 
somatostatin scintigraphy has been reported 
149. In this study positive 
immunohistochemical staining of D2R was also correlated with positive Octreoscan 
findings, which is unsurprising since the high concentration of co-expression of SSTR-2 
and D2R receptors. Since the majority of low and intermediate grade tumours co-express 
somatostatin and D2R, patients with positive somatostatin scintigraphy could potentially 
find benefit from therapy with new chimeric agents with affinity for SSTR and D2R 
receptors perhaps without the need for additional testing for D2R expression.  
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A number of different chimeric molecules combining somatostatin and dopamine 
receptor agonists have been developed. Promising results with in vitro studies have been 
observed with BIM-23A387 which has affinity for SSTR2 and D2R and BIM-23A760 
with affinity for SSTR-2, SSTR-5 and D2R 
167. These chimeric compounds that bind 
both dopamine and SSTRs have also shown encouraging results in vivo and in vitro with 
pituitary adenomas 
168;169.  The lower expression of D2R in intermediate/high grade 
NETs could be an important factor when determining possible sensitivity of these 
tumours to treatment with new chimeric somatostatin-dopamine compounds.  
 
In conclusion this study has demonstrated co-expression of D2R and SSTR-2 and SSTR-
5 in NETs, with higher expression of D2R in low grade rather than high grade NETs.  
 
 
 
C  
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Chapter 3: Expression of the HER 1-4 family of receptor tyrosine 
kinases in Neuroendocrine Tumours 
 
Abstract 
 
Introduction: The type I receptor tyrosine kinase family comprises four homologous 
members: Epidermal growth factor receptor (EGFR), HER-2, HER-3 and HER-4. 
Studies have shown that EGFR and HER-2 play a critical role in oncogenesis. This study 
sought to determine the pattern of expression and the prognostic significance of EGFR, 
HER-2, HER-3 and HER-4 in variety of neuroendocrine tumours using 
immunohistochemistry. 
 
Methods: Receptor expression in 82 paraffin embedded specimens of neuroendocrine 
tumours was studied using immunohistochemistry. The pattern and protein expression 
concentrations for each receptor were correlated with clinical and pathological 
parameters. 
 
Results: EGFR expression was identified in 86.6% samples, HER-2 was not expressed in 
any samples, HER-3 was expressed in 8.5% samples and HER-4 was expressed 91.5%. 
EGFR and HER-4 were co-expressed in 79.3% of cases. HER-3 was correlated with 
better survival. EGFR was not associated with poor prognosis.  
 
Discussion: EGFR, HER-2 and HER-4 expression is not associated with poorer survival. 
HER-3 expression is correlated with better prognosis. Over expression of EGFR and 
HER-4 may offer potential new therapeutic targets.  
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3.1 Introduction 
The HER family is comprised of four distinct receptors: EGFR, HER-2, HER-3 and 
HER-4. These are transmembrane receptors composed of an extracellular ligand-binding 
domain and a cytoplasmic region with enzymatic activity 
146;170. To transduce signals the 
receptors need to either hetero- or homo-dimerize following ligand binding 
170.  HER 
receptor phosphorylation activates a cascade of signalling pathways that include 
controlling apoptosis via PKB/Akt and mitogenic pathways via Ras/ MAP kinase 
171. 
These routes are thought to regulate cellular growth differentiation, proliferation, 
angiogenesis and apoptosis.  
 
Development of humanized antibodies against EGFR and HER-2, have enabled 
inhibition of the downstream signalling pathways, consequently leading to improved 
survival in these patients 
115;172. EGFR inhibition by humanised anti-EGFR antibodies 
(e.g. Cetuximab) has shown positive results in head and neck cancers in combination 
with radiotherapy. Trastuzumab (Herceptin) is a fully humanized monoclonal antibody 
that binds to the extracellular domain of HER-2 and has antiproliferative activity against 
breast cancers over expressing HER-2 
173.  
 
Recent studies have shown that HER family of receptors play a critical role  in 
progression of various cancers 
174-176. Previous studies have demonstrated the expression 
of EGFR in NETs 
115;116. Previous studies demonstrated high EGFR expression in NETs 
115. A number of studies have been performed to assess HER-2 expression in a number 
of different types of NETs, demonstrating different concentrations of expression in 
various NETs 
115;177-180. Expression of all four members of the HER family has not been 
studied in NETs.   
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The aim of this study was to evaluate the expression of HER-2, HER-3 and HER-4 in 
NETs by immunohistochemistry and its association with EGFR and b) to correlate the 
extent of expression with clinico-pathological parameters. 
 
3.2 Materials and Methods 
Consecutive samples of formalin-fixed paraffin-embedded tumour tissue were available 
from 82 patients with a histologically confirmed diagnosis of NET. Of these 58 were 
from surgical resection from patients who had undergone an operation and tumour 
resection. A further 24 samples were from tumour biopsies. The study population 
included all major NET subtypes including: foregut, mid-gut, hindgut, bronchial, 
paraganglioma and NETs of unknown primary (see Table 3.1). Demographic details, 
including tumour stage and survival data. Tumours were graded where possible using 
the TNM system proposed by ENETS consensus group 
19;21. Using this classification 
low grade tumour was regarded as mitotic count <2 per 10 high power fields (HPF) and 
Ki67 ≤2%, intermediate grade as having a mitotic count 2-20 per 10 HPF and Ki67 3-
20% and high grade as mitotic count of >20 per 10 HPF and Ki67 >20. This 
classification currently only encompasses gastroenteropancreatic NETs, for the purposes 
of this study this classification was expanded to include other types of NETs. The study 
was performed under the auspices of the Royal Free Hospital Pathology Department 
ethics recommendation for the studies of archive histology samples.  
 
Three micrometer sections of tumour tissue were dewaxed three times in xylene and 
rehydrated in ethanol. Endogenous peroxidase activity was blocked by incubation in 1% 
hydrogen peroxide, diluted in acetone, for 10 minutes. For HER-3 antibody studies the 
samples were submersed in 10mM citric acid (pH=6.0) and microwaved at 600 watts for 
20 minutes; then allowed to cool at room temperature. Slides for HER-2 and HER-4  
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studies were immersed in 10mM citric acid (pH=6.0) and placed water bath at 98°C for 
45 minutes, following which they were removed and cooled at room temperature for 20 
minutes. Specimens were washed in TBS-Tween and pre-incubated with avidin and 
biotin diluted in 3% normal serum for 20 minutes each.  
 
Primary antibodies comprised: anti-HER-2 polyclonal rabbit (DAKO Ltd), anti-HER-3 
rabbit monoclonal antibody (DAKO Ltd), anti-HER-4 polyclonal rabbit antibody 
(Labvision Ltd). Sections were then incubated with anti-HER 2 antibody (1:250), anti-
HER-4 antibody (1:50) and anti-HER-3 antibody (1: 50) were incubated for 1 hour. 
Biotinlyated 2 antibody was used with slides incubated for 30minutes. The antibody 
binding was visualized by using a DAB peroxidase substrate kit. The sections were 
counterstained with Mayer’s haematoxylin for 3.5 minutes.  
 
Negative controls included substitution of the primary antibody with normal sera. Breast 
cancer tissue was used for positive controls and determining optimal pre-treatment 
conditions for all antibodies.  
 
The EGFR studies 
181  were reviewed in this study in order to correlate EGFR 
immunohistochemical findings with those of HER-2, HER-3 and HER-4. This study 
initially included  98 NET specimens, however due to limited availability of tissue 
immunohistochemical analysis of HER-2, HER-3 and HER-4 was performed in 82 of 
these cases. The remaining 16 cases which had been stained for EGFR were excluded 
from the analysis.   
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3.2a Histological interpretation  
Tumours were classified according to their site of origin, degree of differentiation and 
their initial mitotic index. Two examiners (R.S and J.W) performed the interpretation of 
immuno-histological staining for the antibodies studied independently of each other. 
Any discordant results were then reviewed together to reach agreement or determine an 
average value for disputed sections. The same score was achieved independently in 94% 
(77/82) of cases. Scoring was based on intensity of staining of tumour cells whereby 0= 
negative, 1= weakly positive, 2= moderate, 3= strongly positive. Then extent of tumour 
staining was also scored, whereby 10 random high power fields were assessed and the 
average percentage of positive staining cells in which: 1= <25%,  2= 25-75% and 
3=>75%. The product of the density of staining and the percentage of tumour cells 
staining positive was used as the histological score, giving final values of 0,1,2,3,4,6,9. 
Scores of ≤2 were counted as negative and scores >2 were classed as positive 
164;181. 
 
3.3 Results 
Tumour tissue was available from 82 patients with a histologically confirmed diagnosis 
of NET. All 82 cases were negative for HER-2 (see Figure 3.1). Seven (8.5%) cases 
were positive for HER-3 staining; the staining in these cases was predominantly 
cytoplasmic with some membranous staining. 
 
The surrounding stroma showed weak or negative staining in the majority of cases. Of 
the seven cases that were positive, 3 were paragangliomas, 3 foregut and one mid-gut 
tumour (see Table 3.2). Seventy five (91.5%) cases were positive for HER-4 antibody, 
with staining predominantly membranous and cytoplasmic (see Figure 3.2). Seventy one  
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of the 82 (86.5%) cases reviewed for EGFR staining were positive for EGFR expression, 
the staining of which was predominantly cytoplasmic and perinuclear.  
 
Four cases over-expressed EGFR only, 10 cases expressed only HER-4 receptor and 
none expressed HER-3 receptor alone. EGFR, HER-3 and HER-4 were all expressed in 
6 cases. EGFR and HER-4 were co-expressed in 65 (79.3%) cases. There minimal weak 
staining of the surrounding stroma in cases with EGFR, HER-3 and HER-4. Tumour 
grade could be assessed in 66 of the 82 cases, who had tissue available for MIB-1 or 
Ki67 proliferation index staining. 
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   Number  % 
Patients  82    
Age       
Median  59    
Range  32-88    
Gender       
Male  33  40.2 
Female  49  59.8 
Primary site       
Thymic  1  1.2 
Thyroid  4  4.9 
Bronchial  4  4.9 
Gastric  3  3.7 
Pancreatic  18  23.2 
Duodenal  1  1.2 
Jejunal-Ileal  21  25.6 
Appendiceal  8  9.8 
Colon  4  6.1 
Ovarian/ 
Cervical  4  4.9 
Paraganglioma  6  6.1 
Unknown  8  8.5 
 
Table 3.1. Patient group characteristics 
 
Of these 44 were low grade, 6 intermediate grade and 16 high grade. Multivariant 
statistical analysis did not show any correlation between tumour grade and expression of 
EGFR, HER-2, HER-3 or HER-4. There was no correlation of expression of EGFR with 
HER-3 or HER-4. No correlation\n between HER-3 and HER-4 expression. There was 
no significant difference in expression of EGFR, HER-3 or HER-4 between fore-, mid- 
or hind- gut tumours; with EGFR and HER-4 being co-expressed in all different types of 
NETS.   
 
HER-2 and HER-4 had a negative correlation. HER-3 was positively correlated with 
survival using Spearman correlation (r= 0.272, p= 0.05). EGFR, HER-2 and HER-4 had 
no significant correlation with survival (see Table 3.3).    
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Table 3.2. Immunohistochemistry for EGFR, HER-3 and HER-4 in 82 neuroendocrine 
tumours. (No) is number of cases in total, (+) case is the number of cases with positive 
uptake (i.e. score >2). Intensity scored 1-3, where: 1- weak, 2- moderate and 3- intense. 
Area scored 1-3, where 1- <25%, 2- 25-75% and 3- >75%. 
 
 
 
Site  No.     EGFR        HER-3        HER-4    
      + case  intensity  area  +case  intensity  area  + case  intensity  area 
Thymic  1  1  2  3  0  0  0  1  2  3 
Thyroid  4  4  1-3  1-3  0  0  0  3  1-3  2-3 
Bronchial  4  4  2  2  1  3  1  4  2-3  2-3 
Gastric  3  3  2  1-3  0  0  0  3  3  2-3 
Pancreatic  18  14  1-3  1-3  2  2  1-2  14  1-3  1-3 
Duodenal  1  1  2  3  0  0  0  1  3  3 
Jejunal-Ileal  21  19  1-3  1-3  1  2  3  19  2-3  1-3 
Appendiceal  8  8  2-3  1-3  0  0  0  8  2-3  2-3 
Colon   4  2  2  2  0  0  0  4  2-3  2-3 
Ovarian  3  3  2  2  0  0  0  3  2-3  2 
Cervical  1  1  2  2  0  0  0  1  2-3  2 
Paraganglioma  6  5  1-3  1-3  3  1-3  2-3  6  2-3  2-3 
Unknown  8  6  1-3  1-3  0  0  0  8  1-3  2-3 
                                
TOTAL  82  71        7        75        
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Figure 3.1. Scoring of tumour samples according to immunohistochemical staining. The 
method of creating a histological score for immunohistochemical staining is described in 
the methods.   
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     HER1  HER3  HER4 
HER2  Correlation 
Coefficient  .086  -.103  -.505(**) 
   Sig. (2-tailed)  .447  .364  .000 
         
HER3  Correlation 
Coefficient  .042    .079 
   Sig. (2-tailed)  .712    .483 
         
HER4  Correlation 
Coefficient  .047  .079   
   Sig. (2-tailed)  .681  .483   
         
Survival  Correlation 
Coefficient  .010  .272(*)  .194 
   Sig. (2-tailed)  .937  .032  .130 
         
 
Table 3.3 Correlation Table for a Cohort of 82 Patients with Neuroendocrine tumours. * 
shows significant correlation between HER-3 positive tumours and longer survival. ** 
significant negative correlation between expression of HER-2 and HER-4.  
 
 
3.4 Discussion 
This study demonstrated that HER-2 is not expressed in NETs, whilst EGFR and HER-4 
are frequently and HER-3 infrequently expressed in NETs. Furthermore, HER-3 is 
correlated with better prognosis.  
 
Studies examining EGFR expression have noted significantly worse prognosis in NETs 
expressing EGFR rather than those not 
116. This does not appear to be the case in this 
study, with over 80% of cases expressing EGFR and these tumours did not show a worse 
prognosis. A study by Atkins et al, has demonstrated that immunohistochemical 
expression of EGFR can vary with age of tissue samples 
182, however, in this study the 
percentage of EGFR positive tumours did not differ between samples more or less than 2 
years old.  
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Figure 3.2. Immunohistochemical staining of HER receptors in NETs. A) EGFR staining 
of NET, predominantly cytoplasmic and membranous staining, x200 magnification. B) 
EGFR staining x400 magnification. C) HER-2 staining of breast tumour, predominantly 
membranous staining, x200 magnification. D) HER-2 in NET, no evidence of staining, 
x200 magnification. E) HER-3 predominantly cytoplasmic with some membranous 
staining in NET, x200. F) HER-3 staining of ileal NET, x400 magnification. G) HER-4 
with predominantly membranous and some cytoplasmic staining in NET, x200 
magnification. H) HER-4 staining predominantly membranous pattern, x400 
magnification.  
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HER-2 receptor expression has been demonstrated in intestinal but not gastric NETs by 
Yamaguchi et al 
180, this study used the same Dako antibody though the secondary 
antibody and duration of incubation of primary antibody is not reported. The reasons for 
this difference in staining are unclear and may be related to the age of the slides or the 
scoring system used to interpret the slides. Other studies have also demonstrated variable 
expression of HER-2 in NETs using immunohistochemical and PCR techniques 
179;183. 
The negative expression of HER-2 immunohistochemistry in this study could be due to a 
number of reasons; possibly related to low levels of receptor expression in these 
specimens which were below the threshold of detection by immunohistochemistry. 
 
HER-2 was not expressed in any cases, which is of interest since cell line studies have 
shown that HER-2 is the preferred dimer partner for other receptors 
184. The positive 
controls in this study were breast cancer, which all demonstrated strong grade 3 staining, 
with minimal background staining. Therefore, confirming that the lack of staining was 
not due to technical reasons or the antibody. Even though HER-2 does not act as a 
receptor for EGF, it can decrease the rate of ligand dissociation from the cognate 
receptor, EGFR 
185. Thus, resulting in stronger and more prolonged activation of the 
EGFR signalling network 
170. Furthermore in cell line studies, mitogenic signalling 
appears to be stronger via HER-2 containing heterodimers than any other heterodimers 
170;186. All these factors lead to a stronger more prolonged signalling response following 
activation of HER-2 receptors. It would be interesting to examine HER-2 receptor 
expression using RT-PCR since this may be able to detect lower levels of receptor 
expression than immunohistochemistry.  
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Wang et al, demonstrated HER-3 expression in 6 of 98 (6%) malignant GEP NETs 
179. 
This study identified HER-3 positivity in 6% of GEP NETs (3 of 52 cases) and 50% (3 
of 6 cases) of paragangliomas. This confirms that HER-3 is infrequently expressed in 
NETs. HER-3 expression correlated with improved survival, however, only 7 cases 
showed expression of HER-3; furthermore 3 of these cases were in paragangliomas 
which generally have a more indolent course than GEP NETs. HER-3 over expression 
has been associated with improved outcome with breast cancer in one study 
187. Further 
HER-3 positive cases need to be evaluated to confirm whether this is a consistent 
finding. Interestingly 50% of paraganglioma cases expressed HER-3, again a study of 
more paraganglioma cases needs to be performed to confirm this finding.  
 
Studies performed looking at HER family of receptor expression in other cancers, have 
often found that HER-4 expression is associated with positive prognostic survival. This 
study has not demonstrated expression of HER-4 to be associated with an improved 
prognosis. Currently the role of HER-4 in NET biology is not understood and with 
further understanding of its interactions with other members of the HER family and 
downstream signalling effects one may be able to develop better understanding.  
 
Co-expression of EGFR receptors appears to vary from different tumour groups; 
however, EGFR and HER-4 co-expression was identified in 2.3% of colonic 
adenocarcinoma 
188 and 13.6% of non-small cell lung carcinomas 
140. There is currently 
no evidence that co-expression of EGFR and HER-4 is associated with alteration in 
prognosis. 
 
Expression of only a single receptor was uncommon, with only 4  (4.8%)  cases 
expressing EGFR alone and HER-4 was expressed in ten (8.2%) cases. One reason for  
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this may be that receptor expression may have been below the threshold level of 
immunohistochemical detection. HER-3 was not expressed alone, which is unsurprising 
since it has no intrinsic tyrosine kinase activity 
189. Co-expression of EGFR and HER-4 
has been demonstrated in other tumours 
140. HER-2 co-expression is often linked with 
HER-3 expression, in this study HER-2 expression was absent in these tumour samples 
and HER-3 was rarely expressed.  
 
This study demonstrates that EGFR, HER-3, HER-4 are expressed in neuroendocrine 
tumours. HER-3 expression was associated with better survival, though the number of 
cases was small and also paragangliomas have a different prognosis than GEP NETs. 
The lack of expression of HER-2 may in part explain the less aggressive clinical course 
of these tumours. Recent development of pan-HER receptor inhibitors may provide 
possible therapeutic options in NETs.   
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Chapter 4: Circulating Angiopoietin-1 and Angiopoietin-2 in the serum 
of patients with neuroendocrine tumours  
 
Abstract 
Introduction: Angiogenesis is an essential process in development and growth of 
tumours. There are a large number of angiogenic mediators including the angiopoietin 
family and vascular endothelial growth factor which play an important role in both 
physiological and pathological angiogenesis. This study examines serum concentrations 
of Ang-1 and Ang-2 in patients with neuroendocrine tumour compared to healthy 
controls.  
 
Methods: ELISA for Angiopoietin-1 and Angiopoietin-2 was performed in 47 patients 
with histologically proven NETs and 44 healthy controls. Immunohistochemical staining 
for Ang-2 was performed in patients to demonstrate cellular location of Ang-2. 
 
Results: Serum Ang-2 concentrations were significantly elevated in patients compared to 
controls (median 4756 vs. 2495 pg/ml, p<0.001), whereas  there was no significant 
difference in Ang-1  concentrations. The ratio of Ang-2: Ang-1 was significantly 
elevated in patients compared to controls (0.13 vs. 0.066, p<0.001). Serum Ang-2 
concentrations were significantly elevated in patients with distant metastases compared 
to those without metastasis (median 5080 pg/ml vs. 3360 pg/ml, p=0.01) and there was 
also a significant correlation between Ang-2  concentrations and volume of liver 
metastases, (p<0.014). Time to disease progression was more rapid  in patients with 
serum Ang-2 concentrations >4756 pg/ml (p=0.04).    
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Conclusion: Serum Ang-2 but not Ang -1 is elevated in NET patients. Ang-2 may be a 
useful serum marker for monitoring disease progression and assessment of prognosis 
in patients with NETs. 
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4.1 Introduction  
There are a large number of angiogenic mediators including the angiopoietin family and 
vascular endothelial growth factor which play an important role in both physiological 
and pathological angiogenesis 
190-192. To date four angiopoietins have been identified; 
termed Ang 1-4 
193. Of these Angiopoietin-1 (Ang-1) and Angiopoeitin-2 (Ang-2) are 
the most widely studied and function as ligands for Tie-2, which is a receptor to tyrosine 
kinase specifically expressed on endothelial cells 
194;195.  
 
Ang-1 binds specifically to Tie-2 causing activation by phosphorylation. Ang-1 is 
produced by endothelial cells and pericytes and is widely expressed in adult tissue, 
where it appears to have a stabilizing effect on blood vessels 
196. The role of Ang-1 in 
tumour development is complex and studies have shown both pro- and anti-angiogenic 
effects with this growth factor. Ang-2 is expressed at sites of vascular remodelling 
197 
and promotes vessel destabilization 
198. This appears to be accomplished by Ang-2 
binding to Tie-2 and therefore blocking Ang-1 binding. Ang-2 appears to be a non-signal 
transducing ligand and therefore disrupts normal Tie-2 activation 
199. The endothelial 
cells are then acted upon by various angiogenic factors such as VEGF, which leads to 
proliferation 
135.  
 
In tumours a shift in the balance between pro- and anti-angiogenic factors is thought to 
occur ; termed the ‘angiogenic switch’ resulting in an angiogenic phenotype 
200;201. It has 
been proposed that a change in the ratio of Ang-1: Ang-2 in favour of Ang-2 might play 
a role in this switch 
202. Support comes from animal studies in colonic and gastric 
tumours transfected with Ang-2 which grew larger and heavier in nude mice compared 
to those transfected with Ang-1 
203;204. 
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The serum concentrations of angiopoietins have not been evaluated in NET patients. The 
aim of this study was to measure serum Ang-1 and Ang-2 concentrations in patients with 
NETs and assess their interrelationship and clinical significance.  
 
4.2Materials and Methods 
4.2a Patients  
We prospectively enrolled 47 patients with NETs, between July 2007 and March 2008. 
All patients had histological confirmation, including assessment of morphology and 
immunohistochemical analysis for neuron specific enolase, CgA, synaptophysin and 
PGP9.5. All cases were well or moderately differentiated tumours and no patients 
enrolled in the study had a poorly differentiated NET. The presence of necrosis, number 
of mitoses and Ki-67 index was recorded. Tumours were graded using the system 
proposed by European Neuroendocrine Tumour Society (ENETS) consensus group 
19;21;163. Using this classification low grade tumour was regarded as mitotic count <2 per 
10 high power fields (HPF) and Ki67 ≤2%, intermediate grade as having a mitotic count 
2-20 per 10 HPF and Ki67 3-20%. All patients underwent imaging with CT or MRI and 
appropriate nuclear medicine imaging including somatostatin receptor scintigraphy using 
111In-DTPA-Phe I-Pentetreotide (Octreoscan), within two months of blood sampling to 
enable staging of disease. Serum CgA was measured in all patients at the same time as 
serum collection for the study. All previous and current therapies that patients had 
received were recorded from patient records. The demographics of both groups are 
shown in table 4.1.  
 
Survival data and time to progression of disease was identified in all cases. Time to 
progression was assessed using radiological evidence of disease progression according  
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to RECIST criteria 
205 and was calculated in days from time of blood collection. Patients 
underwent cross sectional imaging for re-staging of their disease on a 3-4 monthly basis. 
 
As control subjects, 44 healthy volunteers who were age and sex matched were enrolled 
in the same period, see Table 4.1. Most subjects in the control group were healthy 
relatives of patients and the remainder were volunteers. All control patients  had no 
previous history of cancer. 
 
The study was approved by the Local Ethical Committee and all participants gave 
written informed consent prior to obtaining samples.  
 
4.2b Enzyme-Linked immunosorbent assays 
Serum samples were obtained from each individual, immediately placed on ice and 
allowed to stand for 30 minutes. Following this the samples were centrifuged at 
3000rpm for 15 minutes. Sera were stored at -80°C. Enzyme linked immunoabsorbent 
assays (ELISA) were used to measure Ang-1 and Ang-2 (Quantikine, R&D systems, 
Minneapolis). Serum samples were diluted as appropriate prior to being added to 
separate microplates, each containing a specific antibody for Ang-1 or Ang-2. The 
mixtures were then incubated for 2 hours on an orbital microplate shaker. Plates were 
then washed four times to remove unbound antigen. Enzyme-linked polyclonal 
antibodies specific for each angiogenic factor were then added and the mixture incubated 
for 2 hours. Plates were then washed four times prior to the substrate solution being 
added to the wells. The colour was allowed to develop following which the stop solution 
was added. The optical density of each well was determined at 540nm.   
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          NET           Control 
Subject number  47  44 
Age  61.4 (34-80)  59.65 (24-86) 
Males  26  23 
Females  21  21 
Primary tumour     
   Bronchial  3   
   Pancreatic  17   
   Jejunal  2   
   Ileal  20   
   Unknown   5   
Functional types     
   Carcinoid syndrome  18   
   Glucagonoma  1   
   Non-functional  28   
Histological grade     
   Low  24   
   Intermediate  23   
Biochemical markers     
   Chromogranin A >60  35    
   Chromogranin A  0-60  12   
   CgA (pMol/L) 
   (Range) 
Median 99  
(range 17->1000)   
Concurrent SST analogues   29   
Previous Therapies     
   Previous chemotherapy  4   
   Radiotargetted therapy  4   
   Surgery  19   
 
Table 4.1. Demographic data. All therapies are previous treatments that patients had 
undergone, except somatostatin (SST) analogues which all patients were currently on at 
time of study. Histological grade was classified using the ENETs proposed system for 
grading 
19. The classification was expanded to include bronchial and tumours of 
unknown primary site.  Chromogranin A measurements were made using commercial 
RIA kit (Roche), which measures the pancreastatin fragment of chromogranin A, normal 
range is 0-60 pMol/L.   
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Chromogranin A was measured using a commercial RIA (Roche) which measures the 
pancreastatin fragment of chromogranin A.  
 
4.2c Immunohistochemical analysis of Angiopoeitin-2 
Formalin-fixed paraffin-embedded tumour tissues were available from 9 patients with a 
histologically confirmed diagnosis of neuroendocrine tumour in whom serum samples 
had been collected for Ang-2 analysis. All cases had been assessed for grade of tumour; 
including Ki67 proliferation index and/or number of mitoses per 10 high power fields 
were available in all cases. The study population comprised of 6 primary pancreatic 
NETs and 3 midgut NETs.  
 
Four micrometer sections of tumour tissue were dewaxed three times in xylene and 
rehydrated in ethanol. Endogenous peroxidase activity was blocked by incubation in 
0.5% hydrogen peroxide and diluted in acetone, for 10 minutes. Slides were microwaved 
for 10minutes at 600w in citrate buffer and then transferred to a humidity chamber. 
Slides were incubated overnight in primary monoclonal Ang-2 antibody at a dilution 
1:50 (Santa Cruz product no. Sc-74403). Slides were washed with Post Primary Block 
(Novolink
TM Max Polymer RE7280 detection kit) for 30 minutes in a humidity chamber 
at room temperature. Slides were washed in TBS-t and left for 5 minutes. Novolink
TM 
Polymer (RE7280-K) was added for 30 minutes in a humidity chamber for 30 minutes, 
following which slides were washed in TBS-t. The sections were then developed with 
Novolink DAB (3, 3’-diaminobenzidine tetrahydrochloride) solution for 5 minutes by 
adding 50μl of DAB chromagen to 1ml of Novolink DAB substrate buffer. The slides 
are counter-stained with Mayer's haematoxylin for 3 minutes. Positive controls for 
Angiopoeitin-2 were renal tissue; negative controls included substitution of the primary  
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antibody with normal sera. An experienced histopathologist (TV.L) performed the 
interpretation of immuno-histological staining for the antibody studied.  
  
4.2d Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. The values were 
generally not normally distributed, so non-parametric tests were used to compare marker 
concentrations between groups, i.e. the Mann-  Whitney  U  test (for two groups) or 
Kruskal-Wallis test (for several groups). Multivariate linear regression analyses were 
used to examine Ang-1 and Ang-2 (on a logarithmic scale) in relation to several other 
factors. Spearman correlation of rank coefficient was used to analyze correlations 
between parameters. Time to disease progression curves was plotted using the Kaplan-
Meier method and the log-rank test applied.  
 
We also evaluated the screening performance of the markers using the detection rate 
(sensitivity), defined as the proportion of NET cases that had concentrations above a 
specified cut-off, and the false-positive rate, defined as the proportion of controls that 
had concentrations above the same cut-off. The likelihood ratio quantifies the ‘power’ of 
the marker and is the detection rate divided by the false-positive rate; the higher the 
value the better the marker. 
 
4.3 Results 
4.3a Serum Ang-1 and -2 concentrations in Patients with NETs 
Figure 4.1 shows scatterplots of the distributions of Ang-1, Ang-2, and the ratio of the 
two. Patients with NETs had significantly higher serum Ang-2 concentrations than the  
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control group (median 4756 vs. 2495 pg/ml), p<0.001. There was still a highly 
statistically significant difference when allowing for age and sex (p<0.001). Median 
serum Ang-1 concentrations were not different between the two groups (39135 pg/ml 
controls vs. 39405 pg/ml cases; p= 0.60). The ratio of Ang-2 to Ang-1 was significantly 
increased in patients (median 0.133 compared to 0.066 in controls p<0.001), but this 
probably largely reflects the difference associated with Ang-2. There was no evidence of 
a correlation between serum Ang-2 and Ang-1 (r=0.11, p=0.49); Ang-1 and plasma CgA 
(r=-0.22, p=0.13); or Ang-2 and plasma CgA (r=0.03, p=0.8). We conducted a 
multivariate analysis to look at the association between each of Ang-1, Ang-2 and the 
ratio, and three prognostic factors: histological grade, CgA and stage. There was some 
evidence of an association between histological grade and Ang-2, even after allowing for 
stage and CgA (p=0.003); the geometric mean was 4140 and 6668 pg/ml in the low and 
intermediate grades respectively. There was no evidence of an association between 
either Ang-1 or Ang-2: Ang-1 ratio and the prognostic factors. 
 
To confirm that there was no significant daily variation in Ang-2 concentrations we 
obtained two matched serum samples from 17 control patients separated by 24 hours. 
There was no significant difference between Ang-2 concentrations (p=0.143) or Ang-1 
(p=0.662).  
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Figure 4.1. Comparisons of Ang-2, Ang-1 and Ang-2: Ang-1ratios in patients with NETs 
(n=47) and controls (n=44). a) Ang-2 concentrations b) Ang-1 concentrations c) ratio of 
Ang-2 to Ang-1  
 
4.3b Angiopoietin concentrations and type of neuroendocrine tumour 
Compared to controls (median 2495 pg/ml), serum Ang-2 was significantly elevated in 
both midgut NETs (median 4790 pg/ml, p< 0.001) and foregut primary NETs (median 
4900 pg/ml, p<0.001). When comparing concentrations between foregut and midgut 
primary tumours, there was no evidence of a difference in serum Ang-2 (median 4900 
pg/ml vs. 4790 pg/ml, p=0.59), serum Ang-1 (median 39100 pg/ml vs. 33750 pg/ml, 
a  b 
      c  
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p=0.28); or the ratio of Ang-2 to Ang-1 (median 0.133 vs. 0.147, p=0.68). There was no 
significant difference in Ang-2 concentrations between patients with functional tumours 
(n=19) and non-functional tumours (n=28) (median 4503 pg/ml vs 4867 pg/ml, p=0.58). 
Furthermore, there was no difference in serum Ang-2 concentrations between the 29 
patients currently on somatostatin analogues and 18 patients who were not (median 4755 
pg/ml vs. 4500 pg/ml, p=0.82). Similarly for Ang-1 concentrations (median 40550 pg/ml 
vs. 33900 pg/ml, p=0.24).  
 
4.3c Angiopoietin concentrations and stage of disease  
Median  Ang-2  concentrations were elevated in patients with metastatic disease 
compared to those with localised disease without distant metastases (median 5081 pg/ml 
vs. 3359 pg/ml, p=0.01); see Figure 4.2.The ratio of Ang-2 to Ang-1 was also somewhat 
higher in patients with distant metastases (0.147 vs. 0.105, p=0.019) (Figure 4.2).  
 
From radiological assessment of CT or MRI scans performed within 2 months of blood 
sampling, visual assessments were made of the volume of liver metastases present. Four 
categories were created; localized disease without metastases, low volume liver 
metastases (involving <25% of liver), intermediate (involving 25-50% of liver) and large 
volume liver metastases (>50% of liver), see Figure 4.4.  
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Figure 4.2. Comparison of serum Ang-2 concentrations (left figure) or the ratio of Ang-2 
to Ang-1 (right figure) in patients with liver metastases (n=41 cases) and those with 
localised disease (n=6).  
control
Localized disease
0
2000
4000
6000
p=0.019
p
g
/
m
l
 
Figure 4.3.  Serum Ang-2  concentrations in patients vs controls. Serum Ang-2 
concentrations are significantly raised in patients with localized non-metastatic disease 
(n=6 cases) compared to healthy controls (n=44).  
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Ang-2 concentrations were significantly higher in patients with localised non-metastatic 
disease (n=6), compared to healthy controls (3360 vs. 2495 pg/ml, p=0.02) (Figure 4.3).   
 
There was a statistically significant difference between the groups -when comparing 
localized disease, low, intermediate and large volume liver metastases- (p=0.014, one 
way ANOVA test), with a suggestion that increased Ang-2 is associated with increased 
tumour burden, Figure 4.4.  
 
4.3d Serum Ang-2 as a marker of disease 
ROC curves for serum Ang-2 were constructed to determine the cut-off values for 
specificity and sensitivity of Ang-2 and Ang-2: Ang-1 ratio. The area under the curve for 
serum Ang-2 was 0.88 and was greater than Ang-1 (0.53), (Figure 4.5). Detection rate, 
false positive rate and likelihood ratio for Ang-2 and the ratio of Ang-2 to Ang-1 are 
shown in Table 4.2. Serum Ang-2 was a better marker than the ratio, with a sensitivity of 
85%, for a false positive rate of 22.7%. The chromogranin A assay has been previously 
validated and a cut off of 60 pmol/ml has been defined. Using this cut off in our study 
chromogranin A had a sensitivity of 80.9%.   
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Figure 4.4. Serum Ang-2 concentrations in controls (n=44) and patients with different 
volumes of tumour load. Patients without metastatic disease (n=6) and those with low 
(<25% liver metastases) (n=11), intermediate (25-50% liver metastases) (n=19) and 
large volume (>50% liver metastases) (n=11) liver metastases. 
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 Figure 4.5. Receiver Operator Curves for Ang-1 (a), Ang-2 (b) and the ratio of Ang-2 to 
Ang-1 (c). AUC: area under the curve 
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Detection 
rate 
(sensitivity) 
               Ang-2            Angiopoeitin-2:1 ratio 
  Cut-off  FPR (%)  C.I (%)  L.R  Cut-off  FPR (%)  C.I (%)  L.R 
70%  >3770  11.4  3.6-24.6  6.1  >0.095  25.0  13.2-
40.3 
2.8 
75%  >3565  15.4  5.2-27.4  4.9  >0.088  31.8  18.6-
47.6 
2.4 
80%  >3447  21.5  9.8-35.3  3.7  >0.074  38.6  24.4-
55.6 
2.1 
85%  >3313  22.7  11.5-
37.8 
3.7  >0.071  38.4  24.4-
52.2 
2.3 
90%  >3172  27.3  15.0-
42.8 
3.3  >0.064  55.6  38.8-
69.4 
1.7 
95%  >2447  55.8  38.8-
69.6 
1.7  >.0527  65.9  50.1-
79.6 
1.5 
 
Table 4.2. Detection rate (sensitivity), false positive rates and likelihood ratio for Ang-2 
and the ratio of Ang-2 to Ang-1 in NETs. The cut-off values for Ang-2 are in pg/ml. 
FPR, is false positive rate; C.I, is confidence interval, L.R, is likelihood ratio.  
 
4.3e Immunohistochemical staining 
Staining for Ang-2 was identified in 5 of the 9 tumour samples. In all cases with positive 
Ang-2 staining, the corresponding serum Ang-2 concentrations were greater than the 
control population, see table 4.3. Of the 4 samples negative for Ang-2 staining the serum 
Ang-2 was raised above the >4756 pg/ml (median Ang-2 value for patient cohort) in 3 
cases. The staining pattern was predominantly cytoplasmic, with clear tumour staining 
present. There was no staining of the background liver tissue and staining was localized 
only to tumour cells and endothelium (Figure 4.6). In one case there was strong staining 
in 10% of tumour cells metastatic to the gallbladder however only moderate 1% staining 
of the surrounding tumour in liver metastases, see Figure 4.6. Ang-2 staining was seen in 
low and intermediate grade tumours as well as pancreatic and midgut tumours. The  
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immunohistochemical studies demonstrate there is intra-tumoural variation in staining 
patterns for Ang-2. 
 
Primary  Grade  Functional  Biopsy site  Ang-2  (pg/ml)  Staining pattern 
Midgut  Low grade  Yes   Liver  6800  Negative 
Midgut  Low grade  Yes   Liver   13708  Moderate staining 
granular staining 10% and 
strong staining in 
cytoplasm  1% of cells 
Midgut  Low grade  Yes  Liver  6205  Negative 
Pancreas  Low grade  No  Pancreas  5983  Negative 
Pancreas  Low grade  No   Liver  6152  Moderate staining 1% 
cells 
Pancreas  Low  Yes  Liver  3815  Strong positivity in 1% 
cells 
Pancreas  Intermediate  Yes  Liver  10540  Strong positivity in 1% 
cells 
Pancreas  Low  No  Liver   3752  Strong positivity in 1% 
cells 
Pancreas  Intermediate  No   Gallbladder/ 
liver 
14846  5% strong positive in 
gallbladder tumour, 1% 
positive staining in liver 
 
Table 4.3.  Immunohistochemical staining for Ang-2 performed in 9 patients. Table 
shows site of primary, location and grade of tumour biopsy and staining pattern for Ang-
2. 
 
4.3f Survival data 
Due to the indolent nature of these tumours, survival data alone is difficult to obtain 
(only 4 patients died during the 8 month follow-up). We therefore examined time to 
disease progression. Patients with progressive disease within 2 months prior to blood 
sampling were excluded from progression analysis. The median serum Ang-2 
concentration in the patient group as a whole was used to divide the patients into two 
groups (cut-off value was 4756 pg/ml). The median follow-up period was 6 months, 
range 4-8 months. NET patients with serum Ang-2 concentrations >4756 pg/ml (n=14) 
had a worse prognosis than those with Ang-2  concentrations ≤4756  pg/ml  (n=22) ,  
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p<0.05 (Figure 4.7). Both groups had similar previous treatments and a similar number 
of patients on somatostatin analogues (see Figure 4.7b).  
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A)                                                                               B) 
 
 
C) 
 
Figure 4.6. A) Ang-2 staining in NET invading the gallbladder, shows strong Ang-2 
positivity in tumour cells and endothelial cells (internal control), x20 magnification. B)  
the top part of the image is normal liver with negative Ang-2 staining, the lower part of 
the image is liver metastatic NET, with scattered Ag-2 positive staining, x10 
magnification. C)  Normal liver showing only endothelial positive staining for Ang-2, 
x20 magnification.     
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Figure 4.7a) 
 
Therapy  Ang-2 ≤4756 (n=22)  Ang-2 >4756 (n=14) 
Concurrent SST analogues   14 (63.6%)  8   (57.1%) 
Prior Therapy     
   Chemotherapy   2   (9.1%)  3   (21.4%) 
   Interferon  2   (9.1%)  0   (0%) 
   Radiotargeted therapy  5   (22.7%)  2   (14.3%) 
   Right hepatectomy  4   (18.2%)  1   (7.1%) 
   Other surgery  3   (13.6%)  5   (35.7%) 
None  3   (13.6%)  1   (7.1%) 
 
Figure 4.7b) 
 
Figure 4.7. a)  Kaplan-Meier curves of time to progression of NETs according to Ang-2 
concentrations. Log rank p=0.03). Demonstrates significantly shorter time to progression 
for patients with an Ang-2 concentration of >4756pg/ml (p<0.05).  b) Treatments 
undergone by patients in the two groups during the course of their illness and the number 
of patients on current somatostatin analogue therapy. 
 
 
4.4 Discussion 
This is the first study to demonstrate elevated serum Ang-2 concentrations and Ang-2: 
Ang-1 ratio in patients with NETs compared to healthy controls. Similar findings have 
been reported in a number of studies looking at serum Ang-2 concentrations in other  
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cancers including colonic, lung and ovarian cancer 
192;206-209. Furthermore, Ang-2 mRNA 
concentrations are elevated in the tumour tissue of a number of other cancers, including 
HCC, prostate cancer and breast cancer 
204;207;210-214. The findings suggest that Ang-2 
was superior to Ang-1 for differentiating NET patients from control samples, and 
distinguishing patients with distant metastasis from those without and appears to 
increase in relation to increasing disease burden. In addition, our multivariate analysis 
suggests that high concentrations of Ang-2 are associated with higher grade tumours.   
 
NETs often progress at a relatively slow rate; however, occasionally they may grow 
rapidly. During periods of growth, or progressive disease there may be a shift in 
proangiogenic factors including Ang-2. This could be a reflection on the biology and 
natural course of NETs. Interpretation of Ang-1 concentrations is difficult due to the 
wide range of values expressed and the complex behaviour of this growth factor. 
Interestingly high concentrations of Ang-1 were not correlated with increased Ang-2 
concentrations. However, the higher ratio of Ang-2 is more commonly associated with 
high tumour load, i.e. >50% liver metastases rather than low volume disease or patients 
without metastasis. Our results support the hypothesis that elevation of Ang-2 being an 
important aspect of tumour angiogenesis.   
 
This study has shown Ang-2 as a marker, with high sensitivity, however lacking 
specificity for use as a single marker for NETs since it is raised in a number of cancers 
and patients with cirrhosis. However, it could potentially have a role as an additional 
marker for monitoring development of recurrent disease or distant metastases, though, 
further validation of this marker will be required. Since CgA lacks sensitivity in cases 
with low tumour volume 
29, Ang-2 concentrations could be useful since there was a 
significant difference in Ang-2 concentrations in controls and patients without metastatic  
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(i.e. low volume) disease, however, the number of patients with localized disease were 
small (n=6). 
 
In our study, while Ang-1 did not have a significant prognostic implication, serum Ang- 
2 was more promising as a potential prognosticator; with concentrations >4756 pg/ml 
associated with earlier time to disease progression. The exact value for the cut-off will 
require prospective validation in another data set.  Whether the concentration of serum 
Ang-2 is also a predictor of survival will require re-evaluation after prolonged follow-up.  
 
Currently there are no accurate biochemical markers to aid in the diagnosis of 
progressive disease in patients with NETs. Even though CgA has been reported to have 
prognostic value especially in midgut carcinoid tumours it is not 100% sensitive 
27. 
Therefore, the use of Ang-2 in patients with NET could serve as a marker indicating 
likelihood of developing progressive disease.  
 
There was no significant difference in Ang-2 concentrations between patients treated 
with SST analogues and those not. Since SST analogues are thought to inhibit 
angiogenesis through a number of pathways the lack of difference between the groups at 
first may seem surprising. However, there may be a number of reasons no difference is 
seen, most importantly is the heterogeneity of the groups. The tumour load of patients on 
somatostatin analogues is often greater than those not on SST analogue therapies, since 
these patients all have metastatic tumours and hence syndromic. We have demonstrated 
patients with large volume disease generally had high Ang-2 concentrations.   
 
We have demonstrated by immunohistochemistry that a minority of NET cells strongly 
express Ang-2 in contrast to the normal liver. We did not find any clear correlation  
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between tumour staining and serum concentrations. There are three explanations for this; 
firstly there may be heterogeneity of expression within the tumour, as we have 
demonstrated clearly in one case, and one small sample many not be representative. 
Secondly the Ang-2 serum concentration appears to be related to tumour burden. Hence 
a small tumour with high Ang-2 expression my result in a lower serum concentration 
than a bulky metastatic tumour with a lower Ang-2 expression. Finally we cannot 
exclude the possibility that the Ang-2 arises from another source but its release is 
associated with tumour.   
 
There were limitations with our study; firstly, the study incorporated a rather diverse 
group of patients including patients with NETs with a foregut, midgut and those with 
unknown primaries. Secondly the study group had a number of different previous 
treatments and some patients had stable disease without any evidence of radiological 
progression, whilst others had progressive disease at time of serum collection. This may 
in part explain the heterogeneity identified with Ang-1 and Ang-2 concentrations.  
  
In conclusion, this is the first study reporting that serum Ang-2 is elevated in patients 
with NETS and that it may serve as a useful marker in NETs for monitoring and 
prognostication. A greater understanding of the role of Ang-1 and -2 in the pathogenesis 
of NETs may provide an opportunity for the development of effective therapy.  
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Chapter 5:  Characterization of proteins from the plasma of   
neuroendocrine tumour patients using 2-D gel electrophoresis and 
tandem mass spectrometry 
 
Abstract 
Introduction: The purpose of this study was to develop techniques for identifying cancer 
biomarkers in human plasma using proteomics. 2-D gel electrophoresis is a recognized 
technique for identifying potential biomarkers in biological tissue.  
 
Material and Methods: Plasma samples from five patients and five healthy controls were 
collected. Samples were fractionated using the immunoaffinity column. Protein 
concentrations of all fractionated samples were calculated using a Bradford assay. 2-D 
gel electrophoresis was performed and the gels fixed prior to staining with colloidal 
brilliant dye stain. Image analysis was performed using ProGenesis SameSpots software 
(non-linear dynamics). Proteins of interest were manually excised and analysed using 
LC-MS/MS. The proteins were identified using Mascot software.  
 
Results:  A total of 4153 protein spots were identified in the 10 gels. Following image 
analysis using ProGenesis Samespots software two protein spots of interest were 
identified between the patient and control gels. These were identified using LC/MS/MS 
as being albumin and pre-albumin. However, the albumin concentrations between the 
patients and controls were the same when concentrations were checked in serum.  
 
Discussion: A large number of protein spots were present in each gel; however, the 
majority of these were the abundantly expressed proteins. Due to the limitations of 2-D  
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gel electrophoresis in identifying proteins expressed below 2.5-10 micromolar 
concentrations this technique may not be suitable for identifying proteins that are not 
abundantly expressed in plasma. 
 
Experimental work 
Sample collection, sample fractionation, 2-D gel electrophoresis was performed by R. 
Srirajaskanthan.  
LC/MS/MS was performed by N. Beaumont.  
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5.1 Introduction 
Neuroendocrine tumour cells synthesise peptides and amine products 
215. In addition to 
secreted hormones other proteins are secreted from these tumours. These secreted 
proteins are thought to have autocrine, paracrine and systemic effects, and may be 
involved in cell stabilization and oncogenesis 
12. A number of these proteins may be 
released into the systemic circulation and can be measured in  sera or plasma, for 
example Chromogranin A, Chromogranin B, gastrin and pancreatic polypeptide 
216. 
There is a need for other accurate markers to aid in the identification of these tumours 
and aid in the management of these patients. 
 
New proteomics technologies, notably development of more sensitive and accurate mass 
spectrometry (MS) techniques, have improved the ability to discover new disease 
biomarkers 
217;218.  Plasma proteomics enables the identification of  proteins present 
within plasma; this technology  has been used successfully to identify markers in a 
variety of cancers 
219;220. A range of different proteomic techniques is available. These 
involve  a variety of techniques each with its own merits. This study used 2-D gel 
electrophoresis and LC-MS/MS. Two-dimensional polyacrylamide gel electrophoresis 
(2-D PAGE) 
221, in which proteins are separated according to charge (pI) by isoelectric 
focusing (IEF) in the first dimension and according to size (molecular weight) by SDS-
PAGE in the second dimension, has a  capacity for the resolution of complex mixtures of 
proteins, permitting the simultaneous analysis of hundreds or even thousands of gene 
products 
222.   
 
A major problem in profiling plasma proteins by 2-D electrophoresis is that the 5 to 10 
most abundant plasma proteins comprise over 85% of total serum protein 
223;224. The  
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proteins that are likely to be of interest are present at significantly lower concentrations. 
The most abundant serum proteins make it difficult to run 2-D gels reproducibly and 
also limit the amount of serum that can be loaded onto 2-D gels. They can also mask the 
differential expression of lower abundance proteins with similar molecular weights and 
iso-electric points 
224. To combat this problem the plasma samples are fractionated prior 
to loading to remove >90% of the 10 most abundant proteins.  
 
The primary objective of this study was to identify either an individual or a panel of 
proteins that are present in the plasma of patients with metastatic neuroendocrine 
tumours. A pilot study focussed on patients with metastatic midgut carcinoid tumours 
between the age range 30-75. This pilot study was performed on 5 patients and 5 healthy 
controls. Once the proteins of interest were  identified they will be validated by 
performing ELISA in the plasma of a large cohort of fifty pateints.  
 
5.2 Materials and Methods 
5.2a Study design 
Plasma samples were obtained from thirty patients and twenty healthy controls. Controls 
were either partners of the patients, who had no co-morbidities or healthy volunteers. 
The control group had no history of cancer or other co-morbidities. The two groups were 
age and sex matched. For the pilot study to identify potential protein markers, 2-D 
electrophoresis was performed on the plasma of 5 patients and 5 healthy controls. Patient 
demographics of the control group are shown in Table 5.1. Protein spots of interest have 
been identified using LC/MS/MS and these proteins were validated in the plasma of the 
large cohort of 30 patients and 20 controls. The study was approved by the Local Ethical  
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Committee and all participants gave written informed consent prior to obtaining 
samples.  
 
5.2b Plasma sample extraction 
Thirty patients and twenty control subjects were fasted for a minimum of 6 hours 
following which they had blood samples taken. Venesection was performed by the same 
individual in all cases, using a 16G vacutainer system. The samples were then 
immediately placed in ice and centrifuged (3000rpm for 10 minutes) within 30 minutes 
of obtaining the sample. The plasma was aliquoted into eppendorfs and stored in a -80°C 
freezer.  
 
5.2c Plasma fractionation 
High abundance proteins were removed using the Aurum serum protein mini-kit (Bio-
Rad). The Aurum serum protein mini kit contains columns filled with a mixture of Affi-
Gel Blue and Affi-Gel protein A. This resin blend allows for the simultaneous removal 
of both albumin and immunoglobulin (Ig) from plasma samples. This column enables 
loading 60µl of plasma and removes over 90% of albumin and immunoglobulin.  
 
Following washing the protein columns with buffer, and centrifuging the column to dry 
the resin bed, 60μl of plasma diluted in 180μl of buffer was added. This was repeatedly 
vortexed gently prior to centriguation. Further buffer was added following which the 
sample was centrifuged. The  residual fractionated sample was  then collected in a 
collection tube and aliquoted into eppendorfs prior to storage in -80°C freezer.  
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5.2d 1-D gel electrophoresis 
Prior to performing 2-D gel electrophoresis a 1-D gel electrophoresis was performed to 
identify whether there was different protein expression (molecular weight) in 1-D. Sixty 
micrograms of fractionated plasma was added to 15 µl of sample buffer.; run on SDS-
page gel over 16 hours. The gel was fixed in a solution of (methanol 20%, acetic acid 
10%) for 1 hour, then stained in commasie blue for 24hours. The gels were extensively 
destained in a solution of 10% methanol for 24 hours, prior to being imaged using 
BioRad GS800 scanner (Figure 5.1).  
5.2e 2-D gel electrophoresis and imaging  
Protein concentration  of all fractionated samples were  calculated using a Bradford 
assay.  
The fractionated plasma samples (160µl) were added to sample buffer (7M urea; 1 M 
thiourea; 4% chaps; 2% ampholytes; 50 Mm DTT) and passive hydrated into 
immobilized pH gradient (IPG) strips (11cm pH 5-8 IPG strips) over a period of 16 
hours.  The protein in the IPG strips was  focused using an Amersham IPGphor 
apparatus for a minimum of 30,000 volt hours. Following IEF focusing the sample 
strips were equilibrated in a loading buffer (7M urea; 1M thiourea; 2% SDS) with 50 
mM DTT for 15 minutes then equilibrated in buffer containing 50 mM iodoacetamide 
for a further 15 minutes. This procedure reduces any disulphide bonds that might 
cross-link proteins and then alkylation prevents re-oxidation of thiol groups during 
electrophoresis. The samples were then separated in the second dimension on 12% 
Tris-glycine gels, which were run overnight.  
 
The gels were then immersed in a fixing solution (Methanol 40%, 10% acetic acid) for 
1 hour. The samples were then stained in colloidal brilliant blue dye stain (Sigma) for  
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24 hours then replaced with fresh dye for a further 24 hours. The gels were extensively 
destained in 20% methanol and digitally imaged on a Bio-Rad GS800 scanner using 
PDQuest 7.3 software.  
 
5.2f Image analysis 
Spatial irreproducibility between 2-D gels by the conventional method of 2-D PAGE is 
an inherent problem. To help overcome this issue the images of the gels can be warped 
to enable them to be overlaid and analyzed using ProGenesis SameSpots software 
(Non-Linear Dynamics). Once these gel-images had been overlaid and warped the gels 
from the two groups were compared. Differences in optical density of less than two-
fold can be identified using this software.  
 
5.2g Analysis of proteins  
Protein spots of interest were defined as spots that were consistently different between 
the two groups of gels as analyzed using ANOVA. These spots were then manually 
removed from the gel and proteins identified using LC/MS/MS. The protein spots were 
then destained and subsequently digested with trypsin (Promega Gold) in 100 mM 
ammonium bicarbonate. The samples were then dried using a SpeediVac, and proteins 
were  extracted with sequential washes of 0.1% trifluoracetic acid (TFA); 10% 
acetonitrile in 0.1% TFA; 40% acetonitrile in 0.1% TFA. The extracted peptides 
(typically less than 40 µl) were then analyzed using LC-MS/MS. A data-determined 
acquisition was performed on MicroMass Q-ToF Micro (Waters) using ProteinLynx 4 
software. Proteins were identified from the .pkl files using Mascot software (Matrix 
Science) 
225. Protein identifications were only accepted with a Mowse score in excess 
of 40, incorporating the identification of at least two peptides.   
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5.3 Results 
The pilot group consisted of 5 patients average age 49 (range40-64). There were three 
males and two females. All patients had midgut neuroendocrine tumours with large 
volume (>25% of liver volume) liver metastases. The 1-D gel showed no difference in 
protein bands between the patients and control groups (Figure 5.1).  
 
   Patient  Control 
Age (median) in yrs  49  45 
Range in yrs  40-64  29-69 
Males  3  3 
Females  2  2 
years since diagnosis  5 (3-8)   
Chromogranin 
>60pg/ml  5   
somatostatin analogues  5   
Previous surgery  1   
 
Table 5.1. Demographic data of patient and control group used in pilot study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 1. SDS-PAGE of 6 patients and 5 controls. 1-D electrophoresis from 6 patients 
(labelled P) and 5 control samples (labelled C). No difference in proteins bands 
identified between the two groups, when analysed using PQ quest software.  
 P        C        P        C       P       C        P       C       P       C        P       P   
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Over four hundred protein spots were identified in each gel when analysed with 
SameSpots software. The total number of protein spots in all the pilot gels was 4153. 
Figure  5.2, illustrates the 2-D gel images from the patients and control samples. 
Following image analysis using Samespots software, three protein spots of interest were 
identified (see Figure 5.3). However, upon closer inspection of the gels, one of these 
spots were actually related to protein trains left by the original protein spot, rather than 
separate proteins. The remaining two spots were upregulated in patient groups. These 
protein spots were excised and identified using LC/MS/MS. The two proteins  were 
identified as being albumin and pre-albumin. Upon reviewing the patients biochemical 
data there was no difference in the albumin concentrations in the sera of the patients in 
the two groups.   
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  PATIENTS  CONTROLS 
 
 
Figure 5. 2. 2-D gel electrophoresis gels from the pilot study. Shows the gels of 5 
patients and 5 controls from the initial pilot study. The proteins of interest are shown in 
the enlarged image next to each gel.  
  
  121 
Due to the lack of significant proteins expressed in  the pilot study,  the following 
alterations were made to the experimental protocol:   
1.  Increase in the size of pilot group to 10 patients all with metastatic midgut NETs. 
This did not identify any new proteins, however, it  did not demonstrate the 
increased expression of pre-albumin or albumin identified in the original pilot 
study.  
2.  Increase in protein load to 180µl, then 200µl to the IEF strip. This led to the loss 
of separation of proteins in the 1-D dimension and produced poorer quality gels.  
3.  Decreased protein load 140µl and 120µl to the IEF strip, led to similar gels seen 
in the initial pilot study, however, it identified a weaker signal from expressed 
proteins and no new protein spots.  
4.  Different pH strips for IEF focussing, pH 3-10 and pH 7-10 were used to see if 
increased proteins were identified using a broader pH range (pH 3-10) strips. 
This however, led to poor separation of proteins which were predominantly 
expressed in the pH 5-8 range (see Figure 5.4).  
5.  Different staining techniques instead of colloidal brilliant blue were trialled, 
including deep purple and florescent pink, however, these did not lead to 
increased visualization of less abundant proteins (see Figure 5.5).  
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Figure 5. 3. Illustrates the protein spots and areas of interest identified using the 
SameSpots software. These protein spots are then compared to the other 11 gels to find 
areas of interest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 5. 4. 2-D electrophoresis gels, the first dimension was performed using pH 3-10 
strips. Most proteins are located within the pH range of 5-8. No difference in protein 
expression was identified between patient and control groups.  
 
patient  control  
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Figure 5. 5. Deep purple staining of 2-D gel electrophoresis. Shows the staining obtained 
using deep purple stain, an alternative staining agent to commasie blue.  
 
 
 
 
 
 
5.4 Discussion  
In total 4153 protein spots were identified in the pilot study, of which three were 
differentially expressed in the patient group when compared to the control group. 
Identification of these three proteins showed that the  spots were albumin and pre-
albumin. The likely cause for this difference is related to a  variation in albumin 
expression which occurs between gel samples.  No other differences in protein spot 
expression between healthy controls and patients with neuroendocrine tumours were 
identified. It is known that chromogranin A is raised in the plasma of patients with 
NETs. The concentration  of expression of this protein in some of our patients was 
 
Control  
Patient   
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>1000picomolar. Yet due to limitations of the 2-D technique we were unable to identify 
chromogranin A expression in plasma.  
 
Upon reviewing the literature there are a number of studies identifying novel biomarkers 
in a number of different cancers. The most commonly used technique is high-throughput 
analysis using SELDI 
226. This system has limitations with reproducibility or sensitivity 
and does not identify specific proteins 
227;228. 2-D electrophoresis with LC/MS/MS to 
identify novel protein markers in cancer has been reported in a number of studies 
229. 
Annexin-1 is one marker of prostate cancer that has been well validated following 
identification using 2-D gel electrophoresis. Studies in pancreatic, lung and ovarian 
cancer have identified other markers which may be useful prognostic indicators 
230. To 
date there are no studies describing identification of protein markers in the plasma of 
patients with NETs.  
 
Plasma is an attractive biological fluid in which to attempt to identify biomarkers since 
obtaining it is minimally invasive and it is relatively abundant. Unfortunately there are a 
number of limitations to 2-D electrophoresis  which have been previously  described 
231;232. Firstly, the technique is unable to identify proteins which are below the threshold 
of detection, which is 2.5-10micromolar. Plasma is known to have between a seven to 
ten fold difference in concentration of expression between the least and most abundant 
proteins. Therefore this difference of expression is difficult to be seen using 2-D gel 
electrophoresis 
233. This was evidenced by the fact that even following fractionation the 
most heavily expressed proteins were albumin, pre-albumin and immunoglobulin. This 
patient to patient variation is a common problem, which makes the correct validation of 
these proteins so important. This variability could be explained by the fact albumin and 
pre-albumin were identified as being increased in the patient group. Alternatively,  
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differences in effectiveness of albumin depletion with the fractionation kit, could explain 
the findings.  
 
To improve the resolution of protein spots different staining methods were trialled, 
including florescent staining. However, these did not provide any improvement in gel 
resolution. To ensure that proteins expressed outside of the pH 5-8  range  were not 
excluded, gels were performed using broad range pH strips 3-11 and also pH strips 7-11. 
The resultant gels did not express as many proteins of interest and again there was no 
difference between controls and patients.  
 
Further work is needed to examine whether removal of the 50 most highly expressed 
proteins enables identification of less commonly found proteins. However, whether this 
will resolve the issue which remains regarding the wide range of level of expression 
remains to be seen.  Due to the technical difficulties and complexities of plasma, the use 
of tumour tissue may enable identification of new markers. There are a number of 
studies which have successfully identified new biomarkers in tumour tissue from a 
variety of cancers. Some of the proteins identified from tumour tissue have been 
identified in serum and consequently validated as serum biomarkers.  
 
In conclusion plasma proteomic analysis using 2-D gel electrophoresis has numerous 
practical limitations and whilst removal of more abundant proteins may potentially 
enable less abundant proteins to be identified the use of other tissues or cell lines may 
provide a better way to identify potential biomarkers.  
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Chapter 6: Novel biomarkers for Neuroendocrine tumours identified 
from analysis of proteomes secreted from NET cell lines. 
 
Abstract 
 
Introduction: Neuroendocrine tumours display diverse tumour biology; however, most 
secrete into the circulation peptides consistent with their neuroendocrine origin, such as 
chromogranin A. This study sought to identify other potential markers for NETs by 
analyzing the secreted proteomes of three neuroendocrine cell lines.   
 
Methods: BON-1, NCI-H727 and SHP-77 cells were grown in serum-free media, and 
the secreted proteins were separated by SDS-PAGE and identified by LC-MS/MS. 
Validation studies of potential markers involved western blotting of NET cell lines, 
immunohistochemistry of NET tumour samples and serum ELISA of NET patients and 
healthy controls. 
 
Results: Two hundred and five proteins were identified from the 3cell lines, of which 61 
were secreted by two or more of the cell lines and 19 by all three lines. Mac-2 binding 
protein (Mac-2BP) was found to be secreted by all three cell lines, and this was 
confirmed by Western blotting.  Immunohistochemical analysis found 29 of 33 NET 
cases, from different primary sites, to be positive for Mac-2BP. Serum Mac-2BP was 
significantly elevated in NET patients, compared with healthy controls (p<0.001).   
 
Discussion: In this study, it is shown that analysis of the secreted proteomes of 
neuroendocrine cell lines can identify potential biomarkers for NETs. Mac-2BP may  
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have a role in the pathophysiology of NETs and may potentially be a biomarker for use 
in the diagnosis and management of this disease. 
 
Experimental work 
The sample collection, sample fractionation, 2-D gel electrophoresis, western blotting, 
serum ELISA and immunohistochemistry  was performed by R. Srirajaskanthan.  
LC/MS/MS and western blotting was performed by N. Beaumont.  
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6.1 Introduction 
The incidence of neuroendocrine tumours (NETs) is 2-5 per 100,000, although recent 
epidemiological data suggests this is rising 
8;154. The five year survival rate for patients 
with midgut metastatic disease is presently 40% 
234.  
 
NETs most commonly arise from the gastroenteropancreatic system, however they can 
originate in other organs 
216;234. NETs of the gut are thought to arise from cells of the 
diffuse endocrine system, which are characterized by the secretion of a variety of 
hormonal peptides and other bioactive  molecules. Chromogranin A (CgA) is the 
biochemical marker in the circulation currently used for monitoring and screening of 
NETs 
12. However, this marker is neither 100% specific nor sensitive, especially for 
patients with low volume disease 
29. Further markers are needed to aid the screening and 
management of NETs.  
 
Proteins from cancer cells are secreted into the circulation. The serum concentrations of 
signature proteins may increase in particular cancers, and  correlate with cancer 
progression and proliferation. Consequently, secreted proteins are important as serum 
biomarkers for some cancers. Examples include carcinoembryonic antigen (CEA) for 
colon cancer, CA-125 for ovarian cancer 
235 and prostate-specific antigen for prostate 
cancer 
236. 
 
A number of studies have investigated the secreted proteomes of cultured cells in the 
search for marker proteins of different 
237;238. This approach is based upon the 
assumption that the proteins secreted by the cell line will be representative of tumor cells 
in vivo. Studies have been performed using cell line models of prostate cancer, breast  
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cancer 
237  and head and neck cancer 
239. Some putative markers were subsequently 
validated using immunological methods on limited numbers of clinical samples. 
However, some of these markers did not prove to be consistently linked with the disease 
when studied in additional clinical samples 
237. This strategy appears to be justified for 
NET because these cells are known to secrete biologically-active amines and proteins 
into the circulation. 
 
The aim of this study was to identify putative protein markers, particularly those that 
could indicate the metastatic spread of NETs. We have analyzed the secreted proteomes 
of three neuroendocrine cell lines and assessed a new putative NET marker using patient 
tissue and serum samples. 
 
 
6.2 Materials and Methods 
6.2a Cell lines 
BON-1, a pancreatic neuroendocrine cell line, and two neuroendocrine lung cancer cell 
lines (NCI-H727 and SHP-77) were used. BON-1 cells were maintained in Dulbecco’s 
modified Eagle’s medium/ F-12 medium (1:1) supplemented with 10% fetal bovine 
serum (FBS), penicillin and streptomycin. NCI-H727 cells were maintained in RPMI 
1640 medium supplemented with 10% FBS, penicillin and streptomycin. SHP-727 cells 
were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS. 
All cells were cultured in 75cm
2 flasks in a humidified incubator at 37°C and 5% CO2.   
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6.2b Cell culture 
Approximately 10
6 cells per cell line were seeded into 75 cm
2 tissue culture flasks. After 
approximately 48 hours when more than 80% confluent, the media were removed. 
Monolayers were washed in serum-free media and then incubated with 8 ml of serum-
free media. After 24 hours, the conditioned media (CM) were collected. Trypan Blue 
exclusion indicated >99% viability of the attached cells. Media with 10% FBS was 
added to the flasks and incubated for a further 48 hours to ensure the attached cells were 
still viable. The CM were centrifuged at 2000 x g for 5 min to remove any cell debris 
and concentrated using a 10 kDa Centricon Mini-Prep (Millipore) to 200 µl. 
Concentrated CM samples were aliquoted and stored at -80°C.   
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6.2c SDS-PAGE and digestion 
Samples of 30 µl of concentrated CM were fortified to 50 mM DTT and 10 µl of 4 x 
Laemmli buffer were added. Samples were separated by SDS-PAGE using 12% Tris-
glycine gels. Samples were stained in colloidal brilliant blue dye (Sigma) for 24 hours, 
then with fresh dye for a further 24 hours. Gels were extensively destained in water 
and digitally imaged on a Bio-Rad GS800 scanner using Quantity One software 
(Biorad). Gels were reduced in 50 mM DTT for one hour and then alkylated in 30 mM 
iodoacetamide for one hour. Each lane of proteins in the gel was cut into 50 bands. 
These were dried in vacuo  prior to digestion with alkylated trypsin (Promega) 
overnight at 37°C in 30 mM ammonium bicarbonate. The resulting mixture of peptides 
was extracted in 20% acetonitrile containing 0.1% trifluoroacetic acid. 
 
6.2d Mass spectrometry 
Peptides were separated by reverse-phase HPLC: a 45-min linear gradient was 
developed from 3% to 50% acetonitrile in 0.1% formic acid on a C18 column (Dionex 
PepMap100, 100mm x 75 µm) using an Ultimate 3000 system (Dionex). Data-
determined acquisition was performed on a MicroMass Q-ToF Micro (Waters) using 
ProteinLynx 4 software. Peak lists were generated by the MassLynx 4.0 PeptideAuto 
program using default parameters, and used by Mascot 2.205 (Matrix Science, UK) to 
interrogate the human sequences (148148 sequences)  of the MSDB 20060831  non-
redundant sequence database annotated 31
st  August 2006 
225. Search parameters allowed 
not more than a single missed cleavage site, all cysteine residues to be modified by 
carbamidomethylation, and variable oxidation of methionine residues. Precursor and 
fragment ion mass tolerance were set to 1.2 and 0.6 Da respectively. Peptide identity  
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were accepted provided that their Mowse scores were above 38 (p < 0.05). The 
assignments were manually verified by checking that there were several consecutive y or 
b-ions. Proteins were accepted on the basis of the combined scores from more than one 
peptide ion; except for one protein identification which was accepted on the basis of data 
from a single peptide because it had eight out of ten consecutive y-ions.    
 
6.2e Analysis of identified proteins 
Mascot accession numbers were uploaded as CSV files to Protein Centre software 
(Proxeon) for the analysis of identified proteins. This software uses a knowledge base 
derived from the published literature to relate gene products to each other based on their 
interaction and function. The cellular localization of proteins in each sample was 
identified and examined in greater detail for proteins expressed in two or more cell lines.  
 
6.2f Validation of proteins 
For validation of possible marker proteins the following assessment was performed: 
western blot analysis of the CM was performed to confirm that the correct protein had 
been identified, immunohistochemical analysis was performed on sections prepared 
from paraffin embedded NET tissue, and serum analysis was performed on samples 
prepared from a cohort of NET patients and controls.  
 
6.2g Western blotting 
Samples of 30 µl of concentrated CM were separated by SDS-PAGE; proteins were 
transferred to PVDF membranes (Invitrogen iBlot) and soaked in blocking solution (5% 
(w/v) skimmed milk powder in TBS-T (20mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.1%  
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(v/v) Tween-20) for 2 hours at room temperature. One membrane was incubated with 
1% (w/v) skimmed milk powder in TBS-T, whilst a duplicate was incubated in the same 
buffer incorporating 1.5 µg/ml anti-Mac-2BP polyclonal mouse antibody (Bender 
Systems). Both membranes were incubated for 16 hours at 4°C. Membranes were 
washed with TBS-T three times for 10 min each and subsequently incubated in 
horseradish peroxidase-conjugated goat anti-mouse IgG antibody (diluted 1: 5,000 in 
blocking solution) for 120 min at room temperature.  After another three washes in TBS-
T, immuno-reactive bands were detected using the enhanced chemi-luminescence 
reaction (ECL, General Electric). 
 
6.2h Immunohistochemistry 
The study population included all major NET subtypes including: 9 foregut, 16 mid-gut, 
2 paragangliomas and 6 NETs of unknown primary. Sections of 3 μm of tumor tissue 
were de-waxed three times in xylene and rehydrated in ethanol. Slides were submersed 
in 10mM citric acid (pH 6.0) for 2 min in a pressure cooker, cooled immediately in 
water, and transferred to fresh water at room temperature for 5 min. All slides were 
blocked in normal horse serum containing avidin and biotin for 40 min, before 
incubation with anti-Mac-2BP rabbit polyclonal antibody (Bender Systems) at a dilution 
of 1:400 for one hour at room temperature. Biotinylated secondary antibody was 
incubated with slides for 30min. Bound antibody was visualized using a DAB 
peroxidase substrate kit. Sections were counterstained with Mayer’s haematoxylin for 
3.5 min. As Mac-2BP expression is upregulated in gastric carcinomas 
240, these were 
selected as positive controls. Negative controls included substitution of the primary 
antibody with normal horse serum.    
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6.2i Tumor classification 
Tumours were classified according to their site of origin, degree of differentiation and 
initial mitotic index. Two examiners (R.S. and J.W.) independently interpreted each 
immunohistological result. Discordances were jointly reviewed to reach agreement or 
determine an average value for disputed sections. Slides were scored on the basis of 
intensity of staining whereby 0 = negative, 1 = weakly positive, 2 = moderate, 3 = 
strongly positive. The extent of tumor staining was also scored, whereby 10 random high 
power fields were assessed to determine the average percentage of positive staining cells 
in which: 1 = <25%, 2 = 25 - 75% and 3 = >75%. The product of the density of staining 
and the percentage of tumor cells staining positive was used as the histological score, 
giving final values of 0,1,2,3,4,6,9 
181. 
 
6.2j Blood analysis  
For Mac-2BP, serum was obtained from 47 patients with proven diagnosis of NETs and 
24 healthy controls. Control subjects had no history of cancer and were age and sex 
matched. The study was approved by the Local Ethics Committee and all participants 
gave written informed consent prior to obtaining samples. The cohort of NET patients 
included 3 paragangliomas, 15 pancreatic, 25 small bowel, 1 large bowel and 3 bronchial 
NETs. Serological measurement of Mac-2BP was performed using an enzyme linked 
immunosorbance assay (ELISA), from Bender Systems. 
 
CgA analysis was performed on blood samples from patients using a radio-immuno 
assay (RIA) kit (Roche). As this assay has previously been validated and is currently 
used in clinical practice, no samples were run on normal healthy controls.  
  
  135 
6.2k Statistical analysis 
Statistical software (Graph Pad Prism Software, San Diego, CA) was used for the 
analysis. All values are given as median (plus range). As the values did not fit a standard 
distribution non-parametric analysis was performed. The Mann-Whitney U test was used 
to compare patients and control groups, and the Kruskal-Wallis test was used to compare 
multiple groups. Spearman correlation of rank coefficient was used to analyze 
correlations between parameters. Spearman correlation was also used to analyze 
correlation between Mac-2BP immunohistochemistry and other parameters.  
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6.3 Results 
6.3a Identification of CM proteins using SDS-PAGE and mass spectrometry 
Using similar amounts of total protein from each CM (Figure 6.1), and after 
contaminants including porcine trypsin, and major human hair and skin keratins had 
been excluded, a total of 205 different proteins were identified in CM preparations from 
the three cell lines. 82 proteins were identified in the BON-1 CM, 102 proteins from 
NCI-H727 CM, and 101 from SHP-77 CM. 42 proteins were identified in the CM from 
two lines only, while 19 proteins were identified in the CM from all three cell lines 
(Figure 6.2). 
 
Sixty one proteins were present in CM preparations from two or more cell lines (Table 
6.1), and 24 of these are known to be extracellular and not permanently bound to cells. 
The number of unique peptides identified from each of these proteins is also shown. All 
of the 205 proteins were identified from two or more unique peptide identifications, 
range 2-20 (mean 6). For the 61 proteins in Table 6.1 the ion score range was from 37 to 
106 (mean 67), and the Mascot score ranged from 40 - 421 (mean 102).  
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Reference 
Protein 
Accession 
Protein  Cell 
line  Loc’n  Mass  Score 
% 
coverag
e 
No. 
peptides 
Ion 
score 
NP_033562  14-3-3 protein 
epsilon  BNS  C  29043  171  34  12  67 
NP_006817  14-3-3 protein 
theta/tau  NS  C  27633  129  13  4  101 
NP_663723  14-3-3 protein 
zeta/delta  BS  C  27614  73  12  3  60 
NP_001605  Actin gamma  BNS  C  41662  151  5  6  106 
NP_006399  AGR2  BS  E  19848  46  14  4  37 
NP_000286  Alpha-1-antitrypsin  NS  E  46737  49  4  3  41 
NP_001624  Alpha-1-
microglobulin  BS  E  38999  77  5  4  56 
NP_0011234
76  Alpha-actinin 1  BNS  C  10543
8  90  6  6  80 
NP_004915  Alpha-actinin-4  BNS  C  10472
3  90  6  9  80 
NP_000475  Alzheimer's disease 
amyloid beta protein  BS  M,E  86944  141  11  12  75 
NP_0010028
58  Annexin A2  BS  C,E  40280  70  7  4  68 
NP_001145  Annexin A5  BNS  C,E  35806  55  8  5  56 
NP_004351  Cadherin 1  BS  M,E  97456  212  8  13  67 
NP_0010095
66  Calsyntenin 1  BNS  M,E  10966
2  135  6  9  89 
NP_006126  CapZ alpha-1  BN  C  32792  87  14  5  64 
NP_001864  Carboxypeptidase E BNS  E  53151  115  13  8  50 
NP_001279  Chloride intracellular 
channel protein 1  NS  M  26792  63  27  9  63 
NP_001266  Chromogranin A   BNS  E  50688  95  3  4  64 
NP_001810  Chromogranin B 
(secretogranin 1)  BNS  E  78276  72  5  5  72 
NP_003460  Chromogranin C 
(secretogranin 2)  BNS  E  70810  97  7  5  81 
NP_005498  Cofilin-1  BS  C  18371  94  27  7  52 
NP_001814  Creatine kinase B  BN  C  42513  120  8  2  90 
NP_000090  Cystatin C  BS  E  15749  128  19  3  72 
NP_001952  Elongation factor 2 
(EF-2)  NS  C  95207  92  3  2  93 
NP_001419  Enolase, alpha  BNS  C  47038  97  4  2  97 
NP_001967  Enolase, beta  NS  C  46801  167  10  6  100 
NP_001966  Enolase, gamma  BNS  C  47138  84  7  4  84 
NP_000025  Fructose-
bisphosphate  BNS  C  39289  49  9  2  49  
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aldolase  
NP_000166  Glucose-6-phosphate 
isomerase  NS  C,E  63016  103  7  6  66 
NP_036545  Glutaminyl-peptide 
cyclotransferase   BS  C  40887  87  25  6  56 
NP_002037 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
BNS  C  35922  49  6  4  49 
NP_004855 
Growth 
differentiation factor 
15 
BS  E  34009  90  10  6  86 
NP_002131 
Heterogeneous 
nuclear 
ribonucleoprotein K 
transcript variant 
    50897  63  22  8  58 
NP_005336 
NP_002146 
NP_006588 
Hsp 70 protein 
1A/6/8  NS  C 
69921 
70897 
70767 
193  27  16  69 
NP_005338  Hsp 70 protein 5  NS  C  72202  133  14  9  79 
NP_003290  Hsp 90 beta 1 
(endoplasmin)  NS  C  92469  131  14  10  61 
NP_031381  HSP90AB1 protein  BNS  C  83133  65  6  5  61 
NP_0010179
63  HSP90AA1 protein  BNS  C  98030  421  25  20  99 
NP_002256  Importin beta, chain 
B  NS  C  97040  40  3  1  40 
NP_002207 
Inter-alpha-trypsin 
inhibitor heavy chain 
2 
BS  E  10633
3  102  15  10  69 
NP_002264  Keratin 8  BS  C  53573  71  6  3  61 
NP_002291 
L-lactate 
dehydrogenase, chain 
H 
NS  C  36507  54  17  7  49 
NP_005557 
L-lactate 
dehydrogenase, chain 
M 
BS  C  36558  126  23  12  69 
NP_005558  Mac-2-binding 
protein  BNS  E  65200  114  8  8  47 
NP_005908  Malate 
dehydrogenase  BN  C  36295  155  29  11  64 
NP_002108  MHC class I antigen; 
HLA-C  BS  M  40649  50  13  3  50 
NP_002406  MIF  BS  E  12345  76  9  3  52 
NP_006175  Nucleobindin 1  NS  C  53748  77  2  2  77 
NP_002565  Peroxiredoxin 1  BS  C  21979  67  18  3  50 
NP_005800  Peroxiredoxin-2  BS  C  21761  45  5  2  45 
NP_005013  Profilin  BS  C  14923  209  23  4  90 
NP_000468  Serum albumin  BNS  E  69368  115  3  2  68  
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NP_006746  TALDO1  NS  C  37409  56  8  6  46 
NP_003237  Thrombospondin 1  BS  E  129383  208  8  12  70 
NP_003245  TIMP1  BS  E  23189  50  5  2  50 
NP_000356  Triosephosphate 
isomerase  BS  C  26538  89  11  7  70 
NP_002760  Trypsin (PRSS1)  BS  E  26558  43  12  4  43 
NP_003339  Ubiquitin-protein 
ligase E2N  BS  C  17007  64  13  2  65 
NP_079493  UL16 binding 
protein 2  BS  M,E  27237  51  11  4  51 
NP_009057  VCP  NS  C  89191  51  18  11  47 
NP_003369  VGF, NGF-
inducible  BNS  E  67275  152  22  18  97 
 
Table 6. 1. Proteins secreted by two or more cell lines.61 proteins were identified from 
two or more cell lines. Proteins found reproducibly in three BON-1 CM analyses are 
shown in bold. Cellular location (Loc’n) was identified using Protein Center and 
extensive literature searches (C, cytoplasmic; E, extracellular and not constitutively 
membrane-bound; M, membrane-bound); in many cases more than one cellular location 
has been reported for proteins.  Cell lines from which proteins were identified are 
indicated (B, BON-1; N, NCI-H727; S, SHP-77). Reference Protein Accession numbers 
are from the NCBI Protein database (National Center for Biotechnology Information, 
USA); Mass is the predicted mass of the precursor in Daltons; Score is the Mowse score; 
Ion score is the highest Mowse score for individual peptides. 
 
Of the 61 proteins identified in CM preparations from two or more cell lines, 
Chromogranins A, B and C were detected in the CM from all three cell lines. CgA 
secretion is consistent with previous studies which had demonstrated that this protein is 
secreted by all three cell lines 
237;241-244. Chromogranin A was used as the positive 
controls for the analysis of each preparation and each cell line during this investigation. 
 
The reproducibility of each protein identified in a secreted proteome was assessed using 
the BON-1 cell line: repetition of the entire procedure demonstrated that 81% of the 82 
BON-1 proteins in Table 6.1 could be reproducibly identified. However when approx.  
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50% less protein was analyzed in a third series of experiments, only 46% of the initial 
set of proteins could be identified. In addition to establishing the importance of sample 
loading, variation in the presence of cytosolic, membrane and extracellular matrix 
(ECM) proteins was also apparent in different CM preparations, indicating empirical 
variations in cell detachment and incorporation of ECM. 
 
 
Figure 6. 1. SDS-PAGE separation of CM preparations. Duplicate aliquots of CM from 
each cell line  were fractionated by SDS-PAGE and stained with Coomassie Blue. 
Marker protein positions and molecular weights (kDa) are indicated. 
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Figure 6. 2. Distribution of proteins secreted by three neuroendocrine cell lines. (A) 
Venn diagram showing in parentheses the total number of different proteins identified in 
the CM for each cell line (B, BON-1; N, NCI-H727; S, SHP-77), as well as the number 
of proteins identified exclusively in one, two or all three cell lines. (B) Pie chart 
illustrating the progressive selection of candidate NET markers from the 205 CM 
proteins exclusively present in CM preparations from one (1 CM), two (2 CM) or three 
(3 CM) cell lines. 
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6.3b Cellular location of CM proteins 
The cellular location of each protein identified using Protein Centre and NCBI 
databases, revealed that many proteins have been reported to be present in more than one 
location. Verification and further refinement of protein localization was based on 
extensive mining of the research literature, though we cannot exclude the possibility that 
intracellular and cell surface proteins or fragments thereof are secreted by the cell lines 
used in this study. Of the 19 proteins found in CM preparations from all three cell lines, 
9 are known to be secreted (Table 6.1).  Furthermore, of these 9 proteins, 5 were found 
in every run performed, including replicates  (Figure 6.2a). These 5 proteins 
(carboxypeptidase E, CgA, NGF-inducible VGF, serum albumin and Mac-2BP) were 
therefore the most suitable for consideration as markers (Figure 6.2b). 
 
Comparison between proteins secreted by NET cell lines and normal tissue 
In this study, we opted to focus on proteins not detected in normal neuroendocrine 
secretory vesicles (SVs), as these may be more sensitive markers and may also be 
involved in tumor development or progression. We compared the soluble proteins from 
neuroendocrine SVs isolated from normal tissue 
245 and the CM preparations in order to 
identify proteins that are not specific to transformed cells: 18 of the 205 proteins from 
NET cell line CMs were found in SVs. 10 of these proteins were present in the 61 
proteins secreted by two or more NET lines, and 3 were present in the 5 secreted 
proteins found in every preparation (Figure 6.2b). Finally, we excluded proteins found 
by Lin et al. 
246 to be commonly identified in comparative proteomic studies of a variety 
of different tissues. Accordingly, albumin was not studied further, leaving Mac-2BP as 
the best candidate marker. 
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6.3c Assessment of Mac-2BP as a marker for NET 
 
Western Blotting 
Mac-2BP has not previously been studied as a potential marker for NET and was 
selected for validation, initially by Western blotting. Blots were performed on the CM 
from all three cell lines in order to test for the presence of Mac-2BP, using a parallel blot 
which was not probed with primary antibody as a negative control (Figure 6.3). Both 
Mac-2BP was identified in the CM from all three cell lines, consistent with the 
identifications made by LC-MS/MS.  
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Figure 6. 3. Western blotting of conditioned media to confirm Mac-2BP expression by 
all NET cell lines. Western blots of equal loadings (30μl) of CM from each cell line (B, 
BON-1; N, NCI-H727; S, SHP-77) using (A) anti-Mac-2BP antibodies and (B) no 
primary antibody.  Marker protein positions and molecular weights (kDa) are indicated. 
 
6.3d Immunohistochemistry 
In order to test whether Mac-2BP was elevated in different types of tumor and 
surrounding stromal tissue, immunohistochemistry was performed on biopsy samples 
from 33 patients with previously diagnosed NET. Twenty-nine of these samples had 
positive staining for Mac-2BP (Figure 6.4a) localized in each case to tumor areas. 
Staining was predominantly cytoplasmic with no nuclear staining apparent (Figure 6.5), 
and was seen in all types of neuroendocrine tumor examined (pancreatic, ileal, 
paraganglioma and tumours of unknown primary origin) (Figure 6.4b). The strength of 
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staining showed no apparent correlation with tumor type. The 4 cases with no detectable 
staining for Mac-2BP were all well-differentiated neuroendocrine carcinomas. We found 
no significant correlation between tumor grade and staining for Mac-2BP. 
 
A 
                
B 
 
Site  Number of cases  Mac-2BP staining 
Total  Positive  Intensity  Area 
Pancreatic  9  9  1-3  1-3 
Ileal  16  15  1-3  1-3 
Paraganglioma  2  1  2  2 
Unknown  6  4  1-3  2-3 
Total  33  29     
 
 
Figure 6. 4. Immunohistochemical analysis of Mac-2BP expression in NET tissue  
(A) Tumor samples from a panel of different NET types were scored according to the 
intensity of immunohistochemical staining for Mac-2BP (histological score). (B) Details 
of the intensity and scoring ranges are shown for each NET type, showing the number of 
cases in total, the number of cases with positive uptake (i.e. score >2), the intensity 
scored on a scale of 1 to 3, where 1 = weak, 2 = moderate and 3 = intense; and the area 
scored on a range of 1-3, where 1 = <25%, 2 = 25-75% and 3 = >75% positively stained.  
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Figure 6. 5. Immunohistochemical staining of NET and normal tissue for Mac-2BP. 
Fixed tissue sections  were stained with anti-Mac-2BP antibody (brown) and nuclei 
counterstained with haematoxylin (blue). (A) Ileal  NET tissue shows predominantly 
cytoplasmic staining of the clusters of NET cells. The surrounding mucosa appears 
normal with no visible staining;  x200 magnification. (B) Midgut NET, clearly 
demonstrating staining of clusters of NET cells and negative staining of the surrounding 
tissue; x200 magnification. (C) Pancreatic NET showing cytoplasmic staining in the 
tumor cells; x400 magnification. (D) Ileal NET, clearly containing NET and normal 
cells. Normal tissue shows no evidence of epithelial staining while adjacent NET cells 
are clearly stained; x400 magnification. (E) Gastric cancer control showing staining 
moderate staining of gastric cancer cells, with minimal background staining; x 200 
magnification.  
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6.3e Serum Mac-2BP concentrations in patients with NET 
Mac-2BP  concentrations were assessed in serum samples from 47 patients and 24 
healthy control subjects (Figure 6.6a). The group of patients with NET taken as a whole 
(3.31 µg/ml, range 0.82-10.66 µg/ml) had a significantly higher serum Mac-2BP 
concentrations than the control group (2.30 µg/ml, range 1.16-3.56 µg/ml, p<0.001). 
When compared according to primary site of NET serum Mac-2BP was significantly 
elevated in NETs that originated from the midgut (3.34 µg/ml, range 0.82-10.66 µg/ml) 
compared to controls (p< 0.001)) as well as pancreatic NET (2.67 µg/ml, range 1.37-
10.50 µg/ml) when compared to controls (p<0.05). There was no significant difference 
in Mac-2BP concentrations between patients with pancreatic or midgut primary tumours. 
There was a positive correlation between CgA and Mac-2BP in patients with mid-gut 
NETs using a Spearman rank correlation (r = 0.36, p = 0.013), but no such correlation in 
pancreatic NETs. 
 
From radiological assessment of cross-sectional imaging performed within 2 months of 
blood sampling, visual assessments (by R.S) were made of the volume of liver 
metastases present. Three categories were created, low volume liver metastases 
(involving <25% of liver), intermediate (involving 25-50% of liver) and large volume 
liver metastases (>50% of liver). When comparing volume of liver metastases and Mac-
2BP concentrations using Kruskal-Wallis one way ANOVA test (Figure 6.6b), there was 
a significant difference between the groups (p = 0.024). This indicates that higher Mac-
2BP concentrations occur in serum with greater tumor burden. 
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Figure 6. 6. Serum Mac-2BP protein concentrations in patients and controls. Serum 
concentrations of Mac-2BP were assayed using an ELISA test. (A) A Mann Whitney U 
test demonstrates that serum Mac-2BP concentrations are significantly higher in patients 
than controls (p<0.001).  (B) A Kruskal Wallis one-way ANOVA test shows significant 
difference  in Mac-2BP  concentrations in NET patients with no metastases, small, 
intermediate and large volume liver metastases (p=0.024). 
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6.3f Assessment of the sensitivity and specificity of serum Mac-2BP as a marker for 
NET 
To investigate whether concentrations of Mac-2BP in the circulation could be useful as a 
marker of NET,  serum samples were taken from patients and control subjects. The 
concentrations of Mac-2BP were measured in the serum by ELISA. Receiver Operator 
Characteristic (ROC) curves for serum Mac-2BP were constructed to determine the cut-
off values (for set sensitivity and associated specificity of the assay for Mac-2BP) for all 
NETs. ROC curves are a graphical method of assessing the characteristic of a diagnostic 
test, by plotting sensitivity (true positive rate) against 1 – specificity (false positive rate). 
These parameters are employed as measures of the proportion of positives and negatives, 
respectively, which are correctly identified.  
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Figure 6. 7. Assessment of serum Mac-2BP as a NET marker. ROC curves and the 
corresponding area under the curve (AUC) are shown for (A) serum Mac-2BP 
concentrations in all types of NET, and (B) serum Mac-2BP from patients with midgut 
primary NETs.   
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Accuracy of the test is measured by the area under the ROC curve: an area of 1 
represents a perfect test, while an area of 0.5 represents a random association, generally 
>0.75 is regarded as a good marker. If the AUC was 0.75, then on average a patient will 
have a more abnormal Mac-2BP than 75% of controls. If the test was perfect, then every 
patient would have a more abnormal test result than every control and hence the AUC 
would equal 1. The AUC for all NETs was 0.77 (Figure 6.7a), which shows Mac-2BP is 
a good marker of NET. Serum Mac-2BP ≥ 2.41 µg/ml, was a highly sensitive marker 
(≥75%) for NETs; the associated specificity relative to the control group was 59.3% 
(Table 6.2). For the detection of mid-gut NET, the area under the curve was slightly 
higher at 0.79 (Figure 6.7b) and, at ≥75% sensitivity, the specificity was 70.8% (cut-off 
value >2.91 μg/ml).  
 
Since this marker is not proposed for population screening but for monitoring the disease 
status of NET patients, a high specificity in identifying patients with disease is more 
useful than a high sensitivity. Mac-2BP achieves 100% specificity for identifying 
disease in all of the NET patients when the cut-off value is increased to >3.58μg/ml, 
corresponding to a detection rate of 47% (Table 6.2).   
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Detection 
rate 
(Sensitivit
y) 
CI  
(%) 
Mac-2BP in all GEP NETs  Mac-2BP in mid-gut NETs 
Cut-off 
µg/ml 
FPR  
(%) 
CI 
(%) 
LR  Cut-off 
µg/ml 
FPR 
(%) 
CI 
(%) 
LR 
47%  32.1-
61.9 
>3.58  0  85.6-100    >3.59  0  85.6-100   
75%  59.7-
86.0 
>2.41  41.7  22.2-
63.4 
1.8
0 
>2.91  29.2  12.2-
44.6 
2.5
6 
80%  66.7-
90.9 
>2.06  58.3  37.4-
78.2 
1.3
7 
>2.30  50.0  29.2-
61.8 
1.6
0 
85%  71.7-
93.8 
>1.97  58.3  36.4-
77.2 
1.4
6 
>2.02  58.3  36.4-
77.9 
1.4
6 
90%  76.9-
96.5 
>1.72  66.6  45.3-
84.3 
1.3
5 
>1.94  58.2  37.0-
77.7 
1.5
5 
95%  85.5-
99.5 
>1.65  70.2  45.3-
84.3 
1.3
5 
>1.70  66.6  44.7-
84.3 
1.4
3 
 
Table 6. 2.  Assessment of serum Mac-2BP as a marker for all gastro-enteropancreatic 
(GEP) NETs and mid-gut NETs. The detection rate (sensitivity) is the total true positive 
results divided by the true positive and false negative results; False positive rate (FPR) is 
100%-specificity; Confidence interval (CI); Likelihood ratio (LR) is sensitivity divided 
by 1-specificity. At concentrations of >3.58 µg/ml Mac-2BP is 100% specific for NETs.   
 
 
6.3g The combination of Mac-2BP and Chromogranin A as biochemical markers of 
NET 
The CgA assay (at a cut-off >60 pg/ml) correctly identified 72.3% (34 out of 47) of the 
NET cases in our patient population. Serum Mac2-BP at a cut-off of >3.58 µg/ml has 
100% specificity for NET (Table 6.2).  Using this threshold, an additional five cases 
(10.6%) were identified as positive for NET. The combination of these two biochemical 
markers correctly identified 82.9% of the NET cases in this cohort of patients.   
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6.4 Discussion 
In this study we analyzed samples of serum-free media that had been conditioned by 
three neuroendocrine cell lines: NCI-H727, BON-1 and SHP-77.  Protein identifications 
were only accepted when at least two peptides from the protein produced a significant 
Mowse score, apart from one case where a convincing series of y-ions was identified. 
This stringency may have reduced the number of proteins identified, but increases the 
confidence of identifications. We identified 9 extracellular proteins including Mac-2BP 
that are secreted by all three cell lines. Mac-2BP is expressed in 88% of 
immunohistochemical samples and serum concentrations of Mac-2BP are significantly 
higher in patients than controls. 
 
BON-1 is a pancreatic neuroendocrine cell line 
243, and NCI-H727 and SHP-77 are 
bronchial neuroendocrine tumor cell lines. In the present study the established NET 
serum markers, chromogranins A, B and C, were identified in the CM of all three lines, 
consistent with the neuroendocrine phenotype of these cells. These proteins have not 
been reported in the secretomes of several non-NET cell lines 
237;239;247-249, and were 
found in normal neuroendocrine secretory vesicles 
245. However, these proteins possess 
limitations as NET biomarkers. 
 
Several other proteins identified here in the CM of NET cell lines  have also been 
identified in other cancer cell lines and have postulated roles in cancer, including heat 
shock protein 70, heat shock protein 90, laminin alpha-5 chain, thioredoxin reductase, 
annexin A2, glutathione-S-transferase, Mac-2BP, and nerve growth factor (NGF) 
inducible VGF 
239;250-252. Consequently they are potential markers of different types of 
tumor. Furthermore, a number of these proteins may be involved in the  
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pathophysiological development or progression of tumours, including NETs. Amongst 
the 9 proteins of specific interest to this study because they were secreted by all 3 cell 
lines, we chose to focus on Mac-2BP for validation because it was reproducibly detected 
in replicate CM preparations, and was not found in normal neuroendocrine secretory 
vesicles or as a commonly occurring component of tissue proteomes.  
 
Other proteins identified in this study may still prove of value as markers: a study by 
Rindi et al. 
252 has previously established that NGF-inducible VGF is expressed in the 
majority of NETs, and it is likely that combinations of markers will prove more specific 
than individual markers. Future work will address the potential value of other proteins in 
this set, individually and in combination. 
 
Mac-2BP is elevated in patients with a variety of different cancers, including breast, 
nasopharyngeal and lung cancer 
253-255. It is associated with poor survival and metastatic 
spread of liver and lung cancers 
256;257. This study indicates that Mac-2BP is also 
elevated in patients with NETs: (i) Mac-2BP concentrations were significantly elevated 
in both pancreatic and mid-gut NETs; (ii) elevation of serum Mac-2BP is related to 
volume of liver metastases; (iii). CgA is currently the most commonly used NET 
marker, but it does not offer accurate prognostic information and its accuracy is 
dependent on the assay used. Furthermore, CgA is labile and blood samples need to be 
collected on ice and stored frozen prior to analysis. Consequently, additional studies are 
warranted to assess a role for Mac-2BP as biochemical NET marker.  
 
Using a threshold of >3.58 µg/ml Mac-2BP is a 100%-specific marker in identifying 
NETs in this study. The low likelihood ratio of Mac-2BP and its high false positive rate 
means that it currently would not be useful as a sole screening marker. We have found  
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that the serum concentrations of Mac 2-BP >3.58 µg/ml can identify additional cases of 
NET which would not have been identified using the standard assay for CgA. Mac-2BP 
could be used as part of a panel of markers for diagnosing NETs; although a large-scale 
study would be needed to validate this approach. The other role for serum concentrations 
of Mac-2BP could be in identifying patients with progressive disease or increases in 
tumor load, since Mac-2BP shows a significant trend with increasing tumor load. 
 
Mac-2 BP, also known as 90K, is an oligomeric glycoprotein composed of subunits of 
approximately 90 kDa 
258;258, and binds galectin-1, -3 and -7. Several lines of evidence 
support a role for galectins in tumor invasion and metastasis. These proteins have been 
reported to mediate apoptosis, cell proliferation and angiogenesis 
251;259.  The 
mechanisms underlying the role of Mac-2BP and galectins in cancer may be related to 
the ability of these proteins to interact  with and modulate cell-cell and cell-matrix 
adhesion and apoptosis 
260;261. Inohara and co-workers found that Mac-2BP can mediate 
homotypic cell adhesion and the formation of multi-cellular aggregates by cross-linking 
galectin-1 and -3 residues on adjacent tumor cells 
262. This process appears to be critical 
for cancer cell survival in the bloodstream and may be a vital step in metastatic 
diffusion. Moreover, Mac-2BP and galectins are also located in the ECM where they 
may play a role in cell attachment by binding to ß1 integrins, collagens, and fibronectin 
261;263. 
 
Further studies will be required to assess the suitability and reliability of Mac-2BP as a 
marker of NET. It will be necessary to determine whether there is diurnal variation of 
Mac-2BP by sampling serum from patient and controls subjects several times a day. A 
study to determine changes in serum Mac-2BP following different treatments such as 
chemotherapy, radiotargetted therapy or surgical resection would be of benefit to  
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identify if Mac-2BP is related to concentration of disease activity. Finally, larger studies 
could assess whether Mac-2BP would be useful as a prognostic marker in patients with 
NETs.   
 
In summary, the identification of the secreted proteome of NET cell lines has established 
a panel of possible biomarkers for NET. Extensive studies will be required to rigorously 
assess the potential of Mac-2BP as a marker for the clinical management of NET and to 
elucidate the pathophysiological role of Mac-2BP. This study provides evidence for the 
utility of this combination of CM preparation, LC-MS/MS and immunological methods 
to identify putative serum markers from cultured cells, and their initial assessment using 
clinical samples. This combination is a powerful strategy for finding and evaluating 
potential serum markers for NETs and other types of cancer.  
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Chapter 7: The role of 
68Ga-DOTATATE PET in patients with 
neuroendocrine tumours and negative or equivocal 
111In-DTPA-
octreotide scintigraphy 
 
Abstract  
 
Introduction: 
111In-DTPA-octreotide scintigraphy is currently the nuclear medicine 
imaging modality of choice for identifying NETs. However, there are cohorts of patients 
in whom scintigraphy is negative or equivocal. The aim of this study was to determine 
whether 
68Ga-DOTATATE PET  identifies lesions and alters clinical management in 
patients with negative or weak positive 
111In-DTPA-octreotide scintigraphy.  
 
Methods: Fifty-one patients with histologically confirmed diagnosis of neuroendocrine 
tumours and negative (35 patients) or equivocal (16 patients) uptake on 
111In-DTPA-
octreotide scintigraphy underwent 
68Ga-DOTATATE PET. Findings were compared by 
using a region-by-region analysis. All findings were verified with CT and/or MRI. 
Following 
68Ga-DOTATATE PET, all cases were reviewed to determine whether the 
68Ga-DOTATATE PET findings resulted in any alteration in management, in terms of 
suitability for peptide receptor therapy, somatostatin analogues and surgery. 
 
Results: Of the 51 patients, 47 had evidence of disease on cross-sectional imaging or 
biochemically. 
68Ga-DOTATATE PET was positive in 41 of these 47 patients (87.2%). 
No false positive lesions were identified. 
68Ga-DOTATATE PET detected 168 of the 
226 lesions (74.3%) which were identified with cross-sectional imaging. 
68Ga-
DOTATATE PET identified significantly more lesions than 
111In-DTPA-octreotide  
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scintigraphy (p<0.0001). 
68Ga-DOTATATE imaging changed management in 36 
patients (70.6%), who were subsequently deemed suitable for peptide receptor targeted 
therapy.  
 
Conclusion: In patients with negative or equivocal 
111In-DTPA-octreotide scintigraphy, 
68Ga-DOTATATE PET imaging identifies additional lesions and may alter management 
in the majority of cases. 
 
Experimental work:  Interpretation of Ga-68-DOTATATE PET and 111-In-DTPA-
Octreotide scintigraphic images was performed by I. Kayani, A.M Quigley and 
J.Bomanji.   
  158 
7.1 Introduction 
Somatostatin receptor (SSTR) overexpression in NETs has enabled development of 
imaging with scintigraphy using radiolabelled somatostatin analogues 
264;265.  To date, 
five SSTRs have been characterised, all of which are expressed in differing frequencies 
in NETs 
266. SSTRs 2 and 5 are expressed in 70–90% of NETs 
165;266. Radiolabelled 
somatostatin analogues can allow visualisation and staging of carcinoid tumours 
expressing SSTRs 2 and 5 
267. The most commonly used radioligand is 
111In-DTPA-
octreotide, which is commercially available as 
111In-pentetreotide. The expression of 
SSTRs in these tumours allows radionuclide therapy, subject to good uptake of 
somatostatin radiolabelled analogues. To date this has been assessed using 
111In-DTPA-
octreotide scintigraphy 
41;103.  
 
111In-DTPA-octreotide binds predominantly to SSTR2-positive cells and emits gamma 
rays which enable imaging of SSTR2-positive NETs 
268. There are limitations with this 
technique, and it has restricted ability to identify lesions of <1 cm and to obtain good 
spatial resolution, even when employing single-photon emission computed tomography 
(SPECT) 
269. In the last few years, studies using 
68Ga-DOTATOC PET in NETs have 
shown promising results, with a higher rate of lesion identification than is achieved with 
conventional 
111In-DTPA-octreotide scintigraphy 
270-272. This study used DOTA-DPhe, 
Tyr-octreotate (DOTATATE), a somatostatin 2 receptor analogue 
273, labelled with 
68Ga, 
a positron emitter. 
68Ga is produced from a 
68Ge/
68Ga generator and therefore is not 
dependent on a cyclotron.  
 
The study had three aims: first, to assess whether 
68Ga-DOTATATE PET imaging 
identifies SSTR2-positive disease in NET patients with negative or weakly positive 
111In-DTPA-octreotide scan; secondly, to establish whether there is any association  
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between tumour histology and lesion identification using 
68Ga-DOTATATE PET; and 
finally, to evaluate whether 
68Ga-DOTATATE PET alters clinical management in 
patients with weak or negative 
111In-DTPA-octreotide scan.  
 
7.2 Materials and Methods 
7.2a Study population 
During the period from November 2006 to March 2008 a total of 312 patients underwent 
111In-DTPA-octreotide scintigraphy. Of these, 51 were referred for 
68Ga-DOTATATE 
PET owing to scintigraphy being negative or showing only low grade uptake of tracer 
(Krenning score <2). Images were reviewed prospectively and clinical data from the 51 
patients (27 men, 24 females; age range 18-80 years, median age 55.5), who were 
imaged with 
68Ga-DOTATATE PET/CT between January 2007 and April 2008. Forty 
five cases underwent chest, abdomen, and pelvis CT scans, 2 had abdominal MRI scans 
and 4 had chest, abdomen, and pelvis CT scans and additional MRI of liver. All patients 
gave informed consent.  
 
The primary tumour origin was as follows: medullary thyroid, 2; thymic carcinoids, 2; 
paraganglioma, 2; hindgut, 2; bronchial, 2; pancreatic, 13; midgut, 22; the remaining six 
patients had cancer of unknown primary origin (Table 7.1). All patients had a previous 
histological diagnosis of NET and all had undergone an 
111In-DTPA-octreotide scan 
within a median time of 4 months (range 1-8 months) of the 
68Ga-DOTATATE PET 
scans. The number of cases from each anatomical site is listed in Table7. 2. Histology 
was available in all cases and tumour grade was classified as low, intermediate or high, 
using the proposed European Neuroendocrine Tumour Society (ENETS) criteria for  
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grading Gastroenteropancreatic NETs 
19;21. The classification was extended to include 
tumours of other sites and cancer of unknown primary origin. 
 
7.2b Image acquisition  
68Ga-DOTATATE PET: Images were acquired 1 h post injection of 120-200 MBq of 
68Ga-DOTATATE. No adverse effects were observed after the injection of 
68Ga-
DOTATATE. Imaging was performed using a dedicated combined GE Discovery LS 
PET/CT unit (Michigan, USA); whole-body examinations (mid brain to mid thigh) were 
performed with the patient supine.  
CT was performed using the four 3.75-mm detectors, a pitch of 1.5 and a 5-mm 
collimation. The CT exposure factors for all examinations were 140 kVp and 80 mA in 
0.8 s. Maintaining patient position, a whole-body PET emission scan was performed and 
covered an area identical to that covered by CT; scans were performed in 3D mode. All 
PET acquisitions were carried out in 3D mode (4 min per bed position), approximately 
30 minutes scanning time. PET images were reconstructed using CT for attenuation 
correction. Transaxial emission images of 4.3 x 4.3 x 4.25 mm
3 were reconstructed using 
ordered subsets expectation maximization (OSEM) with two iterations and 28 subsets. 
The axial field of view was 148.75 mm, resulting in 35 slices per bed position. Long-
acting somatostatin analogues were not stopped prior to imaging with PET or 
111In-
DTPA-octreotide scintigraphy. 
 
111In-DTPA-octreotide SPECT:  Patients were injected with 200 MBq of 
111In-
pentetreotide IV (Covidien, Petten, Netherlands). Whole-body images were acquired at 
24 h post injection on a dual-headed gamma camera (Picker Prism, Phillips Medical 
Technology, Cleveland, Ohio) using a medium-energy collimator. Patients were scanned  
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with a camera speed of 7.2 cm/min, matrix 256 x 1024. Photopeaks were set at 173 and 
247 keV with +/- 10% windows with no offset. Abdominal images were obtained from 
the dome of the liver downwards. An additional chest and/or pelvic SPECT study was 
performed if warranted by the appearances of the whole body, or if abnormalities had 
been identified previously in other areas on cross-sectional imaging. Scan parameters 
were as follows: medium-energy collimator, 60 stops per head at 3º intervals, 25 s per 
stop, 64 x 64 matrix. The same energy window was used as with planar imaging. Images 
were processed and analysed at a workstation using Odyssey software (Phillips Medical 
Technology, Cleveland, Ohio). They were reconstructed using an iterative OSEM 
programme with six iterations and post filtered with a count-optimised Butterworth 
filter. Images were displayed as a full data set of orthogonal slices of 9-mm thickness.  
 
The images from 
68Ga-DOTATATE PET/CT were reported in consensus by an 
experienced dedicated nuclear medicine physician and a dual accredited 
radiologist/nuclear medicine physician, who were unaware of the results of the previous 
111In-DTPA-octreotide study. Areas of abnormal focal uptake were documented. The 
relative uptake of 
68Ga-DOTATATE was evaluated on the basis of intensity of tracer 
uptake (SUVmax). The images from 
111In-DTPA-octreotide scintigraphy were reported 
independently by an experienced nuclear medicine physician. Lesions identified were 
graded using the Krenning score as follows: 0 = no abnormality, 1 = faint uptake; 2 = 
clear uptake in the tumour, similar to the liver; 3 = uptake higher than in the liver; 4 = 
increased accumulation in the tumour much greater than that in the liver 
274.   
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7.2c Interpretation of data 
The number of lesions that could be identified clearly as single foci was determined for 
each patient. To enable a methodical and consistent approach to lesion identification, 
lesions were grouped into three categories: organs (lungs, breast, liver, pancreas, 
gastrointestinal tract, kidney, spleen and pelvis/ovaries), nodal regions (thoracic, 
mesenteric, abdominal and pelvic (excluding mesenteric)) and musculoskeletal system 
(vertebrae, bony thorax, bony pelvis and limb bones). Owing to confluency and inability 
to clearly delineate single liver lesions in some cases, liver metastases were classified as 
one organ metastasis, independent of the number of liver metastases present.  
 
To confirm the presence of lesions, all patients underwent cross-sectional imaging with 
CT or MRI scan. Patients who underwent 
68Ga-PET had combined PET/CT to confirm 
location of disease. Plasma chromogranin A  concentrations were available for all 
patients, and, where appropriate, fasting gut hormone concentrations and urinary 5-
HIAA were also measured. 
 
7.2d Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. The values were 
generally not normally distributed, so non-parametric tests were used to compare marker 
concentrations between groups, i.e. the Mann- Whitney U test (for two groups).  
 
7.3 Results 
In total, 51 patients underwent 
68Ga-DOTATATE PET and 
111In-DTPA-octreotide scan. 
Of these, 47 had evidence of disease on cross-sectional imaging; the four remaining  
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patients had undergone previous curative surgical resection and were under surveillance 
imaging. In the 47 patients with evidence of disease, a total of 226 lesions were 
identified on cross-sectional imaging (including MRI, CT and PET/CT) (Table 7.2). 
Thirty-five cases were negative with 
111In-DTPA-octreotide scintigraphy, while in the 
remaining 16 cases a total of 27 lesions were identified with a Krenning score <2. 
68Ga-
DOTATATE PET identified disease in 41 of 47 patients (87.2%) and detected 168 
(74.3%) of the 226 lesions identified on cross-sectional imaging. The number of lesions 
seen in each organ with each modality is listed in Table 7.3.  
 
7.3a Patient analysis 
Negative 
111In-DTPA-octreotide scintigraphy 
Among the 51 patients, 
111In-DTPA-octreotide was negative with no evidence of uptake 
(other than physiological uptake) in 35 cases. In three of these 35 cases, no disease was 
identified on cross-sectional imaging and patients had normal chromogranin A and 
fasting gut hormone concentrations.  The three patients with no evidence of disease on 
all modalities are considered to be disease free currently; all of these cases had 
undergone previous surgical resection.  
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Demographics  No. 
Male  27 
Female  24 
Mean age(years)  55.5 
Age range (years)  18-80 
   
Primary origin   
Bronchial  2 
Thyroid  2 
Thymic  2  
Pancreatic  13 
Midgut  22 
Hindgut  2 
Paraganglioma  2 
Unknown  6 
   
Histological grade   
Low  28 
Intermediate  19 
High  4 
   
Treatment   
Current therapy with 
somatostatin analogues 
27 
Previous surgery  9 
Previous chemotherapy  10 
 
Table 7. 1. Characteristics of study population 
 
 
The remaining 32 patients all had disease identified in cross-sectional imaging. Among 
these 32 patients, 
68Ga-DOTATATE was positive in 27 (Fig. 7.1 & 7.2). In total, 97 
lesions were identified in the 27 patients with positive 
68Ga-DOTATATE PET, whilst 
cross-sectional imaging identified 125 lesions in the 32 patients with disease.  
 
Five cases which were negative for both 
68Ga-DOTATATE PET and 
111In-DOTA-
octreotide had evidence of disease on cross-sectional imaging. In these cases, 27 lesions 
were identified on CT +/- MRI (Table 7.2). These tumours were all metastatic in nature; 
the primary sites were ileal and pancreatic in one case each, while three were from  
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unknown primaries. Two patients had functional syndromes (both carcinoid) and the 
remaining three had no syndromic features. Histology from these five cases showed two 
low-grade tumours, two intermediate-grade tumours and one high-grade tumour.  
 
Site  Histology 
 
No. 
of 
cases 
111In-DTPA 
octreotide 
scintigraphy 
68Ga-
DOTATATE 
PET 
Cross-
sectional 
imaging 
Bronchial  Low   1  1  1  1 
   Intermediate   1  0  14  14 
Thyroid  Low   1  0  0  1 
   Intermediate   1  0  1  1 
Thymic  Intermediate   1  0  1  4 
   High   1  1  1  1 
Pancreatic  Low   9  12  22  25 
   Intermediate   2  0  2  6 
   High   2  1  4  5 
Ileal  Low   12  7  40  48 
   Intermediate   10  3  38  46 
Paraganglioma  Low   1  1  17  17 
   Intermediate   1  0  12  12 
Unknown  Low   2  0  3  8 
   Intermediate   3  0  7  17 
   High   1  0  0  15 
Hindgut  Low   2  1  5  5 
Total lesions     51
b  27  168  226 
 
Table 7. 2. Total number of lesions identified in each type of NET with the different 
modalities. 
aHistological grade was determined using the proposed ENETS guidelines 
and extrapolated to include thymic carcinoid, unknown primaries and paraganglioma. 
b 
The total number of cases includes the four patients with no evidence of disease on 
cross-sectional imaging.  
 
7.3b Low grade/faint uptake 
111In-DTPA-octreotide scintigraphy 
In  sixteen  cases there was some uptake with 
111In-DTPA-octreotide scintigraphy; 
however, the uptake in the extra-hepatic lesion was low grade and notably less than that 
in the liver. Cross-sectional evidence of disease was identified in 15 of these cases. In 
one case 
111In-DTPA-octreotide scintigraphy identified very low grade uptake in the  
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mediastinum and left lung, which was commented on in view of the fact that the patient 
had medullary thyroid cancer, which had been previously resected.  Subsequently, there 
was no residual disease on cross-sectional imaging or uptake on 
68Ga-DOTATATE PET, 
and plasma tumour markers plus chromogranin A were normal. This was the only false 
positive result seen among all 51 cases. Positive uptake with 
68Ga-DOTATATE PET 
was seen in 14 of the 16 cases with low grade uptake on 
111In-DTPA-octreotide. A total 
of 101 lesions were identified with cross-sectional imaging in the 15 cases with disease; 
of these, 71 (70.3%) were identified with 
68Ga-DOTATATE PET.  
 
68Ga-DOTATATE PET was false negative in one case, which was an intermediate-grade 
non-functional pancreatic tumour. In this case 
111In-DTPA-octreotide scintigraphy 
showed faint uptake in the region of the gallbladder/liver, corresponding to the site of 
liver metastases.   
 
The sensitivity of 
111In-DTPA-octreotide scintigraphy was not determined in view of the 
bias of the sample population. The specificity of 
111In-DTPA-octreotide scintigraphy was 
98%, since there was only one false positive result. The sensitivity of 
68Ga-DOTATATE 
PET was 87.2% and the specificity, 100%.  
 
7.3c Lesion analysis 
Evidence of NET disease was identified in 47 of the 51 patients in this study by cross-
sectional imaging. A total of 226 lesions were identified with CT +/- MRI, whilst 
111In-
DTPA-octreotide scintigraphy identified 27 lesions and 
68Ga-DOTATATE PET 
identified 168 lesions. 
68Ga-DOTATATE PET identified 74.3% of all lesions, which is a  
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significantly higher than was identified by 
111In-DTPA-octreotide scintigraphy 
(p<0.001).  
 
The location of lesions (according to specific body region) identified by 
68Ga-
DOTATATE PET and by 
111In-DTPA-octreotide scintigraphy was compared (Table 
7.3). It is to be noted that SPECT scanning was only performed in the region of the chest 
and abdomen and therefore, skeletal metastases may not have been identified on planar 
imaging.  Thirty-six bony lesions were identified by 
68Ga-DOTATATE PET and CT +/- 
MRI, of which 28 were located in the rib cage or pelvis. Eight bony metastases were 
identified in the long bones (limbs).   
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 Organ/region 
111In-DTPA-
octreotide 
scintigraphy 
68Ga-
DOTATATE 
PET  CT +/- MRI 
Lung  3  9  16 
Breast  0  1  1 
Pancreas  4  6  6 
Liver  6  23  34 
GI tract  0  7  7 
Kidney  2  3  2 
Spleen  0  0  1 
Pelvis/ovaries  4  1  1 
Thoracic nodes  0  17  17 
Mesenteric nodes  1  19  37 
Abdominal nodes  7  27  45 
Vertebrae   0  19  23 
Bones   0  36  36 
Total   27  168  226 
 
Table 7. 3. Location of lesions identified by 
111In-DTPA-octreotide scintigraphy, Ga-
DOTATATE PET and cross-sectional imaging (CT +/- MRI). 
 
7.3d 
68Ga-DOTATATE PET and histology 
Histology was available in all cases. Table 7.4 shows the number of positive cases in 
patients with different grades of disease. The results in respect of 
111In-DTPA-octreotide 
are difficult to interpret in view of the selection of patients chosen. 
68Ga-DOTATATE 
PET showed good lesion recognition with low-grade tumours. The sensitivity of 
68Ga-
DOTATATE PET decreased in the more aggressive and poorly differentiated tumours; 
however, this reduction did not reach significance.  
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Histology 
No. of 
cases  Disease on cross-
sectional imaging 
111In-DTPA-
octreotide 
scintigraphy 
68Ga-DOTATATE 
PET 
Low  28  24  11 (45.8%)  22 (91.7%) 
Intermediate  19  19  3 (15.8%)  16 (84.2%) 
High  4  4  2 (50%)  3 (75%) 
Total  51  47  16  41 
 
Table 7. 4. Number of positive* 
111In-DTPA-octreotide scintigraphy and 
68Ga-
DOTATATE PET results in patients with different histological grades of disease. * 
Positive for 
111In-DTPA-octreotide scintigraphy means those with weak/ equivocal 
uptake. 
 
 
7.3e Positive 
68Ga-DOTATATE PET in conjunction with initially negative CT 
In two cases, patients had undergone initial scans with CT which had been reported as 
normal. One patient had normal biochemical markers and the other had raised 
chromogranin A concentrations. When these patients underwent 
68Ga-DOTATATE 
PET/CT, the PET identified multiple bony metastases; these were found to correspond 
with sclerotic foci on CT when PET/CT fusion images were reviewed.   
 
7.3f Change in clinical management 
To ascertain whether 
68Ga-DOTATATE PET altered the clinical management in patients 
who had already undergone 
111In-DTPA-octreotide scintigraphy, all the case notes were 
reviewed. Change in clinical management was classified into the following four 
categories: (1) consideration of 
90Y-DOTATATE radiotargeted therapy, (2) suitability 
for commencement of somatostatin analogues, (3) altered stage of disease and (4) 
consideration for surgical resection.  
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Among the 51 cases, management was altered in 36 (70.6%) following 
68Ga-
DOTATATE PET. Of these 36 cases, 20 were considered suitable for peptide receptor 
radiotargeted therapy with 
90Y-DOTATATE in view of the strength of tracer uptake on 
68Ga-DOTATATE PET. A further four patients with negative results on both 
68Ga-
DOTATATE and 
111In-DTPA-octreotide scans were excluded from peptide receptor 
therapy with 
90Y-DOTATATE. In seven patients without functional symptoms but with 
positive uptake on 
68Ga-DOTATATE PET, somatostatin analogues were commenced for 
their antiproliferative effects. 
 
In four cases, surgery was regarded as a possible treatment option in view of the limited 
and resectable disease. In 3 cases this was regarding disease localised to abdomen and 
pelvis and one case of disease limited to liver. In these cases 
68Ga-DOTATATE PET 
changed clinical management by confirming that the disease present on cross sectional 
imaging corresponded with areas of tracer uptake with PET imaging; which had not 
been identified with 
111In-DTPA-octreotide scintigraphy. Curative resections were 
performed in two cases, and there was no evidence of recurrence at 12 and 14 months. 
Another patient had debulking surgery of >90% of the tumour load and the remaining 
disease was stable at 6 months post surgery. The fourth case the patient has not 
undergone surgical therapy to date and is considering other treatment options.  
Finally, in one case in which there was no evidence of disease on CT scanning or 
biochemically, low-grade uptake in the mediastinum and left lung was observed on the 
111In-DTPA-octreotide scan. 
68Ga-DOTATATE PET did not reveal any evidence of 
abnormal uptake and the patient was regarded as disease free. In this case 
68Ga-
DOTATATE PET confirmed cross-sectional imaging findings but altered management 
by identifying no evidence of disease uptake, which had been seen on 
111In-DTPA-
scintigraphy.    
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7.4 Discussion 
This study is the first to demonstrate that 
68Ga-DOTATATE PET imaging can identify 
disease in patients with NETs when conventional 
111In-DTPA-octreotide scan is negative 
or shows only faint uptake. Furthermore, 
68Ga-DOTATATE PET imaging changed the 
clinical management in 70% of the patients studied.  
 
Although 
68Ga-DOTATATE PET identified disease in patients with negative or weakly 
positive 
111In-DTPA-octreotide scans, it did not map the full extent of disease. 
68Ga-
DOTATATE PET identified 74.3% of lesions documented by conventional cross-
sectional imaging. There were individual cases in which some lesions were 
68Ga-
DOTATATE avid whilst others were not. This illustrates the variable SSTR expression 
and heterogeneity of NETs, especially with intermediate- and high-grade tumours.  
 
Inherently, PET has superior spatial resolution to conventional SPECT imaging. Reubi 
et al have previously demonstrated that 
68Ga-DOTATATE bound SSTR-2 with a 
considerably higher affinity than 
111In-DTPA-octreotide 
166. The higher affinity of 
68Ga-
DOTATATE for the SSTR-2 may enable smaller lesions to be visualised on the 
PET/CT. It is very likely that SPECT imaging of the entire body would have identified 
more lesions, especially skeletal metastases, but whole-body SPECT is neither practical 
nor comfortable for patients. It was also observed that in areas where 
111In-DTPA-
octreotide SPECT and 
68Ga-DOTATATE PET were performed, the number of lesions 
detected with PET was greater. The 
111In-DTPA-octreotide scintigraphy protocol used in 
this study requires total scan time of 50mins to 1 hour, which for many patients is the 
most that can be tolerated. The SPECT imaging protocol in this study is similar to that  
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recommended in other guidelines 
275. Whilst longer whole body scanning times may 
enable smaller lesions to be visualised the target to background ratio will not be altered.  
 
Studies using 
68Ga-DOTATOC PET have also shown higher sensitivity and specificity 
than 
111In-DTPA-octreotide scintigraphy 
276. A study by Buchmann et al. in 27 patients 
demonstrated an increase in lesion identification with PET compared to 
111In-DTPA-
octreotide SPECT 
270. Another study by Gabriel et al., with a prospective design, 
compared 
68Ga-DOTATOC PET and 
111In-DTPA-octreotide SPECT in 84 patients and 
found that a significantly higher number of lesions were identified with 
68Ga-
DOTATOC PET 
271. 
 
The purpose of our study was not to directly compare the performance of 
111In-DTPA-
octreotide scintigraphy and 
68Ga-DOTATATE PET but to assess the clinical utility of 
68Ga-DOTATATE  PET/CT in a specific clinical subset with negative or low grade 
uptake of 
111In-DTPA octreotide.  In these patients we have clearly demonstrated that 
68Ga-DOTATATE PET imaging leads to changes in management. The role of 
68Ga-
DOTATATE PET seems to be similar to that of 
111In-DTPA-octreotide scintigraphy, in 
that its main clinical uses are in localisation of disease and assessment of suitability for 
treatment with somatostatin analogues and radiotargeted therapy. In this study, 39% of 
patients were deemed suitable for radiotargeted therapy with on the basis of 
68Ga-
DOTATATE PET imaging. To date 8 patients have received 
90Y-DOTATATE peptide 
receptor therapy, of which 7 have completed three cycles of therapy. Of these 7 cases, 5 
have achieved disease stabilization by RECIST criteria and 1 partial response (duration 
of follow-up 6-22months). 1 case showed initial disease stabilization, however, has 
progressed at 12 months post therapy. No difference in treatment response to peptide 
receptor therapy was observed between patients who were positive on 
68Ga- 
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DOTATATE PET and negative on 
111In-DTPA-octreotide scintigraphy compared to 
patients who received such therapy on the basis of positive 
111In-DTPA-octreotide 
scintigraphy. However, long-term follow-up data are required to confirm this finding.   
 
Suitability for somatostatin analogue therapy in patients with non-functional but 
receptor-positive tumours is important in view of the potential antiproliferative action of 
SST analogues. There is evidence of anti-tumour activity of SST analogues in patients 
with functional NETs 
277. It is postulated that patients with non-functional NETs and 
negative 
111In-DTPA-octreotide scintigraphy but positive 
68Ga-DOTATATE PET 
imaging may well benefit from somatostatin analogue therapy.   
 
In our study, 20 (39%) patients were deemed suitable for radiotargeted therapy with 
90Y-
DOTATATE on the basis of 
68Ga-DOTATATE PET imaging. Seven have completed 
therapy with Y-90 DOTATATE, 6 of whom achieved disease stabilization and one 
minor response (<25% reduction in liver metastases size). No statistical difference in 
treatment response to peptide receptor therapy was observed between patients who were 
positive on 
68Ga-DOTATATE PET and negative on 
111In-DTPA-octreotide scintigraphy 
compared to patients who received such therapy on the basis of positive 
111In-DTPA-
octreotide scintigraphy. However, long-term follow-up data are required to confirm this 
finding.  No studies have reported so far on response rates of patients who have 
68Ga-
DOTATATE PET positive but 
111In-DTPA-octreotide scintigraphy NETs.  
 
At the time of primary staging, 
68Ga-DOTATATE PET has an important role in the 
localisation of disease, especially in patients who are negative on 
111In-DTPA-octreotide 
imaging. From a surgical perspective, localisation of the primary lesion, nodal 
involvement and distant metastases is of primary importance. Our study has shown the  
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clinical utility of 
68Ga-DOTATATE PET in this setting, in that it provides accurate 
staging of disease.  
 
SSTR expression decreases as the histological grade of tumour increases, and high-grade 
tumours have limited SSTR expression 
278. In this study, 
68Ga-DOTATATE PET had 
similar sensitivities in identifying disease in low-, intermediate- and high-grade tumours. 
For an accurate assessment of the role of 
68Ga-DOTATATE PET in patients with low-, 
intermediate- or high-grade tumours, a study looking at unselected NET patients would 
be of benefit. Within the literature there is evidence that 
68Ga-DOTATATE PET is of 
limited value in patients with intermediate- and high-grade tumours and that FDG-PET 
may be more suitable for these cases 
273.  
 
Other PET tracers have also been trialled for imaging of NETs, including 
11C-5-
hydroxytryptophan and 
18F-fluoro-L-3,4-dihydroxyphenylalanine. These have shown 
promising results, with higher detection rates than those achieved with 
111In-DTPA-
octreotide SPECT and CT 
279. However, currently these substrates do not provide any 
therapeutic options, unlike somatostatin analogues, and therefore have limited clinical 
roles. 
 
In conclusion 
68Ga-DOTATATE PET imaging detects 74% of lesions in patients with 
negative or faint uptake (Krenning score <2) on 
111In-DTPA-octreotide scintigraphy and 
changes the clinical management in 70.6% of these patients   
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Figure 7. 1. Combined images demonstrating lesions using CT/ PET and 111In-DTPA-
Octreotide scintigraphy. A 69 year old male patient with a low grade metastatic midgut 
NET, A) Arterial phase CT scan identifying multiple arterial enhancing and low 
attenuation liver metastases. B & C) Anterior and posterior whole body 
111In-DTPA-
Octreotide scintigraphy showing low grade (Krenning score =1) mesenteric metastases 
(see arrow) but no liver metastases. D & E) SPECT axial images at level of spleen with 
heterogenous liver uptake and no discernable liver deposits. F) Maximum intensity 
projection (MIPS) image with 
68Ga-DOTATATE PET showing multiple deposits in the 
liver and mesentery. G) 
68Ga-DOTATATE PET  coronal section anterior to the kidney 
shows multiple liver metastases. H) Fused 
68Ga-DOTATATE PET/CT image of figure 
1G. I) Fused axial 
68Ga-DOTATATE PET/CT image at level of spleen showing multiple 
liver metastases. J) 
68Ga-DOTATATE PET axial image at level of spleen showing 
multiple liver metastases.  
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Figure 7. 2. Combined images demonstrating lesions using CT/ PET and 111In-DTPA-
Octreotide scintigraphy. A 42 year old male patient with intermediate grade metastatic 
midgut NET. A) Arterial phase CT at level of splenic hilum, showing two arterially 
enhancing liver metastases. B & C) Anterior and posterior whole body 
111In-DTPA-
Octreotide scintigraphy showing physiological uptake only. D & E) SPECT axial 
111In-
DTPA-Octreotide images at level of the spleen, no discernable liver lesions identified. F) 
MIPs image identifying liver metastases. G) 
68Ga-DOTATATE PET coronal section 
showing liver metastases. H) Fused PET/CT image of figure 2G.  I) Fused axial 
68Ga-
DOTATATE PET/CT image showing large metastatic liver deposit. J) Axial 
68Ga-
DOTATATE PET image showing large metastatic liver deposit.  
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Chapter 8: Overview and Discussion 
 
NETs can arise from almost any organ within the body and demonstrate a diverse range 
of tumour behaviour; ranging from benign to highly malignant poorly differentiated 
tumours.  Whilst many differences are present in tumour biology, there appear to be 
some similarities in terms of receptor expression and cellular pathways involved in 
oncogenesis.  
 
Chapter 2 
Somatostatin receptor expression in NETs is a well recognised feature of these tumours 
and provides the basis for nuclear medicine imaging with radiolabelled somatostatin 
analogues. It is known that low grade well differentiated tumours have high SSTR-2 and 
SSTR-5 expression, however, high grade tumours which are usually poorly 
differentiated loose expression of SSTR receptors. In chapter 2, we demonstrated a 
significant decrease in SSTR-2 and SSTR-5 receptor expression between low and high 
grade tumours, using immunohistochemistry. D2R  expression had previously been 
demonstrated in NETs using RT-PCR, our experiments demonstrated for the first time 
expression of D2R expression in NETs using immunohistochemistry. There is a strong 
correlation of D2R and SSTR-2 expression, in all grades of tumours; which means 
patients with positive somatostatin scintigraphy are likely to have tumours that express 
both SSTR-2 and D2R receptors.  
 
Dimerization of membrane receptors following response to external signal is a well 
recognised phenomenon 
280  and there is also evidence of hetero-oligomerization of 
somatostatin and dopamine receptors 
281. Studies in human SSTR5 and D2R receptors 
tranfected in CHO-K1 cell lines have shown evidence of hetero-oligomerization 
following ligand binding to either receptor 
281. Following receptor activation, of either  
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receptor, there is hetero-dimerization and these results  in enhanced function of the 
receptor. Rocheville et al, illustrated that binding of D2R receptor agonist, quinpirole, 
increased binding affinity of somatostatin by 3000% 
281.  Recently it was demonstrated 
that human D2R and SSTR2 also operate as functional heterodimers following ligand 
stimulation with enhanced functional activity 
148. 
 
Chimeric agents that bind both SSTR and D2R receptors have been developed and 
shown activity in patients with pituitary adenomas and also in in vitro studies in NET 
cell lines 
64;168;169.  Recent studies using the dopamine-somatatin chimeric compound 
BIM-23A760 has demonstrated antiproliferative effects in non-functional pituitary 
tumours 
282.  New chimeric agents such as BIM-23A387 may have a role in symptom 
control for patients with carcinoid syndrome who have become resistant to therapy with 
somatostatin analogues. Clinical studies are currently being designed to evaluate this 
agent in patients with NETs.  
The development of chimeric agents provides a promising avenue to treating patients 
whom have become resistant to therapy with standard somatostatin analogues, and these 
new agents may also have anti-proliferative effects. This study demonstrates that co-
expression of SSTR and D2R receptors and therefore, patients who are SSTR-2 positive 
on 
111In-DTPA-octreotide scintigraphy are likely to express both SSTR-2 and D2R and 
could potentially be suitable for therapy with chimeric molecules.  
 
Chapter 3 
The EGFR family of G-protein coupled receptors are involved in tumour development of 
a number of different cancers, including breast, colon and head and neck squamous cell 
carcinomas. The expression of EGFR in NETs has been previously demonstrated using 
immunohistochemistry and RT-PCR 
115;116. Other studies have demonstrated expression  
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of HER-2 in some NETs. However, to date no studies have examined expression of all 
four HER family receptors in NETs. In Chapter 3, expression of the EGFR receptor 
family (HER-2, HER-3 and HER-4) was studied in NETs using immunohistochemistry. 
The results obtained were analysed in conjunction with a previous study which had 
assessed EGFR expression in the same cases. The EGFR staining from the previous 
study was re-assessed and identified expression in 86.5% of cases.  EGFR expression 
has been correlated with worse prognosis in other cancers. However, this was not 
demonstrated in our study. HER-2 was not expressed in any of the tumours. This finding 
is different from other studies which have demonstrated HER-2 expression in small 
number of cases using immunohistochemistry
180. The reason for different findings is 
unclear, the positive control in this study stained positively for HER-2 with strong 
membrane staining in a HER-2 positive breast cancer. Therefore, it is unlikely that 
technical limitations were responsible for the different in staining identified in this study 
compared to other previously published studies. The other studies were specific to 
pancreatic NETs and therefore, it may be selection bias, or the intensity of the scoring 
system used in between studies that has led to this variation in results. It would be 
interesting to assess for receptor expression in these samples using other techniques 
including RT-PCR, since the threshold of detecting receptor expression would be lower. 
HER-3 was expressed 8.5% (7 of 82 cases) of which 3 were paragangliomas.  There 
appeared to be a survival benefit in patients expressing HER-3, however, since 
paragangliomas have a better outcome than other NETs, it is unclear whether HER-3 can 
be regarded as a possible prognostic factor. Further studies need to be performed in 
patients with NETs to fully evaluate whether HER-3 expression is of prognostic benefit. 
HER-4 was expressed 91.5% of cases, there was no association of prognosis with HER-
4 expression.  EGFR expression was not correlated with HER-3 or HER-4 expression. 
EGFR and HER-4 were co-expressed in 79.3% of cases.   
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This is the first study to demonstrate co-expression of the EGFR family of receptors. 
Importantly the high expression of EGFR may provide a possible therapeutic target for 
anti-EGFR therapy with chimeric monoclonal antibodies 
283. The preliminary results 
from phase II clinical studies looking at Gefitinib in NETs showed initial progression 
free survival, however, no objective clinical response 
117;284. It has been postulated that 
the low response is due to the fact that other signalling pathways are activated following 
inhibition of EGFR receptor 
285. There is evidence that strength of EGFR expression 
does not correlate to response to EGFR inhibitors 
286, furthermore, EGFR negative 
tumours have been shown to be responsive to EGFR inhibitors 
285;287. 
 
With the development of HER-4 monoclonal antibody therapy, the high expression of 
this receptor in NETs may provide a possible role for molecular targeted therapy. 
However, the actual role of HER-4 in tumourogenesis is unclear, with some evidence 
supporting its role as an anti-tumoural receptor, with over-expression associated with 
positive prognostic value 
171;174. Studies in breast cancer have shown conflicting results 
with some reports associating HER-4 expression with short survival and others with 
longer survival 
143;174;288. Further work needs to be done to understand the downstream 
signalling that occurs following activation of HER-4.  
 
Chapter 4 
Tumour angiogenesis is integral to tumour growth and development of tumour 
metastases. A number of pro- and anti-angiogenic factors are produced by the body 
during normal development. In malignancy there is dysregulation of angiogenic factors 
with a predominance of pro-angiogenic factors. We demonstrated elevated Ang-2 in the 
serum in NETs compared to controls. Ang-2 was shown to be a sensitive marker (85.7%  
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sensitivity with Ang-2 >3313pg/ml), however not a specific marker for NETs since it is 
elevated in a number of other malignancies. Ang-1 concentrations were not elevated in 
patients with NETs compared to controls. Therefore, Ang-1 concentrations are not of 
benefit in identifying patients with NETs. It has been postulated that a shift in the Ang-2: 
Ang-1 ratio may in part be responsible for promoting angiogenesis. In this study 
examining the ratio of Ang-2: Ang-1 did not appear to be as a sensitive marker of 
disease as Ang-2  concentration  alone. There was a significant trend in Ang-2 
concentrations with volume of liver metastases. Ang-2 concentrations >4756pg/ml, were 
associated with shorter time to disease progression. This finding has not been 
demonstrated in NETs previously and requires further investigation to determine 
whether Ang-2 can be used to monitor response to different therapies. These initial 
findings of raised Ang-2 concentrations in NETs and its possible role as a prognostic 
marker has opened up a number of other potential studies and further work. We did not 
demonstrate that patients on SST analogues have a lower Ang-2 concentration than those 
not receiving SST analogues. Due to the heterogeneity of the groups studied further 
studies to see whether SST analogues reduce Ang-2 concentrations would be useful. 
 
The vascular nature of NETs and the findings demonstrated in this study does raise the 
question whether analysis of other pro-angiogenic markers such as VEGF may offer a 
role as a prognostic marker. Currently it is difficult to measure a response to therapy in 
patients receiving different palliative therapies, since radiologically the majority of 
patients demonstrate no radiological response to most molecular targeted and 
chemotherapy agents. Reduction in CgA has been demonstrated in patients receiving 
biotherapy with somatostatin analogues though other markers would also be of value in 
demonstrating a response to therapy. There may be a role for Ang-2 in demonstrating a  
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response to therapy. Further studies assessing Ang-2 response to TACE or chemotherapy 
would be interesting.  
Molecular therapies targeted to VEGF have shown promising results in NETs 
119;289;290. 
It would be interesting to see if inhibiting Ang-2 or the Tie-2 receptor would lead to 
inhibition of tumour progression. Ang-2 could potentially be an interesting molecular 
target for NET therapy.   
 
Chapter 5 
The second part of the thesis was aimed at looking at techniques to enable identification 
of NETs and also to monitor disease progression. Tumour markers are generally proteins 
that can be identified in the tumour or biological fluids. In NETs these tumour markers 
are either secreted proteins released from neuroendocrine cells, for example 
chromogranin A, or proteins involved in tumour growth and angiogenesis.  
 
Chromogranin A is one of the best validated general markers for NETs currently 
available. However, it is not a 100% sensitive or specific and is dependent on the assay 
provided. The pancreastatin fragment of chromogranin A is one of the commercially 
available assays currently used, however, this is not marker is not as accurate as 
measuring the whole chromogranin A. Currently there are no biochemical markers that 
offer accurate measure of tumour load. Elevated chromogranin A has been proven to be 
a negative prognostic marker in patients with NETs 
28. To determine whether we could 
identify any new biochemical markers for identifying NET we performed proteomic 
analysis of plasma samples from patients with NETs and compared them to healthy 
controls.  
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2-D protein electrophoresis is a well established technique for identification of proteins 
from various media. In Chapter 5, we analysed the fractionated plasma from patients 
with NETs and compared the protein signatures on gels to those of healthy controls. 
Whilst over 200 protein spots were identified in each gel, a total of 4153 protein spots 
were identified in all gels. Using warping software which enables mapping the gels of 
patients and controls, three proteins of interest were identified; these identified using 
mass spectrometry and found to be albumin and pre-albumin. The most likely 
explanation for this is the fact even though >90% of albumin is removed by fractionation 
prior to gel electrophoresis, however this is not accurately standardised, Consequently, a 
slight increase in amount of albumin in the sample can cause a marked difference in 
expression on the gel.  The main limitation with the use of plasma in 2-D electrophoresis 
is the large dynamic range of protein expression in plasma. Even with fractionation prior 
to electrophoresis, which removes >90% of the 20 most common proteins the expression 
of high abundance proteins is still 3-5 fold higher than that of low expressed proteins. 
Fractionation itself also causes problems in that proteins that may be bound to albumin 
are also lost from the sample. Other proteomic techniques have been used to analyse 
plasma samples, which avoid the use of 2-D gel electrophoresis.  
 
Ideal media to perform 2-D electrophoresis is a one which contains the proteins of 
interest expressed at a moderate to high intensity so that it leaves a clear protein 
signature. Tumour tissue or cell lines are often a good source for identification of tumour 
markers, since the concentrations seen will be at the highest concentration in the tumour. 
Furthermore, the number of other proteins that are expressed in the serum or plasma 
such as albumin will not be as abundant in tissue. Therefore, a further study which may 
be of benefit will be to perform 2-D electrophoresis in resected tumour tissue from 
patients with NETs. In other cancers, tumour tissue based proteomic analysis has led to  
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the identification of a number of potential biomarkers using the 2-D gel electrophoresis 
technique 
291;292.  
 
Proteomics as a field is expanding and the technological advances in equipment is 
enabling a faster and higher throughput of material. The main issues with proteomic 
analysis are  re-producability of results, which is why good proteomic analysis and 
validation of identified biomarkers,  is required. In addition to  the technique we 
employed (2-D gel electrophoresis and LC/MS/MS)  a number of other proteomic 
techniques are available including Surface-enhanced laser desorption/ionization (SELDI) 
in conjunction with TOF/MS. This enables identification of protein peaks of interest 
between patient and control samples. The benefit of this system is that larger number of 
samples can be run however;  further analysis is required to identify the proteins of 
interest.    
 
Chapter 6 
In Chapter 6, proteomic analysis was performed on three known NET cell lines, BON-1 
a pancreatic cell line and two NET lung cancer cell lines(NCI-H727 & SHP-77). A total 
of 266 different proteins were expressed in the three cell lines, and 17 were expressed in 
all three cell lines. These 17 proteins included chromogranin A, chromogranin B, VGF-
nerve inducible factor and Mac-2BP. We performed western blotting to confirm 
presence of Mac-2BP and Chromogranin A in NET cell lines. Validation of Mac-2BP as 
a potential marker for NETs was performed using immunohistochemistry of tumour 
tissue and ELISA of patient serum. 90% of cases demonstrated positive 
immunohistochemical  staining for Mac-2BP in NET tissue. Serum analysis showed 
significantly elevated Mac-2BP in patients compared to controls.  
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Proteomic analysis of NETs cell lines to identify potential serum markers of NETs has 
not been previously described. Using this technique it may be possible to identify a 
number of potential markers which can be used aid in the diagnosis of NETs.  
 
This study has demonstrated for the first time the potential role of Mac-2BP as a 
biomarker in NETs. Other markers of interest are VGF-nerve inducible factor and GDF-
15. Of these VGF-nerve-inducible factor has been previously assessed in NET tissue 
using IHC 
252. However, no studies to date have been performed to assess whether this is 
a suitable plasma marker. GDF-15 has been proposed to be involved in tumourogenesis 
in other studies 
293; though its role in NETs has never been demonstrated.  
 
The pathogenesis of desmoplasia is poorly understood, it is thought to be mediated via 
kinins as well as other proteins. Examination of NET secretory cell lines, looking for 
small secreted particles could potentially identify these proteins. From our study, the 
small proteins <10kDa are yet to be studied, further studies will be aimed at precipitating 
these proteins from the culture free serum and then identifying them using LC/MS/MS.  
 
Further studies to elucidate the role of Mac-2BP in tumour progression in NETs would 
be of interest. Studies to date have identified its role appears to be in tumour metastases. 
However, a volume of research has also focussed on its role in HIV patients. It appears 
to be an integral protein in tumourgenesis with its expression being identified in a 
number of other cancers including breast, colo-rectal and lung cancer 
251;253;258;294. Mac-
2BP also known as 90K is a glyco-protein that binds to galectins. It would be of interest 
to see whether inhibition of Mac-2BP from binding to galectins and beta-1 integrin has 
anti-proliferative effects.  
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Chapter 7  
Imaging of NETs is essential for staging of disease, monitoring response to treatment 
and also with NETs to determine whether tumours are likely to be suitable for 
biotherapy or peptide receptor targeted therapy. Radiological imaging of NETs is 
comprised of conventional cross-sectional imaging (CT and MRI) plus nuclear medicine 
imaging (
111In-DTPA-octreotide scintigraphy). Over the last decade PET imaging has 
become integral to management of patients with certain types of cancer, however, its 
role in NETs is unclear. A number of different radio-ligands have been trialled in NETs. 
We performed a study to examine 
68Ga-DOTATATE PET  imaging is of benefit in 
identifying tumours and altering clinical management in patients with negative or 
equivocal uptake of 
111In-DTPA-octreotide scintigraphy. Traditionally, patients with 
negative uptake on 
111In-DTPA-octreotide scintigraphy would not be considered for 
peptide receptor targeted therapy, since it would be thought their tumours expressed a 
low concentration of SSTR-2 receptors and so the radiolabelled agents would not to take 
up into tumour tissue.  
 
In our study we demonstrated that 
68Ga-DOTATATE PET identified significantly more 
lesions than 
111In-DTPA-octreotide  scintigraphy. Disease was identified in 41 of 47 
patients using 
68Ga-DOTATATE PET all of whom had evidence of disease on cross-
sectional imaging. Management was altered in 70.6% of cases; we concluded that 
68Ga-
DOTATATE PET is a useful imaging modality in patients with negative or equivocal 
uptake on 
111In-DTPA-octreotide scintigraphy.  
 
This study had limitations with regards to the study population, in that we selected a very 
select subset of patients in whom 
111In-DTPA-octreotide  scintigraphy was weak or 
negative. To truly compare 
111In-DTPA-octreotide scintigraphy and 
68Ga-DOTATATE  
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PET, the study population should be unselected patients with similar primary sites. 
Furthermore, SPECT imaging should be performed of the chest and abdomen to enable 
more accurate lesion detection. For planar imaging ideally slower speed of imaging 
could potentially enable higher lesion detection. If this study is performed on a large 
group of patients then sensitivity, specificity and accuracy can be determined for both 
types of imaging.  
 
Other studies of interest will be to see which PET tracer is best for imaging NETs. 68Ga-
DOTATOC, 68Ga-DOTANOC, Fluorodeoxyglucose (FDG) and [11C] 5-hydroxy-L-
tryptophan (5-HTP) have all been evaluated in NETs, with very different findings 
dependent in part on the tumour biology and primary site. It could well be that for 
tumours of different primary site and histological grade different radiotracers enable 
optimal disease localization.  
 
Finally, another study of interest will be to see whether the (standard uptake value) 
SUVmax is reduced between pre- and post- therapy images. This may offer a way to 
assess outcome following therapy, since often there is no radiological change in lesion 
size using cross sectional imaging.  
 
In conclusion NETs are regarded as rare tumours, however, due to their increasing 
incidence and indolent nature, their prevalence is much higher than many other cancers. 
Furthermore, due to their late presentation, palliative measures provide the mainstay of 
management. Therefore, novel treatments other than chemotherapy are required to 
enable symptom control and improve survival. This research has contributed to enabling 
further methods to image these tumours radiologically as well as opening potential 
avenues for monitoring patients with serological markers including Ang-2 and Mac- 
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2BP. Through immunohistochemical studies we have gained a better understanding of 
NET pathophysiology by demonstrating the expression of HER family of receptors as 
well as the co-expression of D2R, SSTR-2 and SSTR-5 receptors.   
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